Sin nombre virus full-length m segment-based dna vaccines

ABSTRACT

The invention contemplates a new synthetic, codon-optimized Sin Nombre virus (SNV) full-length M gene open reading frame (ORF) that encodes a unique consensus amino acid sequence. The SNV ORF was cloned into a plasmid to form the first stable recombinant SNV full-length M gene that elicits neutralizing antibodies. The gene can be engineered into a vaccine system, and is useful to protect mammals against infection with Sin Nombre virus.

BACKGROUND OF THE INVENTION

Hantaviruses are considered Category A Priority Pathogens by theNational Institute of Allergies and Infectious Disease. These virusescause a spectrum of vascular-leak syndromes including hantaviruspulmonary syndrome (HPS) and hemorrhagic fever with renal syndrome(HFRS). Many HPS and HFRS hantaviruses pose a natural threat to personsworking, living or traveling in endemic regions, including militarypersonnel. There is one hantavirus (Andes virus) that has uniqueproperties that make amenable to use as a biological weapon.

Andes virus (ANDV) and Sin Nombre virus (SNV) are the predominant causesof HPS in South and North America, respectively. These rodent-borneviruses were discovered in the early 1990's and have caused severedisease in several hundred persons.

Since the discovery of SNV in 1993, it has caused severe disease in ˜500persons in the United States and Canada, resulting in ˜200 deaths (35%case-fatality rate). SNV is carried by the deer mouse and transmittedvia inhalation or ingestion of contaminated secreta/excreta, or byrodent bite. Most of the fatalities occurred in previously healthyworking-age males. HPS is a disease with rapid onset, and rapidprogression from mild to severe disease (i.e., can occur over theweekend). The disease begins as an influenza-like illness includingfever, headache, nausea, cough, and can progress rapidly to respiratoryfailure and cardiogenic shock. There is no specific therapeutic orvaccine to treat or prevent HPS. Hammerbeck, C. D., Wahl-Jensen, V.,Hooper, J. W. Hantavirus. In: Vaccines for Biodefense and Emerging andNeglected Diseases (A. D. T. Barrett and L. R. Stanberry, Eds.), pp.379-411. London: Academic Press, 2009; Jonsson C. B, J. Hooper, and G.Mertz (2008). Treatment of hantavirus pulmonary syndrome. Antiviral Res.Antiviral Res. 78:162-169.

There is no population with pre-existing immunity to SNV or ANDV andthis virus is lethal in 35-40% of the people it infects. Note that this35-40% case-fatality rate occurs despite treatment in modern intensivecare units. All ages and both sexes are susceptible to ANDY and SNV.Most cases occur in previously healthy working-age males. The incubationperiod is approximately two weeks. Disease onset-to-death is rapid (overthe weekend). In an animal model of HPS (Syrian hamsters), ANDY ishighly lethal by all routes tested including the oral route. SNV ishighly infectious (infectious dose 50% is 2 plaque forming units inSyrian hamsters but does cause lethal disease (Hooper et al., 2001).Thus, an infection model, rather than a lethal disease model, is used toevaluate medical countermeasures to prevent SNV infection.

New-World hantaviruses have been associated with outbreaks of a highlylethal disease, hantavirus pulmonary syndrome (HPS), in the Americas(reviewed in Schmaljohn and Hjelle, 1997, Emerg. Infect Dis. 3, 95-104).The disease is characterized by fever and vascular leakage resulting innon-cardiogenic pulmonary edema followed by shock. Case-fatality for HPScaused by the most prevalent North American and South Americanhantaviruses, Sin Nombre virus (SNV) and Andes virus (ANDY),respectively is 30-50%.

Currently, there are four known hantaviruses associated with hemorrhagicfever with renal syndrome (HFRS): Hantaan virus (HTNV), Dobrava-Belgradevirus (DOBV), Puumala virus (PUUV), and Seoul virus (SEOV). Becausedistinct hantaviruses are usually carried by only one principal rodenthost species, their distribution is generally limited to the range ofthat host (reviewed in Schmaljohn and Hjelle, 1997, Emerg. Infect. Dis.3, 95-104). HTNV, carried by Apodemus agrarius, is found in Asia; DOBV,carried by Apodemus flavicollis, and PUUV, carried by Clethrionomysglareolus, are found in Europe. SEOV is more widely disseminated thanany other recognized hantaviruses because its host, the common urban rat(Rattus norvegicus), is found throughout the world.

There is an alarming paucity of existing medical countermeasures toprevent or treat HPS. There is no vaccine against SNV, ANDY or any otherHPS-associated hantavirus. Moreover, aside from basic research, thereare no funded HPS vaccine development efforts. There is no specific drugto prevent or treat HPS. The treatment for HPS is extracorporealmembrane oxygenation therapy (ECMO) with costs as much as $500,000 perpatient. Expertise at performing adult ECMO resides at only a fewhospitals in the world. Thus, we are poorly prepared to deal withnaturally occurring HPS cases (there have been ˜2500 cases including˜500 in the US since 1993), or the use of hantaviruses as biologicalweapons.

Viruses in the Hantavirus genus (family Bunyaviridae) are enveloped andcontain a genome comprised of three single-stranded RNA segmentsdesignated large (L), medium (M), and small (S) based on size (reviewedin Schmaljohn, 1996, In The Bunyaviridae Ed. R. M. Elliott. New York,Plenum Press p. 63-90). The hantavirus L segment encodes the RNAdependent RNA polymerase, M encodes two envelope glycoproteins (G1 andG2, also known as G_(n) and G_(c)), and S encodes the nucleocapsidprotein (N).

A number of inactivated HFRS vaccines derived from cell culture orrodent brain were developed and tested in Asia (Lee et al., 1990, Arch.Virol., Suppl. 1, 35-47; Song et al., 1992, Vaccine 10, 214-216; Lu etal., 1996, J. Med. Virol. 49, 333-335). Drawbacks of these traditionalkilled-virus vaccines include a requirement for appropriate containmentfor the growth and manipulation of virus, and the necessity to ensurecomplete inactivation of infectivity without destroying epitopes on thevirion important for protective immunity. In order to overcome thesedrawbacks, vaccine approaches involving recombinant DNA technology weredeveloped including: vaccinia-vectored vaccines (Schmaljohn et al. 1990,J. Virol. 64, 3162-3170; Schmaljohn et al. 1992, Vaccine 10, 10-13; Xuet al. 1992, Am. J. Trop. Med. Hyg. 47, 397-404), protein subunitvaccines expressed in bacteria or insect cells (Schmaljohn et al. 1990,supra; Yoshimatsu et al., 1993, Arch. Virol. 130, 365-376; Lundkvist etal., 1996, Virology 216, 397-406), and a hepatitis core antigen-basedrecombinant vaccine (Ulrich et al., 1998, Vaccine 16, 272-280). For areview of hantavirus vaccine efforts see the review by Hooper and Li(Hooper and Li, 2001); Hammerbeck, C. D., Wahl-Jensen, V., Hooper, J. W.Hantavirus. In: Vaccines for Biodefense and Emerging and NeglectedDiseases (A. D. T. Barrett and L. R. Stanberry, Eds.), pp. 379-411).

Vaccination with vaccinia recombinants expressing the M segment ofeither HTNV or SEOV elicited neutralizing antibodies and protectedrodents against infection with both HTNV and SEOV, suggesting that animmune response to Gn-Gc alone can confer protection (Schmaljohn et al.1990, supra; Xu et al. 1992, supra; Chu et al. 1995, J. Virol. 69,6417-6423). Similarly, vaccination with Gn-Gc protein expressed ininsect cells (baculovirus recombinant virus system) elicitedneutralizing antibodies and protected hamsters from infection with HTNV(Schmaljohn et al. 1990, supra). In both the vaccinia and baculovirussystems, vaccination with Gn-Gc provided more complete protection thanGn or Gc alone (Schmaljohn et al. 1990, supra). There are reports thatcandidate DNA vaccines comprised of around 500 nucleotide stretches ofthe Sin Nombre virus (SNV) M gene, or the full-length S gene, areimmunogenic in mice (Bharadwaj, et al., 1999, Vaccine 17, 2836,43) andconferred some protection against infection with SNV in a deer mouseinfection model (Bharadwaj, et al., 2002, J. Gen. Virol. 83, 1745-1751).The protection was surmised to be cell-mediated because there was noconvincing evidence that these constructs elicited a neutralizing, orotherwise protective, antibody response.

There have been several publications reporting the successful use ofplasmid DNA vaccines containing the full-length M gene of SEOV, HTNV,ANDV, including the following reports:

-   1. Hooper, J. W., K I Kamrud, F. Elgh, D. Custer, and C. S.    Schmaljohn (1999). DNA vaccination with hantavirus M segment elicits    neutralizing antibodies and protects against Seoul virus infection.    Virology, 255:269-278.-   2. Hooper, J. W., D. Custer, E. Thompson, and C. S. Schmaljohn    (2001). DNA Vaccination with the Hantaan virus M gene protects    hamsters against three of four HFRS hantaviruses and elicits a    high-titer neutralizing antibody response in rhesus monkeys. Journal    of Virology 75:8469-8477.-   3. Custer, D. M., E. Thompson, C. S. Schmaljohn, T. G. Ksiazek,    and J. W. Hooper (2003). Active and passive vaccination against    hantavirus pulmonary syndrome using Andes virus M genome    segment-based DNA vaccine. Journal of Virology 79:9894:9905.-   4. Hooper, J. W., D. M. Custer, J. Smith, and Victoria Wahl-Jensen.    Hantaan/Andes virus DNA vaccine elicits a broadly cross-reactive    neutralizing antibody response in nonhuman primates (2006). Virology    347:208-216.

In all cases high titer neutralizing antibodies were detected in animals(including nonhuman primates) vaccinated with the full-length M gene DNAvaccines, and protection from infection was achieved in rodent models.Neutralizing antibody responses to Gn-Gc in the aforementioned vaccinestudies correlated with protection, suggesting that neutralizingantibodies not only play an important role in preventing hantavirusinfection, but also might be sufficient to confer protection. Passivetransfer of neutralizing monoclonal antibodies (MAbs) specific to eitherGn or Gc protected hamsters against HTNV infection (Schmaljohn et al.,1990, supra; Arikawa et al., 1992, J. Gen. Virol. 70, 615-624),supporting the idea that neutralizing antibodies alone can conferprotection. This is further supported by the finding that serum fromnonhuman primates vaccinated using a gene gun with DNA vaccinescontaining the HTNV or ANDY full-length M genes protected hamsters frominfection with HTNV or lethal disease caused by ANDY Custer, D. M., E.Thompson, C. S. Schmaljohn, T. G. Ksiazek, and J. W. Hooper (2003).Active and passive vaccination against hantavirus pulmonary syndromeusing Andes virus M genome segment-based DNA vaccine. Journal ofVirology 79:9894:9905). Similarly, sera from rabbits vaccinated with theANDY M gene-based DNA vaccine using electroporation protected hamstersfrom a lethal challenge with ANDY (Hooper J. W., A. M. Ferro, and V.Wahl-Jensen Immune Serum Produced by DNA Vaccination Protects HamstersAgainst Lethal Respiratory Challenge with Andes Virus (2008). Journal ofVirology 82:1332-1338.)

Hitherto, attempts to produce vaccines that produce neutralizingantibodies against SNV have been unsuccessful. For instance, Hjelle etal. (U.S. Pat. No. 6,316,250) attempted to vaccinate with the entire SNVGn or fragments of G1 to generated antibodies. However, their vaccinedid not produce high titer neutralizing antibodies. There are currentlyno serious efforts to develop an HPS vaccine anywhere in the world,including SNV vaccine. (refs 17, 18 below) NIH is currently funding ahandful of academic laboratories working on hantavirus basic research.

The inventors have produced DNA vaccines against other hantavirusesincluding Seoul virus (SEOV), Hantaan virus, (HTNV) Puumala virus (PUUV)and Andes virus (ANDY) (refs 1, 5 and 6 below). There are a number ofissued and pending patents related to these vaccines (refs 23-26 below).SEOV, HTNV, and PUUV cause hemorrhagic fever with renal syndrome (HFRS).All of these DNA vaccines are based on the full-length M gene openreading frame that encodes the Gn and Gc proteins, and all of thesevaccines elicit neutralizing antibodies in animal models. Neutralizingantibodies produced by DNA vaccination have been shown to protectagainst infection and disease in passive transfer studies (refs 3,4below). In addition, the Hantaan and Puumala DNA vaccines have beentested in a phase 1 clinical trial (ongoing). The immunogenicity datagenerated in this phase 1 trial demonstrates that DNA vaccines againsthantaviruses were capable of eliciting neutralizing antibodies inhumans. This was the first time hantavirus neutralizing antibodies havebeen produced in humans using plasmid DNA. The overall seroconversionrate in this phase 1 trial was 43% (12 of 28). One of the most notablefindings was that very high titers of neutralizing antibodies wereachievable. Two of the peak anti-Hantaan virus titers were >1,000 andfour of the peak anti-Puumala virus titers were >1,000. Neutralizingantibody titers as high as 10,240 were achieved for both Hantaan virusand Puumala virus.

The antibody response elicited by the hantavirus M gene-based DNAvaccines have been shown to cross-neutralize some, but not otherhantaviruses. For example, the HTNV DNA vaccine was shown to elicitneutralizing antibodies against Seoul virus and Dobrava virus (a majorcause of HFRS in the Balkans)(ref 1 below). In some cases thecross-neutralizing antibody response is produced in certain speciesusing certain delivery technologies, but not others. This was the casewith our ANDY DNA vaccine. When nonhuman primates were vaccinated withthe ANDY DNA vaccine using a gene gun the sera contained antibodies thatnot only neutralized ANDY but also neutralized SNV and Black Creek Canalvirus (ref. 3 below). Based on those results we concluded that thedevelopment of a SNV-specific DNA vaccine was unnecessary. However,recently we found that when rabbits were vaccinated with the ANDY DNAvaccine using muscle electroporation the sera was unable to neutralizeSNV despite exhibiting very high titer ANDY-neutralizing activity (ref 4below). It is speculated that this could be due to antibody specificitydifferences, antibody avidity differences, or antibody isotypedifferences.

This finding prompted us to reinitiate the development of a SNV Mgene-based DNA vaccine rather than depend on the ANDY DNA vaccine tocross-protect against SNV.

The inventor is named as an inventor on other U.S. patents andpublications, related to vaccines for hantaviruses and poxviruses,namely U.S. Pat. No. 6,451,309; U.S. Pat. No. 6,620,412; U.S. Pat. No.6,562,376, U.S. Pat. No. 7,217,812, and U.S. Patent applicationpublication US-2010-03203024 A1. The entire contents of these patentsare incorporated herein by reference.

SUMMARY OF THE INVENTION

Key to the invention is a novel synthetic, codon-optimized Sin Nombrevirus full-length M gene open reading frame (ORF). To date, there are noreports of a full-length M gene, or SNV M gene ORF, being successfullyengineered into a DNA vaccine plasmid or other mammalian expressionvector. This SNV M gene DNA sequence has been altered (or optimized) insuch a way as to increase the stability of the mRNA and to,theoretically, eliminate sequences that destabilize the plasmid in E.col. In addition, four amino acids that were unique to our full-lengthclone were changed to consensus amino acids based on alignments withfive hantavirus M gene sequences from GeneBank. The ORF nucleic acidsequence was changed without altering the coded amino acid sequence ofthe Sin Nombre M gene product, other than the four aforementioned aminoacids. This was accomplished by codon optimizing the ORF. The process ofcodon optimization not only changed the nucleic sequence, but also itwas intended to allow more efficient codon usage and increased stabilityof the mRNA produced by the plasmid. An algorithm called GeneOptimizer(patent pending), owned by GeneArt was used to allow more efficientcodon usage and stabilization of the mRNA. It is noted that, while theORF was codon optimized, the flanking sequence was unchanged.

This synthetic M gene has been engineered into a plasmid-based vaccinesystem, (i.e, pWRG/SN-M(opt)), and is believed could be subcloned into avirus-vectored vaccine. The preferred DNA plasmid containing thissequence is designated pWRG/SN-M(opt), and its DNA sequence is describedin detail below. pWRG/SN-M(opt) is capable of eliciting goodneutralizing antibody responses against Sin Nombre virus. In fact,pWRG/SN-M(opt), as a DNA vaccine delivered by gene gun, is the firstvaccine of any kind that has elicited convincing levels of neutralizingantibodies against Sin Nombre virus in animals.

The development of this novel SNV full-length M segment and its use as avaccine can be summarized as follows. As mentioned above, it had beenhoped that an Andes virus M gene-based DNA vaccine wouldcross—neutralize with the other HPS virus, Sin Nombre virus. In fact,early results gave indication that this would be the case. When nonhumanprimates were vaccinated with the ANDY DNA vaccine using a gene gun thesera contained antibodies that not only neutralized ANDY but alsoneutralized SNV and Black Creek Canal virus (6). Based on those resultsthe inventor concluded that the development of a SNV-specific DNAvaccine was unnecessary. However, recently the inventor found that whenrabbits were vaccinated with the ANDY DNA vaccine using muscleelectroporation the sera was unable to neutralize SNV despite exhibitingvery high titer ANDY-neutralizing activity (11). The data is publishedin Hooper J. W., A. M. Ferro, and V. Wahl-Jensen Immune Serum Producedby DNA Vaccination Protects Hamsters Against Lethal RespiratoryChallenge with Andes Virus (2008). Journal of Virology 82:1332-1338. Theinventor realized that the ANDY DNA vaccine would not be suitable as avaccine to cross-protect against SNV, so sought a vaccine specificallyfor SNV.

The inventor cloned the full-length M gene from SNV, strain CC107 into aDNA vaccine vector, producing a plasmid with an intact open readingframe—pWRG/SN-M(2a). pWRG/SNV-M(2a) was tested for immunogenicity inrabbits, and it was discovered that high-titer neutralizing antibodieswere produced after 4 vaccinations. This represented the first timehigh-titer SNV neutralizing antibodies were ever produced by anyvaccine.

However, it required more vaccinations than the inventor would havepreferred, so pWRG/SNV-M(2a) was re-designed for optimization. It wasfound that the M gene sequence in pWRG/SNV-M(2a) produced amino acidsthat were unique to our clone (i.e., not in published GeneBank SNV Msequences). This is shown in the Table 1 below, by identifying possiblecloning errors in pWRG/SN-M(2a) M gene ORF and determining consensusamino acid sequence. In Table 1, SN-M(2a) is the amino acid sequence ofthe SNV M open reading frame (ORF) cloned into pWRG/SN-M(2a). Thissequence as aligned with several SNV M gene ORFs from Genebank: AAA68036(SNV strain CC107), AAA68036 (SNV strain CC107 isolate 74), NP_941974(SNV strain NMH10), 083887 (New York virus), AAC54561 (NY-2 virus), andAC54559 (Rhode Island 1 virus). The four amino acids so identified werechanged to the consensus amino acids in the synthetic gene cloned intopWRG/SN-N(opt), see below.

These consensus amino acids were identified at these positions and thenan optimized version of this gene was synthesized. Next, we cloned thesynthetic M gene (SN-M(2a)) into a DNA vaccine vector and named theplasmid pWRG/SN-M(opt). This plasmid pWRG/SN-M(opt) was deposited onJan. 26, 2011 in the American Type Culture Collection, located at 10801University Blvd. Manassas, Va. 20110. The deposit was made under theterms of the Budapest Treaty.

Table 2 shows the nucleic acid differences between the original cloned Mgene (SN-M[2a]) and the optimized M gene (SN-M[opt]).

TABLE 1The amino acid sequence encoded by the ORF cloned into pWRG/SN-M(2a) wasaligned with six SNV M sequences from genebank (accession numbers are shown).There were four positions (the first ″Q″ in line 1; the first ″A″in the line beginning with nucleic acid 241; the first ″G″in the line beginning with  nucleic acid 421; and the third ″P″in the line beginning with nucleic acid 481) that were unique to the cloned ORF (highlighted in bold type and underlined). These amino acids were changed to the consensus amino acidswhen the new gene was synthesized to produce pWRG/SN-M(opt). SN-M(2a)   1 MVGWVCIFLVVLTTATAGLTRNLYEL Q IECPHTVGLGQGYVTGSVETTPILLTQVADLKIAAA6800    1..........................K................................. AAA68036   1 ..........................K.................................NP_941974    1..........................K...................I............. Q83887    1.......S....A.T...........K............................T....  AAC54561   1 ...F........A.T...........K..................G.........T....AAC54559    1............A.T...........K............................T.... consensus   1 ***.***.****.*.***********.******************..********.****SN-M (2a)   61  ESSCNFDLHVPATTTQKYNQVDWTKKSSTTESTNAGATTFEAKTKEVNLKGTCNIPPTTF AAA6800  61 ............................................................AAA68036   61............................................................ NP_941974  61 ..............................................I............. Q83887   61 ...........S.SI......E.A.........S.............S........V...AAC54561   61...........S.SI......E.A.........S.............S........V... AAC54559  61 ...........S.SI......E.A.........S.............S........V...consensus   61***********.*..******.*.*********.************..********.*** SN-M (2a) 121 EAAYKSRKTVICYDLACNQTHCLPTVHLIAPVQTCMSVRSCMIGLLSSRIQVIYEKTYCVAAA6800  121............................................................ AAA68036 121 ...F........................................................NP_941974  121............................................................ Q83887  121............................................................ AAC54561 121 ............................................................AAC54559  121....................Y....................................... consensus 121 ***.****************.***************************************SN-M (2a)  181TGQLIEGLCFIPTHTIALTQPGHTYDTMTLPVTCFLVAKKLGTQLKLAVELEKLITGVSC AAA6800 181 ............................................................AAA68036  181............................................................ NP_941974 181 ............................................................ Q83887 181 ....V..........................I..............I.........ASG.AAC54561  181....V..........................I..............I.........AGG. AAC54559 181 ....V..........................I..............I.........ASG.consensus  181****.**************************.**************.*********...* SN-M(2a) 241 A ENSFQGYYICFIGKHSEPLFVPTMEDYRSAELFTRMVLNPRGEDHDPDQNGQGLMRIAGAAA6800  241T........................................................... AAA68036 241 T...........................................................NP_941974  241T........................................................... Q83887  241T...........L..........M.D.................................. AAC54561 241 T...........L..........M.D..................................AAC54559  241T...........L.......S..M.D.................................. consensus 241 .***********.*******.**.*.**********************************SN-M(2a)  301PVTAKVPSTETTETMQGIAFAGAPMYSSFSTLVRKADPEYVFSPGIIAESNHSVCDKKTV AAA6800 301 ............................................................AAA68036  301............................................................ NP_941974 301 ............................................................ Q83887 301 .I....................................D....................IAAC54561  301.I...........A........................D....................I AAC54559 301 .I......................T.............D...................AIconsensus  301*.***********.**********.*************.*******************.. SN-M(2a) 361 PLTWTGFLAVSGEIERITGCTVFCTLAGPGASCEAYSETGIFNISSPTCLVNKVQKFRGSAAA6800  361............................................................ AAA68036 361 ............................................................NP_941974  361...............K............................................ Q83887  361...............K..........V.................................  AAC54561 361 ...............K..........V.................................AAC54559  361...............K..........V......K.......................... consensus 361 ***************.**********.******.**************************SN-M(2a)  421 EQRINFMCQRVDQ GVVVYCNGQKKVILTKTLVIGQCIYTFTSLFSLIPGVAHSLAVELCV AAA6800  421.............D.............................................. AAA68036 421 .............D..............................................NP_941974  421.............D.............................................. Q83887  421.............D.I............................................ AAC54561 421 .............D.I............................................AAC54559  421.............D.I...............I............................ consensus 421 *************.*.***************.****************************SN-M(2a)  481 PGLHGWATTALLITTCFGWLLIPTVTLIILKILRLLIT PCSHYSTESKFKVILERVKVEY AAA6800  481......................................S..................... AAA68036 481 ......................................S..................... NP_941974  481.......................A..............S..................... Q83887  481........................I.M...........S...........A......... AAC54561 481 ........................I.M...........S...........A.........AAC54559  481........A...............I.M...........S...........A......... consensus 481 ********.**************..*.***********.***********.*********SN-M(2a)  541QKTMGSMVCDICHHECETAKELETHKKSCPEGQCPYCMTITESTESALQAHFSICKLTNR AAA6800 541 ............................................................AAA68036  541............................................................ NP_941974 541 ....................................................A....... Q83887 541 ..........V............................M....................AAC54561  541..........V............................M.................... AAC54559 541 ..........A............................M........L...........consensus  541**********.****************************.********.***.******* SN-M(2a) 601 FQENLKKSLKRPEVRKGCYRTLGVFRYKSRCYVGLVWGILLTTELIIWAASADTPLMESGAAA6800  601...I........................................................ AAA68036 601 ...I........................................................NP_941974  601............................................................ Q83887  601..............KQ......................V.......V............. AAC54561 601 ..............KQ......................V.......V.............AAC54559  601..............KQ.R....................V.......V............. consensus 601 ***.**********..*.********************.*******.*************SN-M(2a)  661WSDTAHGVGIVPMKTDLELDFALASSSSYSYRRKLVNPANQEETLPFHFQLDKQVVHAEI AAA6800 661 ............................................................AAA68036  661............................................................ NP_941974 661 ..........I................................................. Q83887 661 ........................................K...................AAC54561  661....................................D...K................... AAC54559 661 ........................................K...................consensus  661**********.*************************.***.******************* SN-M(2a) 721 QNLGHWMDGITNIKTAFHCYGECKKYAYPWQTAKCFFEKDYQYETSWGCNPPDCPGVGTGAAA6800  721............................................................ AAA68036 721 ............................................................NP_941974  721............................................................ Q83887  721............................................................ AAC54561 721 ............................................................AAC54559  721............................................................ consensus 721 ************************************************************SN-M (2a)  781CTACGVYLDKLRSVGKAYKIVSLKYTRKVCIQLGTEQTCKHIDVNDCLVTPSVKVCMIGT AAA6800 781 ............................................................AAA68036  781............................................................ NP_941974 781 ............................................................ Q83887 781 ........................F...............................L...AAC54561  781........................F...............................L... AAC54559 781 .............G..........F...............................L...consensus  781*************.**********.*******************************.*** SN-M (2a) 841 ISKLQPGDTLLFLGPLEQGGIILKQWCTTSCVFGDPGDIMSTTSGMRCPEHTGSFRKICGAAA6800  841............................................................ AAA68036 841 ............................................................NP_941974  841............................................................ Q83887  841...........................................T..K............. AAC54561 841 ...........................................T..K.............AAC54559  841...........................................T..K............. consensus 841 *******************************************.**.*************SN-M (2a)  901FATTPTCEYQGNTVSGFQRMMATRDSFQSFNVTEPHITSNRLEWIDPDSSIKDHINMVLN AAA6800 901 ............................................................AAA68036  901............................................................ NP_941974 901 ............................................................ Q83887 901 .............I..............................................AAC54561  901.............I.............................................. AAC54559 901 .............I..............................................consensus  901*************.********************************************** SN-M (2a) 961 RDVSFQDLSDNPCKVDLHTQSIDGAWGSGVGFTLVCTVGLTECANFITSIKACDSAMCYGAAA6800  961............................................................ AAA68036 961 ............................................................NP_941974  961............................................................ Q83887  961............................................................ AAC54561 961 ............................................................AAC54559  961............................................................ consensus 961 ************************************************************SN-M (2a) 1021ATVTNLLRGSNTVKVVGKGGHSGSLFKCCHDTDCITEGLAASPPHLDRVTGYNQIDSDKV AAA68001021 ............................................................AAA68036 1021............................................................ NP_9419741021 ............................................................ Q838871021 ............................................................AAC54561 1021............................................................ AAC545591021 ......................S.....................................consensus 1021**********************.************************************* SN-M(2a)1081 YDDGAPPCTIKCWFTKSGEWLLGILNGNWVVVAVLIVILILSILLFSFFCPVRNRKNKANAAA6800 1081...............R............................................ AAA680361081 ............................................................NP_941974 1081.....................................................S...... Q83887 1081...................................................I.G....S. AAC545611081 ...................................................I.G....S.AAC54559 1081...................................................I.G....S. consensus1081 ***************.***********************************.*.****.*

TABLE 2The sequence starts at the Not 1 site and ends at the BstB1 or BglII sitedepending on the construct (BstB1 for SN-M(2a) and BglII for SN-M(opt).SN-M(2a)    1GCGGCCGCGGATCTGCAGGAATTCGGCACGAGAGTAGTAGACTCCGCACGAAGAAGCAAA SN-M(opt)   1 ............................................................SN-M(2a)   61CACTGAATAAAGGATATACAGAATGGTAGGGTGGGTTTGCATCTTCCTCGTGGTCCTTAC SN-M(opt)  61 ...........................G..C.....G...........G.....G..G..SN-M(2a)  121TACTGCAACTGCTGGATTGACACGGAATCTCTATGAATTACAGATAGAATGTCCACATAC SN-M(opt) 121 C..C..C..A..C..CC....C.....C..G..C..GC.GA....C..G..C..C..C..SN-M(2a)  181TGTGGGTCTAGGTCAAGGTTATGTGACAGGTTCTGTAGAAACTACACCTATTCTCTTAAC SN-M(opt) 181 C.....C..G..C..G..C..C.....C..CAGC..G..G..A..C..C..C..GC.G..SN-M(2a)  241ACAGGTAGCTGACCTCAAGATTGAGAGTTCTTGCAATTTTGACTTGCATGTCCCAGCCAC SN-M(opt) 241 C.....G..C.....G...........CAGC.....C..C...C....C..G..C.....SN-M(2a)  301TACTACTCAGAAATACAATCAAGTTGACTGGACTAAAAAAAGTTCTACTACAGAAAGCAC SN-M(opt) 301 C..C..C...........C..G..G........C..G..G..CAGC..C..C..G.....SN-M(2a)  361GAATGCAGGTGCAACTACATTTGAGGCTAAAACAAAAGAGGTAAATTTAAAAGGCACATG SN-M(opt) 361 C..C..C..A..C..C..C..C.....C..G..C.....A..G..CC.G..G.....C..SN-M(2a)  421TAATATTCCTCCAACTACGTTTGAGGCTGCATACAAGTCAAGGAAGACAGTGATTTGTTA SN-M(opt) 421 C..C..C..C..C..C..A........C..C......AGC..A.....C.....C..C..SN-M(2a)  481TGATTTGGCCTGTAATCAAACACATTGTCTTCCTACAGTCCATCTGATTGCTCCTGTTCA SN-M(opt) 481 C..CC.......C..C..G..C..C..C..G..C..C..G..C.....C..C..C..G..SN-M(2a)  541AACATGTATGTCTGTACGGAGCTGTATGATAGGTCTGTTATCTAGCAGGATCCAGGTTAT SN-M(opt) 541 G..C..C...AGC..G........C.....C..C...C.G..C...C..........G..SN-M(2a)  601CTACGAGAAGACATATTGTGTCACGGGTCAGTTAATAGAAGGGCTATGTTTCATTCCAAC SN-M(opt) 601 .........A..C..C..C..G..C..C...C.G..C..G..C..G..C.....C..C..SN-M(2a)  661ACATACAATTGCACTTACACAGCCTGGTCATACTTATGATACTATGACATTGCCTGTGAC SN-M(opt) 661 C..C.....C..C..G..C.....C..C..C..C..C..C..C.....CC....C.....SN-M(2a)  721TTGTTTTTTAGTAGCCAAAAAGTTGGGGACGCAGCTTAAGCTGGCTGTTGAGTTAGAGAA SN-M(opt) 721 C..C...C.G..G.....G...C....C..C.....G........C..G...C.G..A..SN-M(2a)  781ATTGATTACTGGTGTGAGCTGCGCAGAGAATAGCTTCCAAGGTTATTACATCTGTTTTAT SN-M(opt) 781 GC....C..C..C.........A.C.....C........G..C..C........C..C..SN-M(2a)  841TGGAAAACATTCAGAGCCCTTATTTGTACCAACAATGGAAGATTATAGATCAGCTGAGTT SN-M(opt) 841 C..C..G..CAGC......C.G..C..G..C..C...........C...AGC..C...C.SN-M(2a)  901ATTTACTCGTATGGTTTTAAATCCAAGAGGTGAAGATCATGACCCTGATCAAAATGGACA SN-M(opt) 901 G..C..C..G.....GC.G..C..C..G..C..G..C..C.....C..C..G..C..C..SN-M(2a)  961AGGGTTGATGAGAATAGCTGGACCTGTTACTGCCAAGGTACCATCTACAGAAACGACTGA SN-M(opt) 961 G..CC.....C.G..C..C.....C..G..C........G..CAGC..C..G..A..C..SN-M(2a) 1021AACAATGCAAGGAATTGCATTTGCTGGGGCACCAATGTATAGTTCATTCTCAACTCTTGT SN-M(opt)1021 ...C.....G..C.....C..C..C..A..C..C.....C..CAGC...AGC..C..G..SN-M(2a) 1081GAGAAAAGCTGATCCTGAATATGTCTTTTCTCCAGGTATAATTGCAGAATCAAATCATAG SN-M(opt)1081 .C.G..G..C..C..C..G..C..G..CAGC..C..C..C.....C..GAGC..C..C..SN-M(2a) 1141TGTTTGTGATAAAAAGACAGTGCCCCTAACATGGACTGGGTTTCTAGCAGTTTCAGGAGA SN-M(opt)1141 C..G..C..C..G..A..C........G..C.....C..C..C..G..C..GAGC..C..SN-M(2a) 1201GATAGAAAGGATAACAGGCTGTACAGTTTTCTGTACATTGGCTGGACCTGGTGCCAGTTG SN-M(opt)1201 ...C..GC....C..C.....C..C..G.....C..CC....C........C.....C..SN-M(2a) 1261TGAAGCATACTCAGAAACAGGAATCTTCAACATAAGCTCCCCAACTTGCTTGGTAAATAA SN-M(opt)1261 C..G..C...AGC..G.....C...........C...AG...C..C...C....G..C..SN-M(2a) 1321AGTCCAAAAATTTAGAGGTTCAGAACAAAGAATTAATTTTATGTGTCAAAGGGTTGATCA SN-M(opt)1321 G..G..G..G..CC.G..CAGC..G..GC.G..C..C..C.....C..GC....G..C..SN-M(2a) 1381AGGTGTTGTGGTTTACTGTAATGGACAGAAGAAAGTCATTCTTACCAAAACCCTAGTAAT SN-M(opt)1381 G.AC..G.....G.....C..C..C.....A.....G..C..G.....G.....G..G..SN-M(2a) 1441AGGTCAATGTATCTACACATTTACTAGTCTGTTTTCACTGATCCCTGGAGTTGCTCATTC SN-M(opt)1441 C..C..G..C........C..C..C..C.....CAGC...........C..G......AGSN-M(2a) 1501CCTTGCTGTGGAGTTATGTGTTCCAGGTCTTCATGGCTGGGCTACAACAGCACTACTTAT SN-M(opt)1501 ...G..A..C..AC.G..C..G..T..C..G..C..A.....C..C..C..C..G..G..SN-M(2a) 1561TACTTTCTGCTTTGGCTGGCTTCTCATACCAACAGTTACTTTAATTATACTAAAAATCTT SN-M(opt)1561 C..C........C........G..G..C..C.....G..CC.G..C..C..G..G...C.SN-M(2a) 1621AAGGCTATTGACCTTCCCATGCTCGCACTATTCTACAGAATCAAAATTCAAAGTCATTTT SN-M(opt)1621 GC....GC........AGC...AGC.....CAGC..C..G..C..G........G...C.SN-M(2a) 1681AGAAAGAGTCAAGGTGGAGTATCAAAAGACAATGGGTTCAATGGTGTGTGACATTTGTCA SN-M(opt)1681 G...C.C..G...........C..G..A..C.....CAGC........C.....C..C..SN-M(2a) 1741CCATGAATGTGAGACGGCAAAAGAGCTCGAAACACATAAGAAAAGTTGCCCAGAAGGTCA SN-M(opt)1741 ...C..G..C.....A..C........G.....C..C.....G..C.....C..G..C..SN-M(2a) 1801ATGCCCATACTGCATGACAATAACTGAGTCCACTGAGAGTGCATTACAAGCTCATTTTTC SN-M(opt)1801 G.....C...........C..C..A...AG...C.....C..CC.G..G..C..C..CAGSN-M(2a) 1861AATCTGTAAGCTAACGAACAGGTTCCAGGAAAATCTAAAAAAATCATTAAAACGTCCAGA SN-M(opt)1861 C.....C.....G..C...C.............C..G..G..GAGCC.G..G..G..C..SN-M(2a) 1921AGTAAGGAAAGGTTGTTACAGGACATTAGGAGTATTCCGCTACAAGAGCAGGTGCTATGT SN-M(opt)1921 ...GC....G..C..C...C....CC.G..C..G.....G.........C..........SN-M(2a) 1981TGGCTTAGTATGGGGGATCCTCTTGACGACAGAGCTGATTATATGGGCTGCTAGTGCAGA SN-M(opt)1981 G...C.G..G.....C..T..GC....C...........C..C.....C..C..C..C..SN-M(2a) 2041TACCCCTCTAATGGAGTCTGGTTGGTCAGATACAGCACATGGTGTAGGTATAGTCCCTAT SN-M(opt)2041 C.....C..G.....AAGC..G...AGC..C..C..T.....C..G..A..C..G..C..SN-M(2a) 2101GAAAACAGATTTAGAGCTTGACTTTGCCTTGGCCTCATCATCTTCTTATAGTTATAGAAG SN-M(opt)2101 ......C..CC.G..A..G.....C...C.....AGCAGCAGCAGC..C..C..CC.GC.SN-M(2a) 2161AAAGCTTGTAAACCCTGCCAATCAAGAGGAGACACTCCCTTTTCATTTCCAGTTAGATAA SN-M(opt)2161 G.....G..G.....C.....C..G..A........G..C..C..C.....AC.G..C..SN-M(2a) 2221GCAAGTAGTGCATGCAGAAATACAGAACCTAGGGCATTGGATGGATGGCACATTCAACAT SN-M(opt)2221 ...G..G.....C..C..G..C........G..C..C........C.....C.....T..SN-M(2a) 2281AAAGACTGCTTTCCATTGCTATGGAGAATGTAAAAAATATGCCTATCCTTGGCAGACAGC SN-M(opt)2281 C.....C..C.....C.....C..C..G..C..G..G..C.....C..C........C..SN-M(2a) 2341CAAGTGTTTCTTTGAAAAAGATTATCAGTATGAAACAAGCTGGGGCTGTAACCCACCAGA SN-M(opt)2341 ......C.....C..G..G..C..C.....C..G..............C.....C..C..SN-M(2a) 2401TTGCCCAGGAGTAGGGACAGGTTGTACAGCCTGTGGGGTATACTTAGACAAGCTCCGTTC SN-M(opt)2401 C..T..T..C..G..C..C..C.....C.....C..C..G...C.G........G..GAGSN-M(2a) 2461AGTTGGGAAAGCCTATAAAATTGTATCACTCAAATACACGCGAAAGGTGTGTATTCAATT SN-M(opt)2461 C..G..C..G.....C..G..C..G..C..G..G.....C..G..A.....C..C..GC.SN-M(2a) 2521GGGGACAGAACAAACCTGTAAACATATAGATGTTAATGATTGTTTGGTCACCCCGTCTGT SN-M(opt)2521 ...C.....G..G..A..C..G..C..C..C..G..C.....CC....G.....CAGC..SN-M(2a) 2581TAAAGTTTGCATGATAGGTACCATCTCGAAGCTTCAGCCAGGTGACACCTTATTGTTTTT SN-M(opt)2581 G.....C..T.....T..C......AGC.....G.....C..C..T...C.GC....CC.SN-M(2a) 2641GGGCCCTTTAGAGCAAGGTGGGATTATTCTAAAACAATGGTGCACAACATCATGTGTGTT SN-M(opt)2641 ......CC.G..A..G..C..C..C.....G..G..G.....T..C..C..C..C.....SN-M(2a) 2701TGGAGACCCTGGTGATATCATGTCAACAACAAGTGGGATGAGATGCCCTGAGCACACAGG SN-M(opt)2701 C..C.....C..C..C......AGC..C..CTCC..C...C.G.....C........C..SN-M(2a) 2761GTCTTTTAGAAAAATCTGTGGATTTGCTACAACACCTACATGTGAATATCAAGGTAATAC SN-M(opt)2761 CAGC..CC.G..G..T.....C..C..C..C..C.....C..C..G..C..G..C..C..SN-M(2a) 2821AGTGTCTGGATTCCAACGCATGATGGCAACTCGAGATTCTTTTCAATCATTCAATGTGAC SN-M(opt)2821 C.....C..C.....G..G........C..C..G...AGC..C..GAGC.....C.....SN-M(2a) 2881AGAACCACATATTACCAGCAATCGACTGGAATGGATTGATCCAGATAGTAGTATTAAAGA SN-M(opt)2881 C..G..C..C..C........C..G...........C..C..C..C..C..C..C..G..SN-M(2a) 2941CCATATCAACATGGTTTTGAATAGAGATGTTTCCTTCCAAGATCTAAGTGATAATCCATG SN-M(opt)2941 ...C...........GC.C...C.G..C..GAG......G..C..G..C..C..C..C..SN-M(2a) 3001TAAGGTTGATTTGCATACACAATCTATTGATGGGGCTTGGGGATCAGGAGTGGGCTTTAC SN-M(opt)3001 C.....G..CC....C..C..GAGC..C..C..C..C.....CAGC..C........C..SN-M(2a) 3061ATTAGTATGTACTGTAGGTCTTACAGAGTGTGCAAATTTCATAACTTCAATTAAGGCGTG SN-M(opt)3061 .C.G..G..C..A..G..C..G..C.....C..C..C.....C..C..C..C.....C..SN-M(2a) 3121TGATTCTGCTATGTGTTATGGGGCCACAGTTACAAATCTACTCAGAGGGTCTAACACAGT SN-M(opt)3121 C..CAGC..C.....C..C..C.....C..G..C..C..G..GC.G..C..C........SN-M(2a) 3181TAAAGTTGTCGGTAAAGGTGGGCATTCTGGGTCCTTGTTCAAGTGCTGCCATGATACTGA SN-M(opt)3181 G..G..G..G..C..G..C..C..CAGC..CAG.C....T...........C..C..C..SN-M(2a) 3241CTGTACTGAAGAAGGTTTAGCAGCATCACCACCTCATTTAGATAGGGTTACTGGTTACAA SN-M(opt)3241 ...C..C..G.....CC.G..C..CAGC..C.....CC.G..C..A..G..C..C.....SN-M(2a) 3301TCAAATAGATTCTGATAAGGTTTATGATGACGGTGCACCGCCCTGTACAATTAAATGTTG SN-M(opt)3301 C..G..C..CAGC..C.....G..C..C..T..C..C..T.....C..C..C..G..C..SN-M(2a) 3361GTTCACAAAGTCAGGTGAGTGGTTGCTAGGAATTCTTAATGGCAATTGGGTAGTAGTTGC SN-M(opt)3361 ......C...AGC..C......C....G..C..C..G..C.....C.....C..C..G..SN-M(2a) 3421TG1TTTGATTGTAATTTTGATACTATCAATACTCCTGTTCAGCTTCTTTTGTCCTGTTAG SN-M(opt)3421 C..GC....C..G..CC....C..G..T..C..G..............C..C..C..GC.SN-M(2a) 3481AAATAGAAAAAATAAGGCCAATTAGCAAACATATATGTAAGTAAGGGTATGATCATATTA SN-M(opt)3481 G..CC.G..G..C........C......................................SN-M(2a) 3541TATCATTATGCGTATACTCTTATATCTATAATATCTATGTATCCTTATACTCTAACTATT SN-M(opt)3541 ............................................................SN-M(2a) 3601TATATTAATTTTTACTTTTATACAAGTATTAACTAACCCATTACCAGCTAAAAAAAACAA SN-M(opt)3601 ............................................................SN-M(2a) 3661ACCCTTAACACCTATATAATCCCATTTGCTTATTACGAGGCTTTTGTTCCTGCGGAGTCT SN-M(opt)3661 ............................................................SN-M(2a) 3721 ACTACTATTCGAA SN-M(opt) 3721 .......AGATCT

This new SNV vaccine was tested for a capacity to elicit neutralzingantibodies by vaccinating rabbits with the pWRG/SN-M(opt) using muscleelectroporation. Very high titers of SNV neutralizing antibodies wereproduced after only a single vaccination.

The term “antibody” is art-recognized terminology and is intended toinclude molecules or active fragments of molecules that bind to knownantigens. These active fragments can be derived from an antibody of thepresent invention by a number of techniques. For further description ofgeneral techniques for the isolation of active fragments of antibodies,see for example, Khaw, B. A. et al. J. Nucl. Med. 23:1011-1019 (1982).The term “antibody” also includes bispecific and chimeric antibodies andantibodies in nonmammalian species.

By neutralizing antibodies, or NAb, it is meant an antibody whichdefends a cell from an antigen or infectious body by inhibiting orneutralizing any effect it has biologically. For instance, aneutralizing antibody for SNV is an antibody which can inhibit or reducethe biological effects of SNV infection, that is, it binds to the virusand interferes with its ability to infect a cell.

By “high titer” it is meant meant neutralizing antibody titers similarto those produced in individuals that were infected with the virus andsurvived. As described in greater detail in the examples, the presentinventors have found that serum from a vaccine immunized with a DNAvaccine comprising the M segment of Sin Nombre virus contains antibodiesable to neutralize Sin Nombre virus.

As used herein the term “immunogenically active” designates the abilityto stimulate an immune response, i.e., to stimulate the production ofantibodies, particularly humoral antibodies, or to stimulate acell-mediated response. For example, the ability to stimulate theproduction of circulating or secretory antibodies or the production of acell-mediated response in local mucosal regions, (e.g., intestinalmucosa), peripheral blood, cerebral spinal fluid or the like. Theeffective immunizing amount of the immunogenically active component(s)of this invention may vary and may be any amount sufficient to evoke animmune response and provide immunological protection against Sin Nombrevirus infection. Amounts where a dosage unit comprises at least about 5micrograms to about 5 milligrams of plasmid DNA are contemplated. Atleast one dosage unit per patient is contemplated herein as avaccination regimen. In some embodiments, two or more dosage units maybe especially useful. The skilled artisan will quickly recognize that aparticular quantity of vaccine composition per dosage unit, as well asthe total number of dosage units per vaccination regimen, may beoptimized, so long as an effective immunizing amount of the virus or acomponent thereof is ultimately delivered to the animal.

We next combined the SNV DNA vaccine with an Andes virus construct,pWRG/AND-M, and a mixture of the two plasmids was used to vaccinaterabbits using muscle electroporation. High titer neutralizing antibodiesagainst both SNV and ANDY were produced after 1 or 2 vaccinations. TheSNV neutralizing activity was especially potent (titers>10,000 after 1vaccination). Thus, the combination of the pWRG/SN-M(opt) DNA vaccineand pWRG/AND-M DNA vaccine effectively elicited high-titer neutralizingantibodies against the most prevalent and lethal hantavirus in North andSouth America. The novelty and potency of this SNV DNA vaccine and itsutility in alone or in combination with other hantavirus DNA vaccineplasmids is a main focus of this application.

The amino acid one letter code is defined as the following: A=Alanine(Ala), I=Isoleucine (Ile), L=Leucine (Leu), M=Methionine (Met),F=Phenylalanine (Phe), P=Proline (Pro), W=Tryptophan (Trp), V=Valine(Val), N=Asparagine (Asn), C=Cysteine (Cys), Q=Glutamine (Q), G=Glycine(Gly), S=Serine (Ser), T=Threonine (Thr), Y=Tyrosine (Tyr), R=Arginine(Arg), H=Histidine (His), K=Lysine (Lys), D=Aspartic acid (Asp), andE=Glutamic acid (Glu).

As would be understood by someone having skill in this art, thisinvention covers sequences that are not necessarily physically derivedfrom the nucleotide sequence itself, but may be generated in any manner,including for example, chemical synthesis or DNA replication or reversetranscription or transcription, which are based on the informationprovided by the sequence bases in the region(s) from which thepolynucleotide is derived. In addition, combinations of regionscorresponding to that of the designated sequence may be modified in waysknown in the art to be consistent with an intended use.

It is also understood in the art that certain changes to the nucleotidesequence employed in a genetic construct have little or no bearing onthe proteins encoded by the construct, for example due to the degeneracyof the genetic code. Such changes result either from silent pointmutations or point mutations that encode different amino acids that donot appreciably alter the behavior of the encoded protein. It isunderstood that portions of the coding region can be eliminated withoutaffecting the ability of the construct to achieve the desired effect,namely induction of a protective immune response against Sin Nombrevirus. It is further understood in the art that certain advantageoussteps can be taken to increase the antigenicity of an encoded protein bymodifying its amino acid composition. Such changes in amino acidcomposition can be introduced by modifying the genetic sequence encodingthe protein. It is contemplated that all such modifications andvariations of the M segment of Sin Nombre virus are equivalents withinthe scope of the present invention.

The DNA encoding the desired antigen can be introduced into the cell inany suitable form including, a linearized plasmid, a circular plasmid, aplasmid capable of replication, an episome, RNA, etc. Preferably, thegene is contained in a plasmid. In a particularly preferred embodiment,the plasmid is an expression vector, such as pWRG7077. In anotherembodiment, the DNA encoding the desired antigen can be introduced intovirus-based vaccine vectors such as recombinant adenovirus, recombinantvesicular stomatitis virus, or alphavirus replicons. Individualexpression vectors capable of expressing the genetic material can beproduced using standard recombinant techniques.

This invention entails new recombinant SNV DNA sequences which areuseful to elicit neutralizing antibodies against SNV. The DNA sequencesinclude the codon-optimized full-length M segment [designated SN-M(opt)](SEQ ID NO:1), the optimized ORF plus M gene flanking sequences (SEQ IDNO:2), and the optimized open reading frame (ORF) (SEQ ID NO:3).

Thus in one embodiment the invention entails an isolated nucleic acidsequence set forth in SEQ ID NO:1, which is as follows. The Sin Nombrevirus M gene (optimized) open reading frame is underlined. The syntheticopen reading frame and flanking sequence was cloned into the Not I, Bg1II site of pWRG7077 (published). The Not 1 cloning site (GCGGCCGCGG)(SEQ ID NO:7) and the Bg1 II cloning site (GATCT) (SEQ ID NO:8) are inbold. An extraneous sequence having the sequence“ATCTGCAGGAATTCGGCACGAG” (SEQ ID NO:9) is in italics. The flankingsequences include 5′ and 3′ non-translated sequence from the SNV Mgenome segment, and a 24-base sequence (the extraneous sequence) betweenthe Not I site and position +2 of the M gene (not +1 because the firstnucleotide is missing). This sequence was found to be essential forexpression of the Gn protein from the Hantaan virus and Seoul virusfull-length M gene-based DNA vaccine plasmids, pWRG/HTN-M(x) andpWRG/SEO-M, respectably. (See U.S. Pat. No. 7,217,812) It is noted thatexperiments demonstrated that this 24-base sequence was not essentialfor expression of Gn from the Puumala M gene-based DNA vaccine plasmidor the Andes M gene-based DNA vaccine plasmid, but was retained in thoseconstructs (See US Patent Application Publication No. 20100323024 andU.S. Pat. No. 7,217,812, respectively).

Two SNV M segment nontranslated regions are indicated by wavy underline,and are between the extraneous sequence and the beginning of the ORF,and between the end of the ORF and the Bg1 II cloning site.

GGGGGGGGGGGGCGCTGAGGTCTGCCTCGTGAAGAAGGTGTTGCTGACTCATACCAGGCCTGAATCGCCCCATCATCCAGCCAGAAAGTGAGGGAGCCACGGTTGATGAGAGCTTTGTTGTAGGTGGACCAGTTGGTGATTTTGAACTTTTGCTTTGCCACGGAACGGTCTGCGTTGTCGGGAAGATGCGTGATCTGATCCTTCAACTCAGCAAAAGTTCGATTTATTCAACAAAGCCGCCGTCCCGTCAAGTCAGCGTAATGCTCTGCCAGTGTTACAACCAATTAACCAATTCTGATTAGAAAAACTCATCGAGCATCAAATGAAACTGCAATTTATTCATATCAGGATTATCAATACCATATTTTTGAAAAAGCCGTTTCTGTAATGAAGGAGAAAACTCACCGAGGCAGTTCCATAGGATGGCAAGATCCTGGTATCGGTCTGCGATTCCGACTCGTCCAACATCAATACAACCTATTAATTTCCCCTCGTCAAAAATAAGGTTATCAAGTGAGAAATCACCATGAGTGACGACTGAATCCGGTGAGAATGGCAAAAGCTTATGCATTTCTTTCCAGACTTGTTCAACAGGCCAGCCATTACGCTCGTCATCAAAATCACTCGCATCAACCAAACCGTTATTCATTCGTGATTGCGCCTGAGCGAGACGAAATACGCGATCGCTGTTAAAAGGACAATTACAAACAGGAATCGAATGCAACCGGCGCAGGAACACTGCCAGCGCATCAACAATATTTTCACCTGAATCAGGATATTCTTCTAATACCTGGAATGCTGTTTTCCCGGGGATCGCAGTGGTGAGTAACCATGCATCATCAGGAGTACGGATAAAATGCTTGATGGTCGGAAGAGGCATAAATTCCGTCAGCCAGTTTAGTCTGACCATCTCATCTGTAACATCATTGGCAACGCTACCTTTGCCATGTTTCAGAAACAACTCTGGCGCATCGGGCTTCCCATACAATCGATAGATTGTCGCACCTGATTGCCCGACATTATCGCGAGCCCATTTATACCCATATAAATCAGCATCCATGTTGGAATTTAATCGCGGCCTCGAGCAAGACGTTTCCCGTTGAATATGGCTCATAACACCCCTTGTATTACTGTTTATGTAAGCAGACAGTTTTATTGTTCATGATGATATATTTTTATCTTGTGCAATGTAACATCAGAGATTTTGAGACACAACGTGGCTTTCCCCCCCCCCCCGGCATGCCTGCAGGTCGACAATATTGGCTATTGGCCATTGCATACGTTGTATCTATATCATAATATGTACATTTATATTGGCTCATGTCCAATATGACCGCCATGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTCCGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTACGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACACCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAATAACCCCGCCCCGTTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAGATCGCCTGGAGACGCCATCCACGCTGTTTTGACCTCCATAGAAGACACCGGGACCGATCCAGCCTCCGCGGCCGGGAACGGTGCATTGGAACGCGGATTCCCCGTGCCAAGAGTGACGTAAGTACCGCCTATAGACTCTATAGGCACACCCCTTTGGCTCTTATGCATGCTATACTGTTTTTGGCTTGGGGCCTATACACCCCCGCTTCCTTATGCTATAGGTGATGGTATAGCTTAGCCTATAGGTGTGGGTTATTGACCATTATTGACCACTCCCCTATTGGTGACGATACTTTCCATTACTAATCCATAACATGGCTCTTTGCCACAACTATCTCTATTGGCTATATGCCAATACTCTGTCCTTCAGAGACTGACACGGACTCTGTATTTTTACAGGATGGGGTCCCATTTATTATTTACAAATTCACATATACAACAACGCCGTCCCCCGTGCCCGCAGTTTTTATTAAACATAGCGTGGGATCTCCACGCGAATCTCGGGTACGTGTTCCGGACATGGGCTCTTCTCCGGTAGCGGCGGAGCTTCCACATCCGAGCCCTGGTCCCATGCCTCCAGCGGCTCATGGTCGCTCGGCAGCTCCTTGCTCCTAACAGTGGAGGCCAGACTTAGGCACAGCACAATGCCCACCACCACCAGTGTGCCGCACAAGGCCGTGGCGGTAGGGTATGTGTCTGAAAATGAGCTCGGAGATTGGGCTCGCACCGCTGACGCAGATGGAAGACTTAAGGCAGCGGCAGAAGAAGATGCAGGCAGCTGAGTTGTTGTATTCTGATAAGAGTCAGAGGTAACTCCCGTTGCGGTGCTGTTAACGGTGGAGGGCAGTGTAGTCTGAGCAGTACTCGTTGCTGCCGCGCGCGCCACCAGACATAATAGCTGACAGACTAACAGACTGTTCCTTTCCATGGGTCTTTTCTGCAGTCACCGTCCAAGCTT

TCTTCCTGGTGGTGCTGACCACCGCCACAGCCGGCCTGACCCGGAACCTGTACGAGCTGAAGATCGAGTGCCCCCACACCGTGGGCCTGGGCCAGGGCTACGTGACCGGCAGCGTGGAGACAACCCCCATCCTGCTGACCCAGGTGGCCGACCTGAAGATTGAGAGCAGCTGCAACTTCGACCTGCACGTGCCCGCCACCACCACCCAGAAATACAACCAGGTGGACTGGACCAAGAAGAGCAGCACCACCGAGAGCACCAACGCCGGAGCCACCACCTTCGAGGCCAAGACCAAAGAAGTGAACCTGAAGGGCACCTGCAACATCCCCCCCACCACATTTGAGGCCGCCTACAAGAGCAGAAAGACCGTGATCTGCTACGACCTGGCCTGCAACCAGACCCACTGCCTGCCCACCGTGCACCTGATCGCCCCCGTGCAGACCTGCATGAGCGTGCGGAGCTGCATGATCGGCCTGCTGTCCAGCCGGATCCAGGTGATCTACGAGAAAACCTACTGCGTGACCGGCCAGCTGATCGAGGGCCTGTGCTTCATCCCCACCCACACAATCGCCCTGACCCAGCCCGGCCACACCTACGACACCATGACCCTGCCCGTGACCTGCTTTCTGGTGGCCAAGAAGCTGGGCACCCAGCTGAAGCTGGCCGTGGAGCTGGAAAAGCTGATCACCGGCGTGAGCTGCACCGAGAACAGCTTCCAGGGCTACTACATCTGCTTCATCGGCAAGCACAGCGAGCCCCTGTTCGTGCCCACCATGGAAGATTACAGAAGCGCCGAGCTGTTCACCCGGATGGTGCTGAACCCCAGGGGCGAGGACCACGACCCCGACCAGAACGGCCAGGGCCTGATGCGGATCGCCGGACCCGTGACCGCCAAGGTGCCCAGCACCGAGACAACCGAAACCATGCAGGGCATTGCCTTCGCCGGAGCCCCCATGTACAGCAGCTTCAGCACCCTGGTGCGGAAGGCCGACCCCGAGTACGTGTTCAGCCCCGGCATCATTGCCGAGAGCAACCACAGCGTGTGCGACAAGAAAACCGTGCCCCTGACCTGGACCGGCTTCCTGGCCGTGAGCGGCGAGATCGAGCGGATCACCGGCTGCACCGTGTTCTGCACCCTGGCCGGACCTGGCGCCAGCTGCGAGGCCTACAGCGAGACAGGCATCTTCAACATCAGCAGCCCCACCTGCCTGGTGAACAAGGTGCAGAAGTTCCGGGGCAGCGAGCAGCGGATCAACTTCATGTGCCAGCGGGTGGACCAGGACGTGGTGGTGTACTGCAACGGCCAGAAAAAAGTGATCCTGACCAAGACCCTGGTGATCGGCCAGTGCATCTACACCTTCACCAGCCTGTTCAGCCTGATCCCTGGCGTGGCTCATAGCCTGGCAGTCGAACTGTGCGTGCCTGGCCTGCACGGATGGGCCACCACCGCCCTGCTGATCACCTTCTGCTTCGGCTGGCTGCTGATCCCCACAGTGACCCTGATCATCCTGAAGATCCTGCGGCTGCTGACCTTCAGCTGCAGCCACTACAGCACCGAGTCCAAGTTCAAAGTGATTCTGGAACGCGTGAAGGTGGAGTACCAGAAAACCATGGGCAGCATGGTGTGCGACATCTGCCACCACGAGTGCGAGACAGCCAAAGAGCTGGAAACCCACAAGAAGAGCTGCCCCGAGGGCCAGTGCCCCTACTGCATGACCATCACAGAGAGCACCGAGAGCGCCCTGCAGGCCCACTTCAGCATCTGCAAGCTGACCAACCGGTTCCAGGAAAACCTGAAGAAGAGCCTGAAGCGGCCCGAAGTGCGGAAGGGCTGCTACCGGACCCTGGGCGTGTTCCGGTACAAGAGCCGGTGCTATGTGGGCCTGGTGTGGGGCATTCTGCTGACCACAGAGCTGATCATCTGGGCCGCCAGCGCCGACACCCCCCTGATGGAAAGCGGGTGGAGCGACACCGCTCATGGCGTGGGAATCGTGCCCATGAAAACCGACCTGGAACTGGACTTCGCCCTGGCCAGCAGCAGCAGCTACAGCTACCGGCGGAAGCTGGTGAACCCCGCCAACCAGGAAGAGACACTGCCCTTCCACTTCCAACTGGACAAGCAGGTGGTGCACGCCGAGATCCAGAACCTGGGCCACTGGATGGACGGCACCTTCAATATCAAGACCGCCTTCCACTGCTACGGCGAGTGCAAGAAGTACGCCTACCCCTGGCAGACCGCCAAGTGCTTCTTCGAGAAGGACTACCAGTACGAGACAAGCTGGGGCTGCAACCCCCCCGACTGTCCTGGCGTGGGCACCGGCTGTACCGCCTGCGGCGTGTACCTGGACAAGCTGCGGAGCGTGGGCAAGGCCTACAAGATCGTGTCCCTGAAGTACACCCGGAAAGTGTGCATCCAGCTGGGCACAGAGCAGACATGCAAGCACATCGACGTGAACGATTGCCTGGTGACCCCCAGCGTGAAAGTCTGTATGATTGGCACCATCAGCAAGCTGCAGCCCGGCGATACCCTGCTGTTCCTGGGCCCCCTGGAACAGGGCGGCATCATTCTGAAGCAGTGGTGTACCACCTCCTGCGTGTTCGGCGACCCCGGCGACATCATGAGCACCACCTCCGGCATGCGGTGCCCCGAGCACACCGGCAGCTTCCGGAAGATTTGTGGCTTCGCCACCACCCCTACCTGCGAGTACCAGGGCAACACCGTGTCCGGCTTCCAGCGGATGATGGCCACCCGGGATAGCTTCCAGAGCTTCAACGTGACCGAGCCCCACATCACCAGCAACCGGCTGGAATGGATCGACCCCGACAGCAGCATCAAGGACCACATCAACATGGTGCTCAATCGGGACGTGAGCTTCCAGGACCTGAGCGACAACCCCTGCAAGGTGGACCTGCACACCCAGAGCATCGACGGCGCCTGGGGCAGCGGCGTGGGCTTCACACTGGTGTGCACAGTGGGCCTGACCGAGTGCGCCAACTTCATCACCTCCATCAAGGCCTGCGACAGCGCCATGTGCTACGGCGCCACCGTGACCAACCTGCTGCGGGGCTCCAACACAGTGAAGGTGGTGGGCAAGGGCGGCCACAGCGGCAGCCTGTTTAAGTGCTGCCACGACACCGACTGCACCGAGGAAGGCCTGGCCGCCAGCCCCCCTCACCTGGACAGAGTGACCGGCTACAACCAGATCGACAGCGACAAGGTGTACGACGATGGCGCCCCTCCCTGCACCATCAAGTGCTGGTTCACCAAGAGCGGCGAGTGGCTGCTGGGCATCCTGAACGGCAACTGGGTCGTCGTGGCCGTGCTGATCGTGATCCTGATCCTGTCTATCCTGCTGTTCAGCTTCTTCTGCCCCGTGCGGAACCGGAAGAACAAGGCCAAC

ACGTATGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGGCTTCTGAGGCGGAAAGAACCAGCTGGGGCTCGACAGCTCGACTCTAGAATTGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCThis is the full-length optimized SNV M gene of pWRG/SN-M(opt). Thenucleic acids outside the Not 1 and Bg1 II cloning sites are notconsidered significant to the use of the SNV M gene.

Another valuable sequence is the isolated nucleic acid sequence of theSNV M gene (optimized) open reading frame plus the flanking sequence, asshown in SEQ ID NO:2, as follows:

GCGGCCGCGGATCTGCAGGAATTCGGCACGAGAGTAGTAGACTCCGCACGAAGAAGCAAACACTGAATAAAGGATATACAGAATGGTGGGCTGGGTGTGCATCTTCCTGGTGGTGCTGACCACCGCCACAGCCGGCCTGACCCGGAACCTGTACGAGCTGAAGATCGAGTGCCCCCACACCGTGGGCCTGGGCCAGGGCTACGTGACCGGCAGCGTGGAGACAACCCCCATCCTGCTGACCCAGGTGGCCGACCTGAAGATTGAGAGCAGCTGCAACTTCGACCTGCACGTGCCCGCCACCACCACCCAGAAATACAACCAGGTGGACTGGACCAAGAAGAGCAGCACCACCGAGAGCACCAACGCCGGAGCCACCACCTTCGAGGCCAAGACCAAAGAAGTGAACCTGAAGGGCACCTGCAACATCCCCCCCACCACATTTGAGGCCGCCTACAAGAGCAGAAAGACCGTGATCTGCTACGACCTGGCCTGCAACCAGACCCACTGCCTGCCCACCGTGCACCTGATCGCCCCCGTGCAGACCTGCATGAGCGTGCGGAGCTGCATGATCGGCCTGCTGTCCAGCCGGATCCAGGTGATCTACGAGAAAACCTACTGCGTGACCGGCCAGCTGATCGAGGGCCTGTGCTTCATCCCCACCCACACAATCGCCCTGACCCAGCCCGGCCACACCTACGACACCATGACCCTGCCCGTGACCTGCTTTCTGGTGGCCAAGAAGCTGGGCACCCAGCTGAAGCTGGCCGTGGAGCTGGAAAAGCTGATCACCGGCGTGAGCTGCACCGAGAACAGCTTCCAGGGCTACTACATCTGCTTCATCGGCAAGCACAGCGAGCCCCTGTTCGTGCCCACCATGGAAGATTACAGAAGCGCCGAGCTGTTCACCCGGATGGTGCTGAACCCCAGGGGCGAGGACCACGACCCCGACCAGAACGGCCAGGGCCTGATGCGGATCGCCGGACCCGTGACCGCCAAGGTGCCCAGCACCGAGACAACCGAAACCATGCAGGGCATTGCCTTCGCCGGAGCCCCCATGTACAGCAGCTTCAGCACCCTGGTGCGGAAGGCCGACCCCGAGTACGTGTTCAGCCCCGGCATCATTGCCGAGAGCAACCACAGCGTGTGCGACAAGAAAACCGTGCCCCTGACCTGGACCGGCTTCCTGGCCGTGAGCGGCGAGATCGAGCGGATCACCGGCTGCACCGTGTTCTGCACCCTGGCCGGACCTGGCGCCAGCTGCGAGGCCTACAGCGAGACAGGCATCTTCAACATCAGCAGCCCCACCTGCCTGGTGAACAAGGTGCAGAAGTTCCGGGGCAGCGAGCAGCGGATCAACTTCATGTGCCAGCGGGTGGACCAGGACGTGGTGGTGTACTGCAACGGCCAGAAAAAAGTGATCCTGACCAAGACCCTGGTGATCGGCCAGTGCATCTACACCTTCACCAGCCTGTTCAGCCTGATCCCTGGCGTGGCTCATAGCCTGGCAGTCGAACTGTGCGTGCCTGGCCTGCACGGATGGGCCACCACCGCCCTGCTGATCACCTTCTGCTTCGGCTGGCTGCTGATCCCCACAGTGACCCTGATCATCCTGAAGATCCTGCGGCTGCTGACCTTCAGCTGCAGCCACTACAGCACCGAGTCCAAGTTCAAAGTGATTCTGGAACGCGTGAAGGTGGAGTACCAGAAAACCATGGGCAGCATGGTGTGCGACATCTGCCACCACGAGTGCGAGACAGCCAAAGAGCTGGAAACCCACAAGAAGAGCTGCCCCGAGGGCCAGTGCCCCTACTGCATGACCATCACAGAGAGCACCGAGAGCGCCCTGCAGGCCCACTTCAGCATCTGCAAGCTGACCAACCGGTTCCAGGAAAACCTGAAGAAGAGCCTGAAGCGGCCCGAAGTGCGGAAGGGCTGCTACCGGACCCTGGGCGTGTTCCGGTACAAGAGCCGGTGCTATGTGGGCCTGGTGTGGGGCATTCTGCTGACCACAGAGCTGATCATCTGGGCCGCCAGCGCCGACACCCCCCTGATGGAAAGCGGGTGGAGCGACACCGCTCATGGCGTGGGAATCGTGCCCATGAAAACCGACCTGGAACTGGACTTCGCCCTGGCCAGCAGCAGCAGCTACAGCTACCGGCGGAAGCTGGTGAACCCCGCCAACCAGGAAGAGACACTGCCCTTCCACTTCCAACTGGACAAGCAGGTGGTGCACGCCGAGATCCAGAACCTGGGCCACTGGATGGACGGCACCTTCAATATCAAGACCGCCTTCCACTGCTACGGCGAGTGCAAGAAGTACGCCTACCCCTGGCAGACCGCCAAGTGCTTCTTCGAGAAGGACTACCAGTACGAGACAAGCTGGGGCTGCAACCCCCCCGACTGTCCTGGCGTGGGCACCGGCTGTACCGCCTGCGGCGTGTACCTGGACAAGCTGCGGAGCGTGGGCAAGGCCTACAAGATCGTGTCCCTGAAGTACACCCGGAAAGTGTGCATCCAGCTGGGCACAGAGCAGACATGCAAGCACATCGACGTGAACGATTGCCTGGTGACCCCCAGCGTGAAAGTCTGTATGATTGGCACCATCAGCAAGCTGCAGCCCGGCGATACCCTGCTGTTCCTGGGCCCCCTGGAACAGGGCGGCATCATTCTGAAGCAGTGGTGTACCACCTCCTGCGTGTTCGGCGACCCCGGCGACATCATGAGCACCACCTCCGGCATGCGGTGCCCCGAGCACACCGGCAGCTTCCGGAAGATTTGTGGCTTCGCCACCACCCCTACCTGCGAGTACCAGGGCAACACCGTGTCCGGCTTCCAGCGGATGATGGCCACCCGGGATAGCTTCCAGAGCTTCAACGTGACCGAGCCCCACATCACCAGCAACCGGCTGGAATGGATCGACCCCGACAGCAGCATCAAGGACCACATCAACATGGTGCTCAATCGGGACGTGAGCTTCCAGGACCTGAGCGACAACCCCTGCAAGGTGGACCTGCACACCCAGAGCATCGACGGCGCCTGGGGCAGCGGCGTGGGCTTCACACTGGTGTGCACAGTGGGCCTGACCGAGTGCGCCAACTTCATCACCTCCATCAAGGCCTGCGACAGCGCCATGTGCTACGGCGCCACCGTGACCAACCTGCTGCGGGGCTCCAACACAGTGAAGGTGGTGGGCAAGGGCGGCCACAGCGGCAGCCTGTTTAAGTGCTGCCACGACACCGACTGCACCGAGGAAGGCCTGGCCGCCAGCCCCCCTCACCTGGACAGAGTGACCGGCTACAACCAGATCGACAGCGACAAGGTGTACGACGATGGCGCCCCTCCCTGCACCATCAAGTGCTGGTTCACCAAGAGCGGCGAGTGGCTGCTGGGCATCCTGAACGGCAACTGGGTCGTCGTGGCCGTGCTGATCGTGATCCTGATCCTGTCTATCCTGCTGTTCAGCTTCTTCTGCCCCGTGCGGAACCGGAAGAACAAGGCCAAGCAAACATATATGTAAGTAAGGGTATGATCATATTATATCATTATGCGTACTATACTCTTATATCTATAATATCTATGTATCCTTATACTCTAACTATTTATATTAATTTTTACTTTTATACAAGTATTAACTAACCCATTACCAGCTAAAAAAAACAAACCCTTAACACCTATATAATCCCATTTGCTTATTACGAGGCTTTTGTTCCTGCGGAGTCTACTACTAAGATCTThe flanking sequences are the cloning sites plus the SNV M segmentnon-translated regions of SEQ ID NO:1, and also includes the “extraneoussequence” at the 5′ end. The first flanking sequence is:

(SEQ ID: NO 5) ATCTGCAGGAATTCGGCACGAGAGTAGTAGACTCCGCACGAAGAAGCAAACACTGAATAAAGGATATACAGA; the second flanking  sequence is (SEQ ID NO: 6)CAAACATATATGTAAGTAAGGGTATGATCATATTATATCATTATGCGTATACTCTTATATCTATAATATCTATGTATCCTTATACTCTAACTATTTATATTAATTTTTACTTTTATACAAGTATTAACTAACCCATTACCAGCTAAAAAAAACAAACCCTTAACACCTATATAATCCCATTTGCTTATTACGAGGCTTTTGTTCCTGCGGAGTCTACTACTAA

Another valuable sequence is the isolated nucleic acid sequence of theSNV M gene (optimized) open reading frame by itself, as shown in SEQ IDNO:3. As a point of reference, the ORF begins with the ATG start codonand ends with the TAG stop codon. SEQ ID NO:3 is as follows:

ATGGTGGGCTGGGTGTGCATCTTCCTGGTGGTGCTGACCACCGCCACAGCCGGCCTGACCCGGAACCTGTACGAGCTGAAGATCGAGTGCCCCCACACCGTGGGCCTGGGCCAGGGCTACGTGACCGGCAGCGTGGAGACAACCCCCATCCTGCTGACCCAGGTGGCCGACCTGAAGATTGAGAGCAGCTGCAACTTCGACCTGCACGTGCCCGCCACCACCACCCAGAAATACAACCAGGTGGACTGGACCAAGAAGAGCAGCACCACCGAGAGCACCAACGCCGGAGCCACCACCTTCGAGGCCAAGACCAAAGAAGTGAACCTGAAGGGCACCTGCAACATCCCCCCCACCACATTTGAGGCCGCCTACAAGAGCAGAAAGACCGTGATCTGCTACGACCTGGCCTGCAACCAGACCCACTGCCTGCCCACCGTGCACCTGATCGCCCCCGTGCAGACCTGCATGAGCGTGCGGAGCTGCATGATCGGCCTGCTGTCCAGCCGGATCCAGGTGATCTACGAGAAAACCTACTGCGTGACCGGCCAGCTGATCGAGGGCCTGTGCTTCATCCCCACCCACACAATCGCCCTGACCCAGCCCGGCCACACCTACGACACCATGACCCTGCCCGTGACCTGCTTTCTGGTGGCCAAGAAGCTGGGCACCCAGCTGAAGCTGGCCGTGGAGCTGGAAAAGCTGATCACCGGCGTGAGCTGCACCGAGAACAGCTTCCAGGGCTACTACATCTGCTTCATCGGCAAGCACAGCGAGCCCCTGTTCGTGCCCACCATGGAAGATTACAGAAGCGCCGAGCTGTTCACCCGGATGGTGCTGAACCCCAGGGGCGAGGACCACGACCCCGACCAGAACGGCCAGGGCCTGATGCGGATCGCCGGACCCGTGACCGCCAAGGTGCCCAGCACCGAGACAACCGAAACCATGCAGGGCATTGCCTTCGCCGGAGCCCCCATGTACAGCAGCTTCAGCACCCTGGTGCGGAAGGCCGACCCCGAGTACGTGTTCAGCCCCGGCATCATTGCCGAGAGCAACCACAGCGTGTGCGACAAGAAAACCGTGCCCCTGACCTGGACCGGCTTCCTGGCCGTGAGCGGCGAGATCGAGCGGATCACCGGCTGCACCGTGTTCTGCACCCTGGCCGGACCTGGCGCCAGCTGCGAGGCCTACAGCGAGACAGGCATCTTCAACATCAGCAGCCCCACCTGCCTGGTGAACAAGGTGCAGAAGTTCCGGGGCAGCGAGCAGCGGATCAACTTCATGTGCCAGCGGGTGGACCAGGACGTGGTGGTGTACTGCAACGGCCAGAAAAAAGTGATCCTGACCAAGACCCTGGTGATCGGCCAGTGCATCTACACCTTCACCAGCCTGTTCAGCCTGATCCCTGGCGTGGCTCATAGCCTGGCAGTCGAACTGTGCGTGCCTGGCCTGCACGGATGGGCCACCACCGCCCTGCTGATCACCTTCTGCTTCGGCTGGCTGCTGATCCCCACAGTGACCCTGATCATCCTGAAGATCCTGCGGCTGCTGACCTTCAGCTGCAGCCACTACAGCACCGAGTCCAAGTTCAAAGTGATTCTGGAACGCGTGAAGGTGGAGTACCAGAAAACCATGGGCAGCATGGTGTGCGACATCTGCCACCACGAGTGCGAGACAGCCAAAGAGCTGGAAACCCACAAGAAGAGCTGCCCCGAGGGCCAGTGCCCCTACTGCATGACCATCACAGAGAGCACCGAGAGCGCCCTGCAGGCCCACTTCAGCATCTGCAAGCTGACCAACCGGTTCCAGGAAAACCTGAAGAAGAGCCTGAAGCGGCCCGAAGTGCGGAAGGGCTGCTACCGGACCCTGGGCGTGTTCCGGTACAAGAGCCGGTGCTATGTGGGCCTGGTGTGGGGCATTCTGCTGACCACAGAGCTGATCATCTGGGCCGCCAGCGCCGACACCCCCCTGATGGAAAGCGGGTGGAGCGACACCGCTCATGGCGTGGGAATCGTGCCCATGAAAACCGACCTGGAACTGGACTTCGCCCTGGCCAGCAGCAGCAGCTACAGCTACCGGCGGAAGCTGGTGAACCCCGCCAACCAGGAAGAGACACTGCCCTTCCACTTCCAACTGGACAAGCAGGTGGTGCACGCCGAGATCCAGAACCTGGGCCACTGGATGGACGGCACCTTCAATATCAAGACCGCCTTCCACTGCTACGGCGAGTGCAAGAAGTACGCCTACCCCTGGCAGACCGCCAAGTGCTTCTTCGAGAAGGACTACCAGTACGAGACAAGCTGGGGCTGCAACCCCCCCGACTGTCCTGGCGTGGGCACCGGCTGTACCGCCTGCGGCGTGTACCTGGACAAGCTGCGGAGCGTGGGCAAGGCCTACAAGATCGTGTCCCTGAAGTACACCCGGAAAGTGTGCATCCAGCTGGGCACAGAGCAGACATGCAAGCACATCGACGTGAACGATTGCCTGGTGACCCCCAGCGTGAAAGTCTGTATGATTGGCACCATCAGCAAGCTGCAGCCCGGCGATACCCTGCTGTTCCTGGGCCCCCTGGAACAGGGCGGCATCATTCTGAAGCAGTGGTGTACCACCTCCTGCGTGTTCGGCGACCCCGGCGACATCATGAGCACCACCTCCGGCATGCGGTGCCCCGAGCACACCGGCAGCTTCCGGAAGATTTGTGGCTTCGCCACCACCCCTACCTGCGAGTACCAGGGCAACACCGTGTCCGGCTTCCAGCGGATGATGGCCACCCGGGATAGCTTCCAGAGCTTCAACGTGACCGAGCCCCACATCACCAGCAACCGGCTGGAATGGATCGACCCCGACAGCAGCATCAAGGACCACATCAACATGGTGCTCAATCGGGACGTGAGCTTCCAGGACCTGAGCGACAACCCCTGCAAGGTGGACCTGCACACCCAGAGCATCGACGGCGCCTGGGGCAGCGGCGTGGGCTTCACACTGGTGTGCACAGTGGGCCTGACCGAGTGCGCCAACTTCATCACCTCCATCAAGGCCTGCGACAGCGCCATGTGCTACGGCGCCACCGTGACCAACCTGCTGCGGGGCTCCAACACAGTGAAGGTGGTGGGCAAGGGCGGCCACAGCGGCAGCCTGTTTAAGTGCTGCCACGACACCGACTGCACCGAGGAAGGCCTGGCCGCCAGCCCCCCTCACCTGGACAGAGTGACCGGCTACAACCAGATCGACAGCGACAAGGTGTACGACGATGGCGCCCCTCCCTGCACCATCAAGTGCTGGTTCACCAAGAGCGGCGAGTGGCTGCTGGGCATCCTGAACGGCAACTGGGTCGTCGTGGCCGTGCTGATCGTGATCCTGATCCTGTCTATCCTGCTGTTCAGCTTCTTCTGCCCCGTGCGGAACCGGAAGAACAAGGCCAACTAG

SEQ ID NO:2 and SEQ ID NO:3 are especially useful as a DNA cassette. Thepreferred cassette is the SNV optimized M gene cassette in the SNV-M(opt) (preferably taken from the Not 1 site to the Bg1II site, orminimally the ORF (SEQ ID NO:3) operably linked to a promoter) which canbe subcloned into any other vaccine/expression system available, andused to generate active or passive immunity against SN virus. The DNAcassette specifically includes at least SEQ ID NO:2 linked to a promoteroperable in a eukaryotic expression system. Alternatively, the DNAcassette includes the sequence in SEQ ID NO:3 (within pWRG/SN-M(opt))from the ATG start codon to the TAG stop codon.

The peptide encoded by DNA sequence SEQ ID NO:3 is as follows: SN-M(opt)amino acid sequence

MVGWVCIFLVVLTTATAGLTRNLYELKIECPHTVGLGQGYVTGSVETTPILLTQVADLKIESSCNFDLHVPATTTQKYNQVDWTKKSSTTESTNAGATTFEAKTKEVNLKGTCNIPPTTFEAAYKSRKTVICYDLACNQTHCLPTVHLIAPVQTCMSVRSCMIGLLSSRIQVIYEKTYCVTGQLIEGLCFIPTHTIALTQPGHTYDTMTLPVTCFLVAKKLGTQLKLAVELEKLITGVSCTENSFQGYYICFIGKHSEPLFVPTMEDYRSAELFTRMVLNPRGEDHDPDQNGQGLMRIAGPVTAKVPSTETTETMQGIAFAGAPMYSSFSTLVRKADPEYVFSPGIIAESNHSVCDKKTVPLTWTGFLAVSGEIERITGCTVFCTLAGPGASCEAYSETGIFNISSPTCLVNKVQKFRGSEQRINFMCQRVDQDVVVYCNGQKKVILTKTLVIGQCIYTFTSLFSLIPGVAHSLAVELCVPGLHGWATTALLITFCFGWLLIPTVTLIILKILRLLTFSCSHYSTESKFKVILERVKVEYQKTMGSMVCDICHHECETAKELETHKKSCPEGQCPYCMTITESTESALQAHFSICKLTNRFQENLKKSLKRPEVRKGCYRTLGVFRYKSRCYVGLVWGILLTTELIIWAASADTPLMESGWSDTAHGVGIVPMKTDLELDFALASSSSYSYRRKLVNPANQEETLPFHFQLDKQVVHAEIQNLGHWMDGTFNIKTAFHCYGECKKYAYPWQTAKCFFEKDYQYETSWGCNPPDCPGVGTGCTACGVYLDKLRSVGKAYKIVSLKYTRKVCIQLGTEQTCKHIDVNDCLVTPSVKVCMIGTISKLQPGDTLLFLGPLEQGGIILKQWCTTSCVFGDPGDIMSTTSGMRCPEHTGSFRKICGFATTPTCEYQGNTVSGFQRMMATRDSFQSFNVTEPHITSNRLEWIDPDSSIKDHINMVLNRDVSFQDLSDNPCKVDLHTQSIDGAWGSGVGFTLVCTVGLTECANFITSIKACDSAMCYGATVTNLLRGSNTVKVVGKGGHSGSLFKCCHDTDCTEEGLAASPPHLDRVTGYNQIDSDKVYDDGAPPCTIKCWFTKSGEWLLGILNGNWVVVAVLIVILILSILLFSFFCPVRNRKNKAN

There are four residues that are altered in the M(opt) from the M(2a): Kat position 27, T at position 241, D at position 434, and S at position519. The enhanced immunogenicity of pWRG/SN-M(opt) vs pWRG/SN-M(2a) isspeculated to be due to the nucleic acid changes, one or more of thefour amino acid changes, or a combination thereof.

In another embodiment, the invention entails a recombinant DNA constructcomprising:

(i) a vector, and

(ii) the DNA fragment comprising the nucleic acid sequence set forth inSEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3, or a DNA fragment comprising anucleic acid sequence that encodes the amino acid sequence set forth inSEQ ID NO:4, operably linked to a promoter sequence.

As would be understood by someone having skill in this art, the DNAconstructs of our invention will have all necessary structuralcomponents for expression of the DNA fragment of interest (e.g.,promoters functional in mammals, and the like). The vector can take theform of a plasmid such as pCRII (Invitrogen) or pJW4303 (Konishi, E. etal., 1992, Virology 188:714), or any expression vector such as viralvectors e.g. adenovirus or Venezuelan equine encephalitis virus andothers known in the art. Preferably the vector is a recombinantadenovirus or recombinant vesicular stomatitis virus, or alphavirusreplicon. Preferably, a promoter sequence operable in the target cell isoperably linked to the DNA sequence. Several such promoters are knownfor mammalian systems which may be joined 5′, or upstream, of the codingsequence for the encoded protein to be expressed. A suitable andpreferred promoter is the human cytomegalovirus immediate earlypromoter, preferably operably linked to intron A. Another preferredpromoter is the beta-actin promoter or the SV40 promoter. A downstreamtranscriptional terminator, or polyadenylation sequence, such as thepolyA addition sequence of the bovine growth hormone gene, may also beadded 3′ to the protein coding sequence.

Preferably, the construct is the pWRG/SN-M(opt) DNA vaccine plasmid,whose sequence is set forth above and referred to as SEQ ID NO:1.

In a further embodiment, the present invention relates to host cellsstably transformed or transfected with the above-described recombinantDNA constructs. The host cell can be prokaryotic such as Bacillus or E.coli, or eukaryotic such a Saccharomyces or Pichia, or mammalian cellsor insect cells. The vector containing the Sin Nombre virus M genesequence is expressed in the bacteria and the expressed product used fordiagnostic procedures or as a vaccine. Please see e.g., Maniatis et al.,1985 Molecular Cloning: A Laboratory Manual or DNA Cloning, Vol. I andII (D. N. Glover, ed., 1985) for general cloning methods. The DNAsequence can be present in the vector operably linked to a highlypurified IgG molecule, an adjuvant, a carrier, or an agent for aid inpurification of Sin Nombre virus proteins or peptides. The transformedor transfected host cells can be used as a source of DNA sequencesdescribed above. When the recombinant molecule takes the form of anexpression system, the transformed or transfected cells can be used as asource of the protein or peptide encoded by the DNA. The DNA can be usedas circular or linear, or linearized plasmid as long as the Sin Nombrevirus sequences are operably linked to a promoter which can be expressedin the transfected cell.

In another embodiment, the invention entails vaccines against infectionwith Sin Nombre virus. In a method for eliciting in a subject an immuneresponse against Sin Nombre virus, the method comprises administering toa subject a DNA fragment comprising a genome segment of hantavirus. Inone preferred embodiment, the vaccine composition comprises an effectiveimmunizing amount of SNV plasmid DNA, which plasmid DNA comprises one ormore of the recombinant DNA constructs described above, and apharmacologically acceptable carrier. That is, the recombinant DNAconstruct should minimally include (i) a vector, and (ii) the DNAfragment comprising the nucleic acid sequence set forth in SEQ ID NO:1,SEQ ID NO:2 or SEQ ID NO:3, or a DNA fragment comprising a nucleic acidsequence that encodes the amino acid sequence set forth in SEQ ID NO:4.The DNA fragment is operably linked to a promoter sequence. Thepharmacologically acceptable carrier may be any carrier that is known inthe art, which is safe and effective for a SNV DNA vaccine. Examples ofsuch carriers include PBS, water, saline, Tris-EDTA, and mixtures ofthese.

The vaccine composition may which further comprise an adjuvant. Theadjuvant may be any one that is known in the art, which is safe andeffective for a SNV DNA vaccine. As used herein the term “adjuvant”refers to any component which improves the body's response to a vaccine.The adjuvant will typically comprise about 0.1 to 50% vol/vol of thevaccine formulation of the invention, more preferably about 1 to 50% ofthe vaccine, and even more desirably about 1 to 20% thereof. Examples ofsuch adjuvants include CpG (cystein-phosphate-guanine) oligodeoxynucleicacid, or plasmid DNA-encoded heat labile enterotoxins, or alum.

The immunizing amount of SNV plasmid DNA is preferably between about 5micrograms (e.g., with gene gun administration) and about 5 milligrams(e.g., electroporation or other forms of administration). By “immunizingamount”, it is meant the amount of vaccine or immunogenic compositionthat is needed to raise high titers of neutralizing antibodies inresponse to the composition.

One unique aspect of our invention is that it can further comprise oneor more additional vaccine components of other hantaviruses, to make abi-valent, tri-valent, multivalent or pan-virus vaccine. In oneembodiment, a DNA vaccine is contemplated that elicits an immuneresponse against multiple HPS-associated hantaviruses and protectsagainst more than one HPS virus. Such a DNA vaccine comprises one of theSNV sequences described above (SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3),in combination with an HPS hantavirus M gene DNA vaccine (such as M geneDNA vaccine from one or more of Black Creek Canal virus, Bayou virus,New York virus, Andes virus and Laguna Negra virus) such that each Mgene is expressed in the subject. The respective M gene DNA sequencesmay each be part of respective recombinant constructs that each include(i) a vector and (ii) the desired DNA fragment that is operably linkedto a promoter sequence. A preferred HPS virus is Andes virus.

In another embodiment, a DNA vaccine elicits an immune response againstboth HFRS and HPS hantavirus and protects against all the hantavirusescausing severe disease by providing to a subject a DNA vaccinecomprising one of the SNV sequences described above (SEQ ID NO:1, SEQ IDNO:2 or SEQ ID NO:3), in combination with at least one HFRS hantavirus Mgene DNA vaccine (such as Hantaan M gene DNA vaccine, Puumala M gene DNAvaccine, Seoul M gene DNA vaccine and Dobrava M gene DNA) such that eachM gene is expressed in the subject. Furthermore, the M gene DNA vaccinefrom one or more of another HPS-associated virus (such as Black CreekCanal virus, Bayou virus, New York virus, Andes virus and Laguna Negravirus) may be included, to strengthen the HPS component. The respectiveM gene DNA sequences may each be part of respective recombinantconstructs that each include (i) a vector and (ii) the desired DNAfragment that is operably linked to a promoter sequence.

The SNV M gene or the other HPS or HFRS M gene may be administeredseparately, i.e. on seperate vectors, or may be combined on the samevector as is described in one aspect of this invention. For instance, apan-HPS virus vaccine can include any of SEQ ID NO:1, SEQ ID NO:2, orSEQ ID NO:3, and a suitable Andes M gene sequence (in whole, or an ORFwith flanking sequences, or simply the ORF). A preferred Andes M genesequence is SEQ ID NO:10, which is the full-length ANDY M gene describedin U.S. Pat. No. 7,217,812 (and the sequence is referred to as SEQ IDNO:8 therein).

A preferred Puumala M gene sequence is SEQ ID NO:11, which is thefull-length PUUV M gene described in U.S. patent publication number20100323024 (and the sequence is referred to as SEQ ID NO: 1 therein). Apreferred Hantaan M gene sequence is SEQ ID NO:12, which is thefull-length HNTV M gene described in U.S. Pat. No. 7,217,812 (and thesequence is referred to as SEQ ID NO:7 therein). A preferred Seoul Mgene sequence is SEQ ID NO:13, which is the full-length Seoul M genedescribed in U.S. Pat. No. 7,217,812 (and the sequence is referred to asSEQ ID NO:3 therein). The preferred HPS/HFRS vaccine combinationincludes Hantaan, Puumala, Andes, and Sin Nombre DNA vaccines, althoughSeoul DNA vaccine is also a good component for the combined vaccine. Anyof these M genes can be used in full-length, or just the ORF withflanking sequences, or simply the ORF. As someone skilled in this artwould understand, this invention entailing the combination of hantavirusM genes is not limited at all to these specific M genes—these are merelyexamples, and any M gene isolated or derived or improved or otherwisealtered from the hantavirus (e.g., an altered Seoul M gene, or anon-optimized Puumala M gene).

The vaccine may involve the delivery of pWRG/SN-M(opt) DNA (SEQ IDNO:1), or the DNA of SEQ ID NO:2 or SEQ ID NO:3 (or, if a multivalentvaccine is employed, one or more of the above-described sequences of theother HPS- or HFRS-associated viruses) by any of several platforms usedto deliver gene-based vaccines. For example, the vaccine could comprisea composition comprising inert particles and a nucleic acid coated ontothe inert particles producing nucleic acid coated particles. The nucleicacid will comprise a promoter operative in the cells of a mammal andfurther comprise (or even consist essentially of or consist of) SEQ IDNO:1, SEQ ID NO:2 or SEQ ID NO:3. As would be understood by someonehaving skill in this art, the ORF sequence (SEQ ID NO:3) is essential(and for the other HPS- or HFRS-associated viruses, the ORF of therespective M gene). The flanking region between the cloning sites andthe ORF are preferably included, as they may be helpful for efficientexpression. The inert particle may be gold particles, silver particles,platinum particles, tungsten particles, polystyrene particles,polypropylene particles, polycarbonate particles, and the like, as wouldbe understood by someone having ordinary skill in this art. Inparticular, it is preferred that the inert particle is suitable for usein a gene gun.

The invention further encompasses a method for inducing a protectiveimmune response against Sin Nombre virus infection in a mammal,comprising the step of accelerating into epidermal cells of the mammalin vivo a composition comprising inert particles and a nucleic acidcoated onto the inert particles producing nucleic acid coated particles,such that said nucleic acid is expressed (e.g., gene gunadministration). The nucleic acid will comprise a promoter effective andfunctional in the cells of a mammal and SEQ ID NO:1, SEQ ID NO:2 or SEQID NO:3.

Electroporation is another method of administration. Electroporationinvolves injecting plasmid DNA into a tissue (e.g. muscle or skin) andthen applying micropulses of an electric field causing transientpermeability of the cells of the vaccine. This transient permeabilityallows for a more efficient take-up of the DNA vaccine plasmid.

In a more general method for inducing a protective immune responseagainst Sin Nombre virus infection in a mammal, a composition isadministered to a mammal comprising a nucleic acid comprising a promoteroperative in the cells of a mammal and one of SEQ ID NO: 1, SEQ ID NO:2or SEQ ID NO:3. It is generally preferred that the chosen sequence beinserted into a plasmid, and the plasmid administered. To that end,preferably the nucleic acid is a component of one of theabove-referenced DNA constructs. However, it is known that a linearpiece of DNA consisting of only a promoter and the gene-of-interest canelicit an immune response. Thus, one option for the composition is thatit comprises SEQ ID NO: 1, SEQ ID NO:2 or SEQ ID NO:3 plus anappropriate promoter. One preferred method comprises the step ofadministering a composition comprising an effective immunizing amount ofSNV plasmid DNA, which plasmid DNA comprises one of the recombinant DNAconstruct described above; and a pharmacologically acceptable carrier.Another preferred method comprises the step of administering acomposition comprising an effective immunizing amount of EQ ID NO: 1,SEQ ID NO:2 or SEQ ID NO:3 operably linked to a promoter operative inthe cells of a mammal plus an appropriate promoter; and apharmacologically acceptable carrier. Appropriate pharmacologicallyacceptable carriers are discussed elsewhere in this document.Preferably, the immunizing amount of SNV plasmid DNA is between about 5micrograms and about 5 milligrams.

In another embodiment, this invention provides a method for raising hightiters of neutralizing antibodies against Sin Nombre virus in a mammalor a bird. The method comprises the step of administering a compositioncomprising a SNV plasmid DNA which comprises one or more of therecombinant DNA constructs described above (including SEQ ID NO:1, SEQID NO:2 or SEQ ID NOT:3); and a pharmacologically acceptable carrier.Preferably, the titers are at least 100, and more preferably are atleast 10,000. As someone having ordinary skill in this art wouldrecognize, in the context of hantavirus infection, titers with a levelof at least 100 are significant, and considered “high” because they are10 times higher than the minimal titer of 10 that has been used toevaluate vaccines against HFRS (a titer of 10 indicates there was a 50%reduction in plaque forming units when virus was combined with serum fora final dilution of 1:10). Titers of >10,000 are similar to thoseproduced in person who have developed HPS and survived.

High titers are obtained even with only one dose or administration ofthe composition, although additional doses or vaccinations can boosttiters even higher. The pharmacologically acceptable carrier can be anysuch carrier known in the art which is safe and does not hampereffectiveness of the composition. Examples are mentioned above, andthroughout this document. The amount of the composition required forraising high titers of neutralizing antibodies is between about 5micrograms and about 5 milligrams. The inventors discovered that thecomposition was effective in both mammals and birds.

The invention also encompasses post-exposure prophylactics, or passivevaccines, for treating or preventing Sin Nombre virus infections, forsomeone who has already been exposed to Sin Nombre virus and may beinfected. Polyclonal antibodies may be obtained using methods known inthe art, from a population of vaccines (human or animal) vaccinated witha Sin Nombre virus DNA vaccine comprised of a plasmid expressing SEQ IDNO:1, SEQ ID NO:2 or SEQ ID NO; 3, such as pWRG/SN-M(opt).Alternatively, polyclonal or monoclonal antibodies could be produced inanimals using the pWRG/SN-M(opt) plasmid, or a plasmid containing SEQ IDNO:2 or SEQ ID NO:3, operably associated with a promoter and any otherelements needed for expression of the sequence. The methods entailadministration of a therapeutically or prophylactically effective amountof the antibodies which protect against Sin Nombre virus disease incombination with a pharmaceutically acceptable carrier or excipient. Forinstance, a therapeutic composition for ameliorating symptoms of SinNombre virus infection may comprise a composition comprising thesepolyclonal antibodies, and a pharmaceutically acceptable excipient. Forinstance, pWRG/SN-M(opt) may be used to vaccinate ducks, sheep, ortransgenic cows or rabbits to produce polyclonal neutralizing antibodiesfor use in humans.

The invention also entails a method for diagnosis of Sin Nombre virusinfection by assaying for the presence of Sin Nombre virus in a sampleusing the above-described antibodies. For instance, a method for thediagnosis of Sin Nombre virus infection may comprise the steps of:

(i) contacting a sample from an individual suspected of having SinNombre virus infection with a composition comprising the polyclonalantibodies (e.g., the pWRG/SN-M(opt) plasmid could be used to producediagnostic antibodies in any of several species of animals—goats,rabbits, etc.); and

(ii) detecting the presence or absence of Sin Nombre virus infection bydetecting the presence or absence of a complex formed between Sin Nombrevirus antigens and antibodies specific therefor.

In addition, the invention encompasses novel immunoprobes and test kitsfor detection of Sin Nombre virus infection comprising antibodiesaccording to the present invention. For immunoprobes, the antibodies aredirectly or indirectly attached to a suitable reporter molecule, e.g.,and enzyme or a radionuclide. The test kit includes a container holdingone or more antibodies according to the present invention andinstructions for using the antibodies for the purpose of binding to SinNombre virus to form an immunological complex and detecting theformation of the immunological complex such that presence or absence ofthe immunological complex correlates with presence or absence of SinNombre virus. For instance, the kit may include kit may include acontainer holding one or more polyclonal antibodies of the presentinvention which binds a Sin Nombre virus antigen, and ancillary reagentssuitable for use in detecting Sin Nombre virus antigens, andinstructions for using any of the antibodies or polyclonal antibodiesdescribed herein for the purpose of binding to SNV antigen to form animmunological complex and detecting the formation of the immunologicalcomplex such that the presence or absence of the immunological complexcorrelates with presence or absence of Sin Nombre virus antigens in thesample. Examples of containers include multiwell plates which allowsimultaneous detection of Sin Nombre virus in multiple samples.

Further, the invention contemplates a method for producing pseudotypedviruses for use in serologic assays or delivery of gene therapies toendothelial cells targeted by hantavirus glycoproteins. The invention asused for this purpose would comprise the following steps. The plasmidpWRG/SN-M(opt) or derivative thereof would be used to transfect cells orstably transform cells. Cells expressing the Sin Nombre glycoproteinscould then be infected with viruses engineered to produce progeny thatincorporate the Sin Nombre glycoproteins into progeny virus surfaceenvelopes. Pseudotype virus systems include retrovirus systems andvesicular stomatitis virus systems. Pseudotypes have been produced usingthe hantavirus full-length M gene plasmids, including pWRG/SN-M(opt).The pseudotypes can be used for testing for neutralizing antibodies.They also may be used to deliver genes to endothelial cells in aclinical setting. For example, gene therapy viruses containing the SinNombre glycoproteins on their surface will target to certain endothelialcells.

The invention also entails a therapeutic composition for amelioratingsymptoms of Sin Nombre virus infection. The composition includespolyclonal or monoclonal antibodies specifically raised against one ofSEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3. The composition may be combinedwith a pharmaceutically acceptable carrier and/or an adjuvant, such asthe examples as described herein.

Other embodiments are discussed below. The invention is described infurther detail by the non-limiting examples and text below.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1A-1D. Hantavirus neutralizing antibodies produced in rabbitsvaccinated with full-length hantavirus M gene-based DNA vaccines usingmuscle electroporation. FIG. 1A: Hantaan, Puumala, and Andes DNAvaccines. Groups of 3 rabbits were vaccinated with either the HantaanDNA vaccine, pWRG/HTN-M(x) (described in U.S. Pat. No. 7,217,812), orthe Puumala DNA vaccine, pWRG/PUU-M(s2) (described in U.S. PatentPublication No. 20100323024) on days 0, 14, 28, and 32 by muscleelectroporation (Invoio Elgen device, dose was 0.4 mg of DNA perinjection. Sera were collected on weeks 0, 28, 56, and 116 and tested inhomotypic PRNT. Symbols represent the mean of two separate PRNT±SE. FIG.1B: The same data from panel A were combined to show mean titers for thegroups. In addition, published data from rabbits vaccinated with theAndes DNA vaccine, pWRG/AND-M, are included. Note the vaccination dayswere different for the Andes DNA vaccine (shown in grey arrows). FIG.1C: Sin Nombre DNA vaccines. The first generation SNV full-length M genebased DNA vaccine, pWRG/SNV-M(2a), was tested in three rabbits. Theanimals were vaccinated four times (arrows) and sera were tested for SNVneutralizing antibodies. High-titer neutralizing antibody could beproduced after multiple vaccinations. The second generation plasmid,pWRG/SN-M(opt), was tested in rabbits. Rabbits were vaccinated on days0, 28, 56 and 84. Sera collected on the indicated days were tested forSNV neutralizing antibodies. High-titers were achieved after 2, orfewer, vaccinations (sera from day 28 was not collected). FIG. 1D: Thesame data from panel C were combined to show mean titers for thegroups±SE.

FIGS. 2A and 2B. Neutralizing antibody data from rabbits vaccinated withpWRG/SN-M(opt) (also designated as pWRG/SN-M(opt)). Rabbits werevaccinated on days 0, 28, 56 and 84. Sera collected on days 0, 56, and70 where tested for Sin Nombre virus neutralizing antibodies by plaquereduction neutralization test (PRNT). The neutralizing antibody titersare shown. FIG. 2A. The titers are the reciprocal of the highestdilution reducing the number of plaques in the media alone wells by 80%.FIG. 2B. Raw plaque numbers for one representative rabbit are shownbefore vaccination, after 2 (day 56) and after 3 (day 70). Note thatthere is 100% neutralization out to a 1:10,240 dilution for the day 70serum. The numbers 6281, 6282, 6283, and 5284 are designations for thedifferent rabbits vaccinated.

FIGS. 3A and 3B. HPS vaccine. Plasmid mixtures were tested in rabbitsusing muscle electroporation (EP). Three rabbits were vaccinated bymuscle EP on day 0, 21, and 42 with a 1:1 mixture of the pWRG/SN-M(opt)and pWRG/AND-M DNA (described in U.S. Pat. No. 7,217,812) vaccineplasmids. Sera were collected at the indicated time points and plaquereduction neutralization tests (PRNT) were performed. Neutralizingantibodies were produced against both SNV and ANDY after a singlevaccination. Overall, the neutralizing antibody titers were greateragainst SNV (shown in FIG. 3A) than ANDY (shown in FIG. 3B) Device=IchorTri-grid device; Dose=2.0 mg mixed DNA/injection, 1 injection pervaccination. (Unpublished) The numbers 6214, 6215, and 6216 aredesignations for the different rabbits vaccinated.

FIG. 4A-4C. Mixed hantavirus DNA vaccines are feasible. Three mixturesof hantavirus DNA vaccine plasmids delivered by muscle electroporationwere tested in rabbits. FIG. 4A: Experimental design. Groups of threerabbits were vaccinated three times by muscle electroporation using theIchor Tri-grid at three-week intervals. The HFRS mixture was comprisedof equal volumes of Hantaan and Puumala DNA vaccine plasmids,pWRG/HTN-M(x) and pWRG/PUU-M(s2), respectively. The HPS mixture wascomprised of equal volumes of Andes and Sin Nombre DNA vaccine plasmids,pWRG/AND-M and pWRG/SN-M(opt), respectively. The HFRS/HPS mixture wascomprised of equal volumes of the Hantaan, Puumala, Andes, and SinNombre DNA vaccine plasmids. The mixtures contained 1 mg of each plasmidper dose. FIG. 4B: Neutralizing antibody titers for individual rabbitsare shown. The virus used in the neutralization test is shown on they-axis. Sera from days 0, 21, 42, and 63 were tested. FIG. 4C: Meanneutralizing titers for each group plus/minus standard error. The datademonstrate that it is possible to mix hantavirus DNA vaccines into asingle-injection vaccine and produce neutralizing antibodies againstmultiple hantaviruses. The HFRS DNA vaccine was more effective atneutralizing Puumala virus and Hantaan virus and the HPS DNA vaccine wasmore effective at neutralizing Andes virus and Sin Nombre virus. TheHFRS/HPS DNA vaccine elicited neutralizing antibodies against all fourhantaviruses after a single vaccination for all but one rabbit.

FIG. 5. PRNT80 GMT against HTNV, PUUV, SNV, and ANDY for each DNAvaccine formulation after 1, 2, or 3 vaccinations are shown. These dataare from the same experiment shown in FIG. 2; however PRNT80 GMT areshown here. PRNT80 titers are a more stringent measure of neutralizingantibodies that PRNT50. The HFRS mix (pWRG/HTN-M[x] and pWRG/PUU-M[s2])produced GMTs>100 against HTNV and PUUV. The HPS mix (pWRG/SN-M[opt] andpWRG/AND-M) produced GMTs>100 against SNV and ANDY. And the HFRS/HPS mix“pan-hantavirus” produced GMTs>100 against all four hantaviruses. PUUVPRNT endpoints after 1 vaccination were not determined beyond 640(indicated by ≧). < indicates GMT was below detection. These datademonstrate the utility of using the SN DNA vaccine as part of HPSvaccine or a pan-hantavirus DNA vaccine.

FIGS. 6A and 6B. pWRG/SN-M(opt) DNA vaccine is immunogenic andprotective in hamsters. Groups of 7-8 hamsters received 2 vaccinations(week 0, 3), or three vaccinations (week 0, 3, 6) with pWRG/SN-M(opt),or 3 vaccinations with a negative control DNA vaccine, or no vaccine.Vaccinations were performed using a gene gun. FIG. 6A: Sera collected onweek 9 were tested for SNV neutralizing antibody by SNV PRNT. Eachsymbol represents the PRNT50 titer of an individual hamster. Thegeometric mean titer and 95% confidence interval for each group areshown. The limit of detection was a titer of 20 (dashed line).Seroconversion rates after 2 or 3 vaccinations were 62.5% (5 of 8) and71.4% (5 of 7), respectively. The immune response was lower than what weobserved in rabbits using electroporation, but was nevertheless evidencethat the pWRG/SN-M(opt) plasmid was immunogenic in hamsters. FIG. 6B:The hamsters were challenged with 200 pfu of SNV by the intramuscularroute on week 11. Sera were collected on week 16 and tested by ELISA forevidence of SNV infection (note that SNV infects hamsters but is notlethal). A positive ELISA indicates the hamsters were infected with SNV(i.e., not protected). 2 vaccinations with pWRG/SN-M(opt) protected62.5% of the hamsters and 3 vaccinations protected 100% of the hamsters.All of the negative control hamsters were infected. < indicates titerwas below level of detection.

FIG. 7. The pWRG/SN-M(opt) plasmid was used to make pseudovirions thatwere specifically neutralized by rabbit sera containing SNV neutralizingantibodies. 293T cells were transfected with pWRG/SN-M(opt) and then,after 24 hr, were “infected” with recombinant vesicular stomatitis virus(VSV) that had the G protein deleted and replaced with the Renillaluciferase gene (VSV deltaG luciferase reporter core virus system wasprovided by Robert Doms, University of Pennsylvania). After 48 hr at 37C, the supernatant was harvested and pseudovirion particles werepurified on a sucrose gradient. Two different preparations ofpseudovirions (prep 1, top panel; prep 2, bottom panel) where then mixedwith serial dilutions of naïve rabbit sera, anti-SNV rabbit sera, oranti-VSV-G antibody (as control) and incubated for 1 hr at 37 C. Themixtures were then used to infect BHK cells in a 96-well format for 24hours. Cell lysates were harvested, combined with luciferase substrate,and the luciferase reporter activity in Relative Luminescent Units (RLU)was measured using a luminometer. Symbols represent the average value ofduplicates. The data demonstrate that the anti-SNV rabbit sera, but notthe other sera, reduced the RLU activity (neutralized the pseudovirions)in a dose dependent manor. This assay can be used to measure SNVneutralizing antibodies in any sera including humans vaccinated withcandidate HPS vaccines, or naturally infected with hantaviruses

FIG. 8. The nonoptimized version of the Sin Nombre DNA vaccine,pWRG/SN-M(2a), was tested for the capacity to produce neutralizingantibodies in an avian species. Ducks were vaccinated with 0.4 mg ofplasmid DNA using muscle electroporation on days 0, 14, and 42. Sera wascollected on days 0, 28, and 56 and tested for SNV neutralizingantibodies by PRNT. Higher titers are expected using the optimizedpWRG/SN-M(opt) plasmid. These data demonstrate that the Sin Nombre DNAvaccine can be used to produce high titer neutralizing antibodies inavian species. This antibody is reasonably expected to be purified fromeggs and may be used in humans or other mammals as post-exposureprophylactics or therapeutics, or as diagnostic reagents. The duck IgYnaturally loses the Fc fragment of the antibody and this, it isbelieved, will make the molecule less reactogenic when used in a humanas a therapeutic or post-exposure prophylactic.

DETAILED DESCRIPTION OF THE INVENTION

Supplemental to the previous description of the invention, the followingfurther details are provided.

The inventor has created a novel, synthetic codon optimized Sin Nombrevirus full-length M gene, ORF plus flanking sequences, and ORF, that areeach stably maintained in a DNA vaccine plasmid, and elicit goodneutralizing antibodies in animal models. Heretofore, there was no fulllength Sin Nombre M gene clone stably inserted it on an expressionplasmid, which could be successfully expressed. Likewise, this is thefirst time any vaccine, of any kind, has been shown to elicit high titerneutralizing antibodies and protect against SNV infection in an animalmodel.

The inventor cloned the full-length M gene from SNV, strain CC107 into aDNA vaccine vector (i.e., RNA was purified, reverse transcribed to cDNA,PCR amplified, and cloned into a DNA vaccine plasmid [pWRG7077]).Ultimately, the inventor was able to produce a unique plasmid with anintact open reading frame (designated pWRG/SN-M(2a) or “M(2a)”). It wasconfirmed that this plasmid could produce the Gn and Gc protein in cellculture. pWRG/SN-M(2a) was tested for immunogenicity in rabbits usingmuscle electroporation technology. Three rabbits were vaccinated onweeks 0, 2, 4, 6 with 0.4 mg of DNA per vaccination. Sera were collectedon weeks 0, 4, and 8. PRNT were performed to detect SNV neutralizingantibodies. The data demonstrated that high-titer neutralizing antibodywere produced after 4 vaccinations (FIG. 1). The titers reached wereover 10,000, which is considered are similar to those produced in personwho have developed HPS and survived. In the art of immunology, andespecially regarding hantaviruses, any titer over 100 would beconsidered good, and useful for vaccine purposes. This was the firsttime high-titer SNV neutralizing antibodies were ever produced by anyvaccine, confirming the uniqueness of the M(2a) plasmid. Nevertheless,one undesirable result was that the M(2a) required more vaccinations toraise high-titers than the inventor's previous hantavirus vaccines,namely the HTNV, PUUV, or ANDY M gene-based DNA vaccines.

In an attempt to improve immunogenicity and potency, the M(2a) plasmidwas refined by (1) first determining any possible flaws in the openreading frame and (2) obtaining the synthesis of a codon-optimizedversion of the SNV M gene. The inventor analyzed the M gene sequence inpWRG/SN-M(2a) and discovered amino acids that were unique to the clone(i.e., not in published GeneBank SNV M sequences) (Table 1). Heidentified consensus amino acids at these positions and then had anoptimized version of this gene synthesized (work contracted toGeneArt)(Table 2). Next, the synthetic M gene was cloned into a DNAvaccine vector and the resultant plasmid was named pWRG/SN-M(opt) (or“M(opt)”). The sequence of the pWRG/SN-M(opt) plasmid is given in SEQ IDNO:1. M(opt) was tested for a capacity to elicit neutralizing antibodiesby vaccinating rabbits with the pWRG/SN-(opt) using muscleelectroporation. Four rabbits were vaccinated on weeks 0, 4, and 8 with1 mg of DNA per vaccination. Sera were collected on weeks 0, 8 and 10.PRNT were performed to detect SNV neutralizing antibodies. Very hightiters of SNV neutralizing antibodies were produced after only 2vaccinations (week 8 sera) with pWRG/SN-M(opt) (FIG. 2) After 3vaccinations (week 10 sera) there was 100% neutralization in all fourrabbits even when the sera was diluted ≧1:5,000. This was a significantimprovement over the M(2a) results—2 vaccinations is consideredacceptable to be convenient enough for human or animal use.

Having found the pWRG/SN-M(opt) to be a potent DNA vaccine, the inventornext combined the SNV DNA vaccine with the pWRG/AND-M. A mixture of thetwo plasmids was used to vaccinate rabbits using muscle electroporation.High titer neutralizing antibodies against both SNV and ANDY wereproduced after 1 or 2 vaccinations (FIG. 3). The SNV neutralizingactivity was especially potent (titers>10,000 after 1 vaccination).Thus, the combination of the pWRG/SN-M(opt) DNA vaccine and pWRG/AND-MDNA vaccine effectively elicited high-titer neutralizing antibodiesagainst the most prevalent and lethal hantavirus in North and SouthAmerica. The novelty and potency of this SNV DNA vaccine was surprisingand unexpected.

In summary, the inventor produced two plasmids that elicited high titerneutralizing antibodies against SNV in animal models. Thus, one point ofnovelty of the invention is that it elicits Sin Nombre virusneutralizing antibodies, and with significantly high titers. To the bestof the inventor's knowledge, there is no other SNV vaccine that elicitsantibodies that directly neutralize Sin Nombre virus.

Vaccines and Immunogenic Compositions

To summarize, the vaccines and immunogenic compositions comtemplated bythis invention include: (1) Sin Nombre virus vaccines and immunogeniccompositions; (2) Sin Nombre virus+other HPS viruses (e.g., Andes virus)vaccines and immunogenic compositions; (3) Sin Nombre virus vaccines andimmunogenic compositions+HFRS viruses (e.g., Puumula and Hantaanviruses) vaccines and immunogenic compositions; and (4) Sin Nombrevirus+other HPS viruses (e.g., Andes virus) vaccines and immunogeniccompositions+HFRS viruses (e.g., Puumula and Hantaan viruses) vaccinesand immunogenic compositions. These vaccines and immunogeniccompositions, when transfected into mammalian cells, result in theexpression of proteins that mimic the Gn and Gc surface glycoproteins ofSNV and the other hantaviruses targeted. When these DNA vaccines orimmunogenic compositions are introduced into the cells of a vaccine, thevaccine produces a neutralizing antibody response against SNV, and, ifrelevant, the other hantavirus(es). Neutralizing antibody responses aresufficient to confer protection against SNV and the other hantaviruses.Thus, SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, and derivatives thereof,represent a candidate vaccine for the prevention of HPS caused by SNV.Moreover, these novel sequences, and derivatives thereof, can be used togenerate anti-SNV immunotherapeutics and diagnostic antibodies inanimals. (The term transfected is used herein to refer to cells whichhave incorporated the delivered foreign DNA vaccine, whichever deliverytechnique is used.)

As noted above, there is no vaccine or drug to prevent or treat HPS. Oneof the embodiments of the invention described herein is a DNA vaccinebased on the M-gene segment of Sin Nombre virus. The M genome segmentencodes the two proteins found on the virus surface.

One embodiment of the invention encompasses DNA vaccines. DNAvaccination involves administering antigen-encoding polynucleotides invivo to induce the production of a correctly folded antigen(s) withinthe target cells. The introduction of the DNA vaccine will cause to beexpressed within those cells the structural protein determinantsassociated with the pathogen protein or proteins. The processedstructural proteins will be displayed on the cellular surface of thetransfected cells in conjunction with the Major HistocompatibilityComplex (MHC) antigens of the normal cell. Even when cell-mediatedimmunity is not the primary means of preventing infection, it is likelyimportant for resolving established infections. Furthermore, thestructural proteins released by the expressing transfected cells canalso be picked up by antigen-presenting cells to trigger systemichumoral antibody responses.

The DNA vaccine according to the present invention is inherently safe,is not painful to administer, and should not result in adverse sideeffects to the vaccinated individual. In addition, the invention doesnot require growth or use of Sin Nombre virus, which is a biosafetylevel 3 (BSL-3) virus, and is a BSL-4 virus if the virus is grown tohigh levels or used in animals.

In order to achieve the immune response sought, a DNA vaccine constructcapable of causing transfected cells of the vaccinated individual toexpress one or more major viral antigenic determinant is necessary. Thiscan be done by identifying regions of the viral genome which code forviral glycoproteins or capsid components, and joining such codingsequences to promoters capable of expressing the sequences in cells ofthe vaccine. Alternatively, the viral genome itself, or parts of thegenome, can be used.

In a preferred embodiment, the vaccine is a plasmid basedcodon-optimized Sin Nombre virus (SNV) M gene open reading frame. The Mgene encodes for two proteins that form a part of the viral capsid. Innature these are glycosylated during synthesis in mammalian cells whichwould occur after vaccination. SNV is one of several viruses that causeHantavirus Pulmonary Syndrome, a disease with high mortality (20-50%).There have been several hundred cases in the Americas over the pastseveral years. This vaccine has been shown to induce high neutralizingantibody titers in animals and therefore would be useful for a humanvaccine. Two hantavirus DNA vaccines—Hantaan and Puumala—have been shownto induce neutralizing antibodies in human clinical trials.(Presentation given: “Preclinical and Phase 1 Clinical Studies of a DNAVaccine for HFRS Caused by Hantaviruses” J. Hooper, to the AmericanSociety of Microbiology Biodefense Meeting, held in Baltimore, February,2010)

As noted above, attempts to produce SNV vaccine that produceneutralizing antibodies against SNV have been unsuccessful. Here, forthe first time, the inventor has synthesized a codon-optimizedfull-length M gene open reading frame and cloned it into a DNA vaccineexpression vector (e.g., pWRG-SN-M(opt)). The nucleotide sequences arecompletely unique because the ORF has been optimized. Regarding thepreferred embodiment pWRG/SN-M(opt), hamsters and rabbits vaccinatedwith pWRG/SN-M(opt) using a gene gun developed neutralizing antibodiesas measured by plaque reduction neutralization test (PRNT) with PRNT50titers ranging from 10,240-over 81,920 in rabbits by electroporation; inhamsters, less than 20-1,280 by gene gun. This is believed to be thefirst candidate SNV vaccine that successfully elicits neutralizingantibodies against SNV.

In its preferred vaccine embodiment, the SNV virus M gene-based DNAvaccine is a plasmid that consists of a well-characterized backbone thatenables expression of the above-described synthentic, codon-optimized,SNV virus full-length M gene, or the ORF with or without flankingsequences. Preferred examples are SEQ ID NO:1, SEQ ID NO:2 and SEQ IDNO:3. It can be used in other vaccine systems and systems for generatingSNV neutralizing antibodies.

In this application we describe the elicitation of protective immunityto SNV alone or with other hantaviruses by DNA vaccines. The gene(s) ofinterest, in our case, a synthetic Sin Nombre virus M gene having atleast one of the sequences identified herein as SEQ ID NO:1, SEQ IDNO:2, and SEQ ID NO:3, is controlled by a mammalian or virus promoter(e.g., the cytomegalovirus immediate early promoter followed by intronA) that facilitates expression of the naked DNA gene product(s) withinthe vaccine's cells. Preferably, Intron A is included. It is preferredeven to use pWRG/SN-M(opt) as the DNA vaccine plasmid. Thisintracellular expression can elicit both humoral and cell-mediatedimmune responses (Robinson and Torres, 1997, supra; and Gregoriadis,1998, supra). Methods of DNA delivery include needle inoculation,needle-free jet injection, oral or pulmonary delivery, and inoculationby particle bombardment (i.e., gene gun) and electroporation—bywell-known methods for each. Needle inoculation and needle-free jetinjection may be made with or without electroporation. Delivery may beintramuscular or intradermal, as appropriate.

A suitable construct for use in the method of the present invention ispWRG7077 (4326 bp)(PowderJect Vaccines, Inc., Madison, Wis.). pWRG7077includes a human cytomegalovirus (hCMV) immediate early promoter (IE)and a bovine growth hormone polyA addition site. Between the promoterand the polyA addition site is Intron A, a sequence that naturallyoccurs in conjunction with the hCMV IE promoter that has beendemonstrated to increase transcription when present on an expressionplasmid. Downstream from Intron A, and between Intron A and the polyAaddition sequence, are unique cloning sites into which the hantavirus MDNA can be cloned. Also provided on pWRG7077 is a gene that confersbacterial host-cell resistance to kanamycin. Any of the fragments thatencode hantavirus Gn and/or Gc or nucleocapsid peptides can be clonedinto one of the cloning sites in pWRG7077, using methods known to theart.

The DNA can be delivered by injection into the tissue of the recipient,oral or pulmonary delivery and inoculation by particle bombardment(i.e., gene gun). Any of these methods can be used to deliver DNA aslong as the DNA is expressed and the desired antigen is made in thecell. Two methods are exemplified in this application, both shown to besuccessful in eliciting a protective immune response in the vaccine.

In one aspect of the invention, the DNA vaccine is delivered by coatinga small carrier particle with the DNA vaccine and delivering theDNA-coated particle into an animal's epidermal tissue via particlebombardment. This method may be adapted for delivery to either epidermalor mucosal tissue, or delivery into peripheral blood cells, and thus maybe used to induce humoral, cell-mediated, and secretory immune reponsesin the vaccinated individual.

To deliver DNA vaccines by particle bombardment, we chose to use thePowderJect-XR™ gene gun device described in WO 95/19799, 27 Jul. 1995.Other instruments are available and known to people in the art. Thisinstrument, which delivers DNA-coated gold beads directly into epidermalcells by high-velocity particle bombardment, was shown to moreefficiently induce both humoral and cell-mediated immune responses, withsmaller quantities of DNA, than inoculation of the same DNAs by otherparenteral routes (Eisenbraun, M. et al., 1993, DNA Cell. Biol. 12: 791;Fynan, E. F. et al., 1993, Proc. Natl. Acad. Sci. USA 90: 11478; Haynes,J. R. et al., 1994, AIDS Res. Hum. Retroviruses 10: Suppl. 2:S43;Pertmer, T. M. et al., 1995, Vaccine 13: 1427). Epidermal inoculation ofthe DNA candidate vaccines also offers the advantages of gene expressionin an immunologically active tissue that is generally exfoliated within15 to 30 days, and which is an important natural focus of viralreplication after tick-bite (Bos, J. D., 1997, Clin. Exp. Immunol. 107Suppl. 1:3; Labuda, M. et al., 1996, Virology 219:357; Rambukkana, A. etal., 1995, Lab. Invest. 73:521; Stingl, G., 1993, Recent Results CancerRes. 128:45; Evans et al., Vaccine, 2009, Vol. 27(18), pp. 2506-2512;Yager et al., Expert Rev. Vaccines, 2009, Vol. 8(9), pp. 1205-1220).

The technique of accelerated particles gene delivery or particlebombardment is based on the coating of DNA to be delivered into cellsonto extremely small carrier particles, which are designed to be smallin relation to the cells sought to be transformed by the process. TheDNA sequence containing the desired gene can be simply dried onto asmall inert particle. The particle may be made of any inert materialsuch as an inert metal (gold, silver, platinum, tungsten, etc.) or inertplastic (polystyrene, polypropylene, polycarbonate, etc.). Preferably,the particle is made of gold, platinum or tungsten. Most preferably, theparticle is made of gold. suitably, the particle is spherical and has adiameter of 0.5 to 5 microns, preferably 1 to 3 microns.

The DNA sequence containing the desired gene prepared in the formsuitable for gene introduction can be simply dried onto naked gold ortungsten pellets. However, DNA molecules in such a form may have arelatively short period of stability and may tend to degrade ratherrapidly due to chemical reactions with the metallic or oxide substrateof the particle itself. Thus, if the carrier particles are first coatedwith an encapsulating agent, the DNA strands have greatly improvedstability and do not degrade significantly even over a time period ofseveral weeks. A suitable encapsulating agent is polylysine (molecularweight 200,000) which can be applied to the carrier particles before theDNA molecules are applied. Other encapsulating agents, polymeric orotherwise, may also be useful as similar encapsulating agents, includingspermidine. The polylysine is applied to the particles by rinsing thegold particles in a solution of 0.02% polylysine and then air drying orheat drying the particles thus coated. Once the metallic particlescoated with polylysine were properly dried, DNA strands are then loadedonto the particles.

The DNA is loaded onto the particles at a rate of between 0.5 and 30micrograms of DNA per milligram of gold bead spheres. A preferable ratioof DNA to gold is 0.5 5.0 ug of DNA per milligram of gold. A sampleprocedure begins with gamma irradiated (preferably about 30 kGy) tefzeltubing. The gold is weighed out into a microfuge tube, spermidine (freebase) at about 0.05 M is added and mixed, and then the DNA is added. A10% CaCl solution is incubated along with the DNA for about 10 minutesto provide a fine calcium precipitate. The precipitate carries the DNAwith it onto the beads. The tubes are microfuged and the pelletresuspended and washed in 100% ethanol and the final product resuspendedin 100% ethanol at 0.0025 mg/ml PVP. The gold with the DNA is thenapplied onto the tubing and dried.

The general approach of accelerated particle gene transfectiontechnology is described in U.S. Pat. No. 4,945,050 to Sanford. Aninstrument based on an improved variant of that approach is availablecommercially from PowderJect Vaccines, Inc., Madison Wis., and isdescribed in WO 95/19799. All documents cited herein supra and infra arehereby incorporated in their entirety by reference thereto. Briefly, theDNA-coated particles are deposited onto the interior surface of plastictubing which is cut to a suitable length to form sample cartridges. Asample cartridge is placed in the path of a compressed gas (e.g., heliumat a pressure sufficient to dislodge the particles from the cartridgee.g., 350 400 psi). The particles are entrained in the gas stream andare delivered with sufficient force toward the target tissue to enterthe cells of the tissue. Further details are available in the publishedapparatus application.

The coated carrier particles are physically accelerated toward the cellsto be transformed such that the carrier particles lodge in the interiorof the target cells. This technique can be used either with cells invitro or in vivo. At some frequency, the DNA which has been previouslycoated onto the carrier particles is expressed in the target cells. Thisgene expression technique has been demonstrated to work in prokaryotesand eukaryotes, from bacteria and yeasts to higher plants and animals.Thus, the accelerated particle method provides a convenient methodologyfor delivering genes into the cells of a wide variety of tissue types,and offers the capability of delivering those genes to cells in situ andin vivo without any adverse impact or effect on the treated individual.Therefore, the accelerated particle method is also preferred in that itallows a DNA vaccine capable of eliciting an immune response to bedirected both to a particular tissue, and to a particular cell layer ina tissue, by varying the delivery site and the force with which theparticles are accelerated, respectively. This technique is thusparticularly suited for delivery of genes for antigenic proteins intothe epidermis.

A DNA vaccine can be delivered in a non-invasive manner to a variety ofsusceptible tissue types in order to achieve the desired antigenicresponse in the individual. Most advantageously, the genetic vaccine canbe introduced into the epidermis. Such delivery, it has been found, willproduce a systemic humoral immune response.

To obtain additional effectiveness from this technique, it may also bedesirable that the genes be delivered to a mucosal tissue surface, inorder to ensure that mucosal, humoral and cellular immune responses areproduced in the vaccinated individual. There are a variety of suitabledelivery sites available including any number of sites on the epidermis,peripheral blood cells, i.e. lymphocytes, which could be treated invitro and placed back into the individual, and a variety of oral, upperrespiratory, and genital mucosal surfaces.

Gene gun-based DNA immunization achieves direct, intracellular deliveryof DNA, elicits higher levels of protective immunity, and requiresapproximately three orders of magnitude less DNA than methods employingstandard inoculation.

Moreover, gene gun delivery allows for precise control over the leveland form of antigen production in a given epidermal site becauseintracellular DNA delivery can be controlled by systematically varyingthe number of particles delivered and the amount of DNA per particle.This precise control over the level and form of antigen production mayallow for control over the nature of the resultant immune response.

The invention further covers passive vaccines for treating or preventingSin Nombre virus infections comprising a therapeutically orprophylactically effective amount of the antibodies of the presentinvention which protect against Sin Nombre virus disease in combinationwith a pharmaceutically acceptable carrier or excipient. As described ingreater detail herein, the present inventor has found that serum from avaccine immunized with a DNA vaccine comprising the Sin Nombre virus Msegment described above contains antibodies able to neutralize SinNombre virus and display in vitro and in vivo Sin Nombre virusneutralization properties.

The invention also contemplates a new recombinant DNA vaccine approachthat involves vaccination with naked DNA expressing individual SinNombre virus genome segment cDNAs. Naked DNA vaccination involvesdelivery of plasmid DNA constructs with a gene(s) of interest into thetissue of the vaccine (reviewed in Robinson and Torres, 1997, Semin.Immunol. 9, 271-283; and Gregoriadis, 1998, Pharm. Res. 15, 661-670).DNA vaccination mimicks the de novo antigen production and MHC classI-restricted antigen presentation obtainable with live vaccines, withoutthe risks of pathogenic infection. Also, this DNA vaccine approachallows delivery to mucosal tissues which may aid in conferringresistance to viral introduction since entry of the virus may be throughmucosal tissues.

This vaccine was also tested for a capacity to elicit neutralizingantibodies in rabbits using muscle electroporation as the means ofvaccine delivery. The electroporation device and dose of DNA deliveredis compatible with human use (Ichor Tri-grid device). Well-known methodsof electroporation are effective for this DNA vaccine. For instance,Hooper et al. (February 2008), describes methods useful for this.(Hooper et al., “Immune Serum Produced by DNA Vaccination ProtectsHamsters against Lethal Respiratory Challenge with Andes Virus”, J.Virology, February 2008, Vol. 82, No. 3, pp. 1332-1338; also see, vanDrunen, et al., Expert Rev. Vaccines, 2010, Vol. 9(5), pp. 503-517). Inaddition, mammals such as rabbits can be vaccinated by muscleelectroporation with a DNA vaccine plasmid such as pWRG/SN-M(opt) torapidly generate sera containing high-titer SNV neutralizing antibodies.Sera can be collected and tested for neutralizing antibodies by PRNT.

Vaccination with the SNV M gene-based DNA vaccine, calledpWRG/SN-M(opt), elicits high-titer neutralizing antibodies. It is widelybelieved in the field that neutralizing antibodies are surrogateendpoints of protective immunity, so any vaccine that elicits high-titerneutralizing antibodies has utility as a vaccine. This vaccine could beused to immunize against North American HPS. In addition, it could becombined with other hantavirus DNA vaccines to create a pan-hantavirusvaccine. In short, the plasmid containing the synthetic codon-optimizedSNV M gene is exceedingly effective at eliciting neutralizingantibodies.

For a HPS vaccine composition or immunogenic composition, thecomposition will have at least one of the above-described SNV sequences(SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3), plus at least one otherM-gene (e.g., whole full-length or ORF or ORF plus flanking sequences)from a different (non-SNV) HPS. Examples of other HPS viruses includeBlack Creek Canal virus, Bayou virus, New York virus, Andes virus, andLaguna Negra virus. A preferred HPS vaccine or immunogenic compositioncomprises at least one of the above-described SNV sequences, and theAndes M-gene—preferably plasmid pWRG/AND-M(x) (SEQ ID NO:10), below:

gggggggggg ggcgctgagg tctgcctcgt gaagaaggtg   40ttgctgactc ataccaggcc tgaatcgccc catcatccag   80ccagaaagtg agggagccac ggttgatgag agctttgttg  120taggtggacc agttggtgat tttgaacttt tgctttgcca  160cggaacggtc tgcgttgtcg ggaagatgcg tgatctgatc  200cttcaactca gcaaaagttc gatttattca acaaagccgc  240cgtcccgtca agtcagcgta atgctctgcc agtgttacaa  280ccaattaacc aattctgatt agaaaaactc atcgagcatc  320aaatgaaact gcaatttatt catatcagga ttatcaatac  360catatttttg aaaaagccgt ttctgtaatg aaggagaaaa  400ctcaccgagg cagttccata ggatggcaag atcctggtat  440cggtctgcga ttccgactcg tccaacatca atacaaccta  480ttaatttccc ctcgtcaaaa ataaggttat caagtgagaa  520atcaccatga gtgacgactg aatccggtga gaatggcaaa  560agcttatgca tttctttcca gacttgttca acaggccagc  600cattacgctc gtcatcaaaa tcactcgcat caaccaaacc  640gttattcatt cgtgattgcg cctgagcgag acgaaatacg  680cgatcgctgt taaaaggaca attacaaaca ggaatcgaat  720gcaaccggcg caggaacact gccagcgcat caacaatatt  760ttcacctgaa tcaggatatt cttctaatac ctggaatgct  800gttttcccgg ggatcgcagt ggtgagtaac catgcatcat  840caggagtacg gataaaatgc ttgatggtcg gaagaggcat  880aaattccgtc agccagttta gtctgaccat ctcatctgta  920acatcattgg caacgctacc tttgccatgt ttcagaaaca  960actctggcgc atcgggcttc ccatacaatc gatagattgt 1000cgcacctgat tgcccgacat tatcgcgagc ccatttatac 1040ccatataaat cagcatccat gttggaattt aatcgcggcc 1080tcgagcaaga cgtttcccgt tgaatatggc tcataacacc 1120ccttgtatta ctgtttatgt aagcagacag ttttattgtt 1160catgatgata tatttttatc ttgtgcaatg taacatcaga 1200gattttgaga cacaacgtgg ctttcccccc ccccccggca 1240tgcctgcagg tcgacaatat tggctattgg ccattgcata 1280cgttgtatct atatcataat atgtacattt atattggctc 1320atgtccaata tgaccgccat gttgacattg attattgact 1360agttattaat agtaatcaat tacggggtca ttagttcata 1400gcccatatat ggagttccgc gttacataac ttacggtaaa 1440tggcccgcct ggctgaccgc ccaacgaccc ccgcccattg 1480acgtcaataa tgacgtatgt tcccatagta acgccaatag 1520ggactttcca ttgacgtcaa tgggtggagt atttacggta 1560aactgcccac ttggcagtac atcaagtgta tcatatgcca 1600agtccgcccc ctattgacgt caatgacggt aaatggcccg 1640cctggcatta tgcccagtac atgaccttac gggactttcc 1680tacttggcag tacatctacg tattagtcat cgctattacc 1720atggtgatgc ggttttggca gtacaccaat gggcgtggat 1760agcggtttga ctcacgggga tttccaagtc tccaccccat 1800tgacgtcaat gggagtttgt tttggcacca aaatcaacgg 1840gactttccaa aatgtcgtaa taaccccgcc ccgttgacgc 1880aaatgggcgg taggcgtgta cggtgggagg tctatataag 1920cagagctcgt ttagtgaacc gtcagatcgc ctggagacgc 1960catccacgct gttttgacct ccatagaaga caccgggacc 2000gatccagcct ccgcggccgg gaacggtgca ttggaacgcg 2040gattccccgt gccaagagtg acgtaagtac cgcctataga 2080ctctataggc acaccccttt ggctcttatg catgctatac 2120tgtttttggc ttggggccta tacacccccg cttccttatg 2160ctataggtga tggtatagct tagcctatag gtgtgggtta 2200ttgaccatta ttgaccactc ccctattggt gacgatactt 2240tccattacta atccataaca tggctctttg ccacaactat 2280ctctattggc tatatgccaa tactctgtcc ttcagagact 2320gacacggact ctgtattttt acaggatggg gtcccattta 2360ttatttacaa attcacatat acaacaacgc cgtcccccgt 2400gcccgcagtt tttattaaac atagcgtggg atctccacgc 2440gaatctcggg tacgtgttcc ggacatgggc tcttctccgg 2480tagcggcgga gcttccacat ccgagccctg gtcccatgcc 2520tccagcggct catggtcgct cggcagctcc ttgctcctaa 2560cagtggaggc cagacttagg cacagcacaa tgcccaccac 2600caccagtgtg ccgcacaagg ccgtggcggt agggtatgtg 2640tctgaaaatg agctcggaga ttgggctcgc accgctgacg 2680cagatggaag acttaaggca gcggcagaag aagatgcagg 2720cagctgagtt gttgtattct gataagagtc agaggtaact 2760cccgttgcgg tgctgttaac ggtggagggc agtgtagtct 2800gagcagtact cgttgctgcc gcgcgcgcca ccagacataa 2840tagctgacag actaacagac tgttcctttc catgggtctt 2880ttctgcagtc agggtccaag cttgcggccg cggatctgca 2920ggaattcggc acgagagtag tagactccgc acgaagaagc 2960aaaaaattaa agaagtgagt ttaaaatgga agggtggtat 3000ctggttgttc ttggagtctg ctatacgctg acactggcaa 3040tgcccaagac catttatgag cttaaaatgg aatgcccgca 3080cactgtgggt ctcggtcaag gttacatcat tggctcaaca 3120gaactaggtt tgatctcaat tgaggctgca tctgatataa 3160agctcgagag ctcttgcaat tttgatcttc atacaacatc 3200tatggcccag aagagtttca cccaagttga atggagaaag 3240aaaagtgaca caactgatac cacaaatgct gcgtccacta 3280cctttgaagc acaaactaaa actgttaacc ttagagggac 3320ttgtatactg gcacctgaac tctatgatac attgaagaaa 3360gtaaaaaaga cagtcctgtg ctatgatcta acatgtaatc 3400aaacacattg tcagccaact gtctatctga ttgcacctgt 3440attgacatgc atgtcaataa gaagttgtat ggctagtgtg 3480tttacaagca ggattcaggt gatttatgaa aagacacatt 3520gtgtaacagg tcagctgatt gagggtcagt gtttcaaccc 3560agcacacaca ttgacattat ctcagcctgc tcacacttat 3600gatactgtca cccttcctat ctcttgtttt ttcacaccaa 3640agaagtcgga gcaactaaaa gttataaaaa catttgaagg 3680aattctgacg aagacaggtt gcacggagaa tgcattgcag 3720ggttattatg tgtgtttttt agggagtcat tcagaacctt 3760taattgttcc gagtttggag gacatacggt ctgctgaagt 3800tgttagtagg atgcttgtac accctagggg agaagaccat 3840gatgccatac agaattcaca aagtcactta agaatagtgg 3880gacctatcac agcaaaagtg ccatcaacta gttccacaga 3920taccctaaag gggacagcct ttgcaggcgt cccaatgtat 3960agctctttat ctacactagt cagaaatgca gacccagaat 4000ttgtattttc tccaggtata gtacctgaat ctaatcacag 4040tacatgtgat aagaagacag tacctatcac atggacaggc 4080tacctaccaa tatcaggtga gatggaaaaa gtgactggat 4120gtacagtttt ttgtacacta gcaggacctg gtgctagttg 4160tgaggcctat tctgaaaatg gtatatttaa catcagttct 4200ccaacatgtc ttgtaaacaa agtccaaaga tttcgtggat 4240ctgaacagaa aataaatttt atctgtcagc gggtagatca 4280ggatgttgtt gtatactgca atgggcaaaa gaaagtcata 4320ttaaccaaaa ctttggttat tgggcagtgt atttatacat 4360tcacaagcct attttcattg atgcctgatg tagcccactc 4400attggctgta gaattatgtg tcccgggatt acatgggtgg 4440gccactgtca tgcttctatc aacattctgc tttgggtggg 4480tcttgattcc tgcggtcaca ttaataatat taaagtgtct 4520aagggttttg acgttttctt gttcccatta cactaatgag 4560tcaaaattta aattcatcct ggaaaaagtt aaaattgaat 4600accaaaagac tatgggatca atggtgtgcg atgtatgtca 4640tcatgagtgt gaaacagcaa aagaacttga atcacataga 4680cagagttgta tcaatggaca atgtccttat tgcatgacaa 4720taactgaagc aactgaaagt gccttgcaag cccattattc 4760catttgtaaa ttggcaggaa gatttcagga ggcactgaaa 4800aagtcactta aaaagccaga ggtaaaaaaa ggttgttaca 4840gaacactcgg ggtatttaga tataaaagta gatgttatgt 4880gggtttggta tggtgcctat tgttgacatg tgaaattgtt 4920atttgggccg caagtgcaga gactccacta atggagtcag 4960gctggtcaga tacggctcat ggtgttggtg agattccaat 5000gaagacagac ctcgagctgg acttttcact gccttcttca 5040tcctcttaca gttataggag aaagctcaca aacccagcca 5080ataaagaaga gtctattccc ttccacttcc agatggaaaa 5120acaagtaatt catgctgaaa tccaacccct gggtcattgg 5160atggatgcga catttaatat taagactgca tttcattgtt 5200atggtgcatg ccagaaatac tcttatccat ggcagacatc 5240taagtgcttc tttgaaaagg actaccagta tgaaacaggc 5280tggggctgta atcctggtga ctgcccaggg gttgggactg 5320gatgcactgc ttgtggtgtt tatctcgata aactaaaatc 5360tgttgggaag gcctataaga taatttcttt aaaatatacc 5400agaaaggttt gtattcagtt aggaacagaa caaacttgca 5440agcatattga tgcaaatgat tgtttagtga caccatctgt 5480gaaagtttgc atagtgggca cagtttcaaa acttcaacca 5520tctgatactc ttttgttctt aggtccacta gaacaagggg 5560gaatcattct taagcaatgg tgcacaacat catgtgcatt 5600tggggaccct ggtgatatca tgtccactcc cagtggtatg 5640aggtgtccag agcacactgg atcatttagg aaaatttgcg 5680gttttgctac tacaccagtt tgtgaatatc aaggaaatac 5720catttctgga tataaaagaa tgatggcaac aaaagattca 5760ttccaatcat ttaacttaac agaacctcac atcacaacaa 5800acaagcttga atggatcgac ccagatggga atacaagaga 5840ccacgtaaac cttgtcttaa atagagatgt ctcatttcag 5880gatttaagtg ataacccctg taaagtagac ctacacacac 5920aagcaataga aggggcatgg ggttctggtg tagggtttac 5960actcacatgt actgtcggat taacagagtg cccaagtttt 6000atgacatcaa ttaaggcatg tgacctagct atgtgttatg 6040gatcaacagt aacaaacctt gccaggggct ctaatacagt 6080gaaagtagtt ggtaaaggag gccattcagg gtcctcattt 6120aaatgctgtc atgatacaga ttgctcctct gaaggtttac 6160ttgcatcagc ccctcatctt gagagggtaa caggattcaa 6200tcaaattgat tcagataagg tttatgatga tggtgcacca 6240ccttgcacat tcaaatgctg gttcactaag tcaggtgagt 6280ggcttcttgg gatcttaaac gggaattgga ttgttgttgt 6320agtgcttgtt gtgatactca ttctctctat cataatgttc 6360agtgttttgt gtcccaggag agggcacaag aaaactgtct 6400aagcattgac ctcaactcct acattagatc atatacattt 6440atgcacttcc tcatatttag ctgcactaag atattaataa 6480actctagtta ttgactttat aagattatta tggaactaac 6520ctcacttaaa aaaaacaaat actttactca tatataactc 6560catattctct taccgaggat tttgttcctg cggagcatac 6600tactaggatc tacgtatgat cagcctcgac tgtgccttct 6640agttgccagc catctgttgt ttgcccctcc cccgtgcctt 6680ccttgaccct ggaaggtgcc actcccactg tcctttccta 6720ataaaatgag gaaattgcat cgcattgtct gagtaggtgt 6760cattctattc tggggggtgg ggtggggcag gacagcaagg 6800gggaggattg ggaagacaat agcaggcatg ctggggatgc 6840ggtgggctct atggcttctg aggcggaaag aaccagctgg 6880ggctcgacag ctcgactcta gaattgcttc ctcgctcact 6920gactcgctgc gctcggtcgt tcggctgcgg cgagcggtat 6960cagctcactc aaaggcggta atacggttat ccacagaatc 7000aggggataac gcaggaaaga acatgtgagc aaaaggccag 7040caaaaggcca ggaaccgtaa aaaggccgcg ttgctggcgt 7080ttttccatag gctccgcccc cctgacgagc atcacaaaaa 7120tcgacgctca agtcagaggt ggcgaaaccc gacaggacta 7160taaagatacc aggcgtttcc ccctggaagc tccctcgtgc 7200gctctcctgt tccgaccctg ccgcttaccg gatacctgtc 7240cgcctttctc ccttcgggaa gcgtggcgct ttctcatagc 7280tcacgctgta ggtatctcag ttcggtgtag gtcgttcgct 7320ccaagctggg ctgtgtgcac gaaccccccg ttcagcccga 7360ccgctgcgcc ttatccggta actatcgtct tgagtccaac 7400ccggtaagac acgacttatc gccactggca gcagccactg 7440gtaacaggat tagcagagcg aggtatgtag gcggtgctac 7480agagttcttg aagtggtggc ctaactacgg ctacactaga 7520agaacagtat ttggtatctg cgctctgctg aagccagtta 7560ccttcgaaaa aagagttggt agctcttgat ccggcaaaca 7600aaccaccgct ggtagcggtg gtttttttgt ttgcaagcag 7640cagattacgc gcagaaaaaa aggatctcaa gaagatcctt 7680tgatcttttc tacggggtct gacgctcagt ggaacgaaaa 7720ctcacgttaa gggattttgg tcatgagatt atcaaaaagg 7760atcttcacct agatcctttt aaattaaaaa tgaagtttta 7800aatcaatcta aagtatatat gagtaaactt ggtctgacag 7840ttaccaatgc ttaatcagtg aggcacctat ctcagcgatc 7880tgtctatttc gttcatccat agttgcctga ctc 7913

For a HPS+HFRS, or pan-hantavirus, vaccine composition or immunogeniccomposition, the composition will have at least one of theabove-described SNV sequences (SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3),plus at least one other M-gene (e.g., whole full-length or ORF or ORFplus flanking sequences) from an HFRS virus. Examples of HFRS virusesinclude Seoul virus, Hantaan virus, Pumuula virus, and Dobrava virus. Inaddition, the vaccine composition or immunogenic composition may furtherinclude one or more of the above-described other HPS M-genes (e.g.,whole full-length or ORF or ORF plus flanking sequences). A preferredHPS+HFRS vaccine or immunogenic composition comprises at least one ofthe above-described SNV sequences, and one or more of Puumala M-geneplasmid (preferably plasmid pWRG/PUU-M(s2) shown below as SEQ ID NO:11or the ORF shown below as SEQ ID NO:14), Hantaan M-gene plasmid(preferably plasmid pWRG/HTN-M(x) shown below as SEQ ID NO:12), andSeoul (preferably plasmid pWRG-SEO-M which is Seoul hantavirus Msegment, strain SR-11, subcloned into DNA vector pWRG7077, and shownbelow as SEQ ID NO:13).

pWRG/PUU-M(s2) DNA vaccine plasmid (SEQ ID NO: 11) (the underlined section indicates the ORF)-GGGGGGGGGGGGCGCTGAGGTCTGCCTCGTGAAGAAGGTGTTGCTGACTCATACCAGGCCTGAATCGCCCCATCATCCAGCCAGAAAGTGAGGGAGCCACGGTTGATGAGAGCTTTGTTGTAGGTGGACCAGTTGGTGATTTTGAACTTTTGCTTTGCCACGGAACGGTCTGCGTTGTCGGGAAGATGCGTGATCTGATCCTTCAACTCAGCAAAAGTTCGATTTATTCAACAAAGCCGCCGTCCCGTCAAGTCAGCGTAATGCTCTGCCAGTGTTACAACCAATTAACCAATTCTGATTAGAAAAACTCATCGAGCATCAAATGAAACTGCAATTTATTCATATCAGGATTATCAATACCATATTTTTGAAAAAGCCGTTTCTGTAATGAAGGAGAAAACTCACCGAGGCAGTTCCATAGGATGGCAAGATCCTGGTATCGGTCTGCGATTCCGACTCGTCCAACATCAATACAACCTATTAATTTCCCCTCGTCAAAAATAAGGTTATCAAGTGAGAAATCACCATGAGTGACGACTGAATCCGGTGAGAATGGCAAAAGCTTATGCATTTCTTTCCAGACTTGTTCAACAGGCCAGCCATTACGCTCGTCATCAAAATCACTCGCATCAACCAAACCGTTATTCATTCGTGATTGCGCCTGAGCGAGACGAAATACGCGATCGCTGTTAAAAGGACAATTACAAACAGGAATCGAATGCAACCGGCGCAGGAACACTGCCAGCGCATCAACAATATTTTCACCTGAATCAGGATATTCTTCTAATACCTGGAATGCTGTTTTCCCGGGGATCGCAGTGGTGAGTAACCATGCATCATCAGGAGTACGGATAAAATGCTTGATGGTCGGAAGAGGCATAAATTCCGTCAGCCAGTTTAGTCTGACCATCTCATCTGTAACATCATTGGCAACGCTACCTTTGCCATGTTTCAGAAACAACTCTGGCGCATCGGGCTTCCCATACAATCGATAGATTGTCGCACCTGATTGCCCGACATTATCGCGAGCCCATTTATACCCATATAAATCAGCATCCATGTTGGAATTTAATCGCGGCCTCGAGCAAGACGTTTCCCGTTGAATATGGCTCATAACACCCCTTGTATTACTGTTTATGTAAGCAGACAGTTTTATTGTTCATGATGATATATTTTTATCTTGTGCAATGTAACATCAGAGATTTTGAGACACAACGTGGCTTTCCCCCCCCCCCCGGCATGCCTGCAGGTCGACAATATTGGCTATTGGCCATTGCATACGTTGTATCTATATCATAATATGTACATTTATATTGGCTCATGTCCAATATGACCGCCATGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTCCGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTACGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACACCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAATAACCCCGCCCCGTTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAGATCGCCTGGAGACGCCATCCACGCTGTTTTGACCTCCATAGAAGACACCGGGACCGATCCAGCCTCCGCGGCCGGGAACGGTGCATTGGAACGCGGATTCCCCGTGCCAAGAGTGACGTAAGTACCGCCTATAGACTCTATAGGCACACCCCTTTGGCTCTTATGCATGCTATACTGTTTTTGGCTTGGGGCCTATACACCCCCGCTTCCTTATGCTATAGGTGATGGTATAGCTTAGCCTATAGGTGTGGGTTATTGACCATTATTGACCACTCCCCTATTGGTGACGATACTTTCCATTACTAATCCATAACATGGCTCTTTGCCACAACTATCTCTATTGGCTATATGCCAATACTCTGTCCTTCAGAGACTGACACGGACTCTGTATTTTTACAGGATGGGGTCCCATTTATTATTTACAAATTCACATATACAACAACGCCGTCCCCCGTGCCCGCAGTTTTTATTAAACATAGCGTGGGATCTCCACGCGAATCTCGGGTACGTGTTCCGGACATGGGCTCTTCTCCGGTAGCGGCGGAGCTTCCACATCCGAGCCCTGGTCCCATGCCTCCAGCGGCTCATGGTCGCTCGGCAGCTCCTTGCTCCTAACAGTGGAGGCCAGACTTAGGCACAGCACAATGCCCACCACCACCAGTGTGCCGCACAAGGCCGTGGCGGTAGGGTATGTGTCTGAAAATGAGCTCGGAGATTGGGCTCGCACCGCTGACGCAGATGGAAGACTTAAGGCAGCGGCAGAAGAAGATGCAGGCAGCTGAGTTGTTGTATTCTGATAAGAGTCAGAGGTAACTCCCGTTGCGGTGCTGTTAACGGTGGAGGGCAGTGTAGTCTGAGCAGTACTCGTTGCTGCCGCGCGCGCCACCAGACATAATAGCTGACAGACTAACAGACTGTTCCTTTCCATGGGTCTTTTCTGCAGTCACCGTCCAAGCTTGCGGCCGCGGATCTGCAGGAATTCGGCACGAGAGTAGTAGACTCCGCAAGAAACAGCAAACACAGATAAATATGGGCGAGCTGTCCCCTGTGTGCCTGTACCTGCTGCTGCAGGGCCTGCTGCTGTGTAACACCGGAGCCGCCAGGAACCTGAACGAGCTGAAGATGGAGTGCCCCCACACCATCAGACTGGGCCAGGGCCTGGTGGTGGGCAGCGTGGAGCTGCCCAGCCTGCCCATCCAGCAGGTGGAGACCCTGAAGCTGGAGAGCAGCTGTAACTTCGACCTGCACACCAGCACAGCCGGCCAGCAGAGCTTCACCAAGTGGACCTGGGAGATCAAGGGCGACCTGGCCGAGAACACCCAGGCCAGCAGCACCAGCTTCCAGACCAAGAGCAGCGAGGTGAACCTGAGAGGCCTGTGCCTGATCCCCACACTGGTGGTGGAGACCGCCGCCAGAATGAGAAAGACCATCGCCTGCTACGACCTGAGCTGTAACCAGACCGTGTGTCAGCCTACCGTGTACCTGATGGGCCCTATCCAGACCTGTATCACCACCAAGAGCTGCCTGCTGTCCCTGGGCGATCAGAGAATCCAGGTGAACTACGAGAAAACCTACTGTGTGAGCGGCCAGCTGGTGGAGGGCATCTGCTTCAACCCCATCCACACCATGGCCCTGAGCCAGCCTAGCCACACCTACGACATCATGACCATGATGGTGAGATGCTTTCTGGTGATCAAGAAGGTGACCAGCGGCGACAGCATGAAGATCGAGAAGAACTTCGAGACCCTGGTGCAGAAGAATGGCTGTACCGCCAACAACTTCCAGGGCTACTACATCTGCCTGATCGGCAGCAGCAGCGAGCCCCTGTACGTGCCCGCCCTGGACGACTACAGAAGCGCCGAGGTGCTGTCCAGAATGGCCTTCGCCCCCCACGGCGAGGACCACGACATCGAGAAAAACGCCGTGTCCGCCATGAGAATCGCCGGCAAGGTGACCGGCAAGGCCCCCAGCACCGAGTCCAGCGACACCGTGCAGGGCATCGCCTTCAGCGGCAGCCCCCTGTACACCTCCACCGGCGTGCTGACCAGCAAGGACGACCCCGTGTACATCTGGGCCCCTGGCATCATCATGGAGGGCAACCACAGCATCTGTGAGAAGAAAACCCTGCCCCTGACCTGGACCGGCTTCATCAGCCTGCCCGGCGAGATCGAGAAAACCACCCAGTGTACCGTGTTCTGTACCCTGGCCGGACCTGGCGCCGACTGTGAGGCCTACAGCGAGACCGGCATCTTCAACATCAGCAGCCCCACCTGCCTGATCAACCGGGTGCAGAGGTTCAGAGGCAGCGAGCAGCAGATCAAGTTTGTGTGCCAGCGGGTGGACATGGACATCACCGTGTACTGTAACGGCATGAAGAAGGTGATCCTGACCAAGACACTGGTGATCGGCCAGTGTATCTACACCTTCACCAGCATCTTCTCCCTGATCCCCGGCGTGGCCCACAGCCTGGCCGTGGAGCTGTGTGTGCCCGGCCTGCACGGCTGGGCCACCATGCTGCTGCTGCTGACCTTCTGCTTCGGCTGGGTGCTGATCCCTACCATCACCATGATCCTGCTGAAGATCCTGATCGCCTTCGCCTACCTGTGCTCCAAGTACAACACCGACAGCAAGTTCAGAATCCTGATCGAGAAAGTGAAGCGGGAGTACCAGAAAACCATGGGCAGCATGGTGTGTGAAGTGTGCCAGTACGAGTGTGAGACCGCCAAGGAGCTGGAGTCCCACAGAAAGAGCTGCTCCATCGGCAGCTGCCCCTACTGCCTGAACCCCAGCGAGGCCACCACCTCCGCCCTGCAGGCCCACTTCAAAGTGTGTAAGCTGACCAGCCGGTTCCAGGAGAACCTGAGGAAGTCCCTGACCGTGTACGAGCCCATGCAGGGCTGCTACAGAACCCTGAGCCTGTTCCGGTACAGGAGCCGGTTCTTTGTGGGCCTGGTGTGGTGTGTGCTGCTGGTGCTGGAGCTGATTGTGTGGGCCGCCAGCGCCGAGACCCAGAACCTGAATGCCGGCTGGACCGACACCGCCCACGGCAGCGGCATCATCCCCATGAAAACCGACCTGGAGCTGGACTTCAGCCTGCCTAGCAGCGCCTCCTACACCTACAGGCGGCAGCTGCAGAATCCTGCCAACGAGCAGGAGAAGATCCCCTTCCACCTGCAGCTGTCCAAGCAGGTGATCCACGCCGAGATTCAGCACCTGGGCCACTGGATGGACGCCACCTTCAACCTGAAAACCGCCTTCCACTGCTACGGCAGCTGTGAGAAGTACGCCTACCCTTGGCAGACCGCCGGCTGCTTCATCGAGAAGGACTACGAGTACGAGACCGGCTGGGGCTGTAATCCTCCTGATTGCCCCGGAGTGGGCACCGGCTGTACTGCATGTGGCGTGTACCTGGACAAGCTGAAGTCTGTGGGCAAGGTGTTCAAGATCGTGTCCCTGAGGTACACCCGGAAAGTGTGTATCCAGCTGGGCACCGAGCAGACCTGTAAGACCGTGGACAGCAACGATTGCCTGATCACAACCAGCGTGAAAGTGTGTCTGATCGGCACCATCAGCAAGTTCCAGCCCAGCGATACCCTGCTGTTTCTGGGCCCCCTGCAGCAGGGCGGCCTGATCTTCAAGCAGTGGTGTACCACCACCTGCCAGTTCGGCGATCCCGGCGATATCATGAGCACCCCCACCGGCATGAAGTGCCCTGAGCTGAACGGCAGCTTCCGGAAGAAGTGTGCCTTCGCCACCACCCCTGTGTGTCAGTTCGACGGCAACACCATCAGCGGCTACAAGCGGATGATCGCCACCAAGGACAGCTTCCAGTCCTTCAACGTGACCGAGCCCCACATCAGCACCAGCGCCCTGGAGTGGATCGATCCCGACAGCAGCCTGAGGGACCACATCAACGTGATCGTGTCCAGGGACCTGAGCTTCCAGGACCTGAGCGAGACCCCCTGCCAGATCGACCTGGCCACCGCCAGCATCGATGGCGCCTGGGGCAGCGGAGTGGGCTTCAACCTGGTGTGTACAGTGAGCCTGACCGAGTGTAGCGCCTTCCTGACCAGCATCAAAGCCTGTGACGCCGCCATGTGTTACGGCAGCACCACCGCCAACCTGGTGAGAGGCCAGAACACCATCCACATTGTGGGCAAAGGCGGCCACAGCGGCAGCAAGTTTATGTGCTGCCACGACACCAAGTGTAGCAGCACCGGCCTGGTGGCCGCTGCCCCCCACCTGGACAGAGTGACCGGCTACAACCAGGCCGACAGCGACAAGATTTTCGACGACGGAGCCCCTGAGTGTGGCATGAGTTGCTGGTTCAAGAAGAGCGGCGAGTGGATTCTGGGCGTGCTGAACGGGAATTGGATGGTGGTGGCCGTGCTGGTCGTGCTGCTGATCCTGAGCATCCTGCTGTTCACCCTGTGCTGCCCTAGGAGACCCAGCTACCGGAAGGAGCACAAGCCCTGAGTTTTGCTTACTAACATAATTATTGTATTCTGTTTATTGACACAATTACCATATGATTAACTGTATTCCCCCATCTTATATCTTATATAATATTCTTTATTTAATCACTATATAGAAAAAAAACTAGCACTTTACTAATTAAATTACCCCATACCGATTATGCCTGGACTTTTGTTCCTGCGGAGCATACTACTAGGATCTACGTATGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGGCTTCTGAGGCGGAAAGAACCAGCTGGGGCTCGACAGCTCGACTCTAGAATTGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCPuumala synthetic full-length M-segment ORF- SEQ ID NO: 14ATGGGCGAGCTGTCCCCTGTGTGCCTGTACCTGCTGCTGCAGGGCCTGCTGCTGTGTAACACCGGAGCCGCCAGGAACCTGAACGAGCTGAAGATGGAGTGCCCCCACACCATCAGACTGGGCCAGGGCCTGGTGGTGGGCAGCGTGGAGCTGCCCAGCCTGCCCATCCAGCAGGTGGAGACCCTGAAGCTGGAGAGCAGCTGTAACTTCGACCTGCACACCAGCACAGCCGGCCAGCAGAGCTTCACCAAGTGGACCTGGGAGATCAAGGGCGACCTGGCCGAGAACACCCAGGCCAGCAGCACCAGCTTCCAGACCAAGAGCAGCGAGGTGAACCTGAGAGGCCTGTGCCTGATCCCCACACTGGTGGTGGAGACCGCCGCCAGAATGAGAAAGACCATCGCCTGCTACGACCTGAGCTGTAACCAGACCGTGTGTCAGCCTACCGTGTACCTGATGGGCCCTATCCAGACCTGTATCACCACCAAGAGCTGCCTGCTGTCCCTGGGCGATCAGAGAATCCAGGTGAACTACGAGAAAACCTACTGTGTGAGCGGCCAGCTGGTGGAGGGCATCTGCTTCAACCCCATCCACACCATGGCCCTGAGCCAGCCTAGCCACACCTACGACATCATGACCATGATGGTGAGATGCTTTCTGGTGATCAAGAAGGTGACCAGCGGCGACAGCATGAAGATCGAGAAGAACTTCGAGACCCTGGTGCAGAAGAATGGCTGTACCGCCAACAACTTCCAGGGCTACTACATCTGCCTGATCGGCAGCAGCAGCGAGCCCCTGTACGTGCCCGCCCTGGACGACTACAGAAGCGCCGAGGTGCTGTCCAGAATGGCCTTCGCCCCCCACGGCGAGGACCACGACATCGAGAAAAACGCCGTGTCCGCCATGAGAATCGCCGGCAAGGTGACCGGCAAGGCCCCCAGCACCGAGTCCAGCGACACCGTGCAGGGCATCGCCTTCAGCGGCAGCCCCCTGTACACCTCCACCGGCGTGCTGACCAGCAAGGACGACCCCGTGTACATCTGGGCCCCTGGCATCATCATGGAGGGCAACCACAGCATCTGTGAGAAGAAAACCCTGCCCCTGACCTGGACCGGCTTCATCAGCCTGCCCGGCGAGATCGAGAAAACCACCCAGTGTACCGTGTTCTGTACCCTGGCCGGACCTGGCGCCGACTGTGAGGCCTACAGCGAGACCGGCATCTTCAACATCAGCAGCCCCACCTGCCTGATCAACCGGGTGCAGAGGTTCAGAGGCAGCGAGCAGCAGATCAAGTTTGTGTGCCAGCGGGTGGACATGGACATCACCGTGTACTGTAACGGCATGAAGAAGGTGATCCTGACCAAGACACTGGTGATCGGCCAGTGTATCTACACCTTCACCAGCATCTTCTCCCTGATCCCCGGCGTGGCCCACAGCCTGGCCGTGGAGCTGTGTGTGCCCGGCCTGCACGGCTGGGCCACCATGCTGCTGCTGCTGACCTTCTGCTTCGGCTGGGTGCTGATCCCTACCATCACCATGATCCTGCTGAAGATCCTGATCGCCTTCGCCTACCTGTGCTCCAAGTACAACACCGACAGCAAGTTCAGAATCCTGATCGAGAAAGTGAAGCGGGAGTACCAGAAAACCATGGGCAGCATGGTGTGTGAAGTGTGCCAGTACGAGTGTGAGACCGCCAAGGAGCTGGAGTCCCACAGAAAGAGCTGCTCCATCGGCAGCTGCCCCTACTGCCTGAACCCCAGCGAGGCCACCACCTCCGCCCTGCAGGCCCACTTCAAAGTGTGTAAGCTGACCAGCCGGTTCCAGGAGAACCTGAGGAAGTCCCTGACCGTGTACGAGCCCATGCAGGGCTGCTACAGAACCCTGAGCCTGTTCCGGTACAGGAGCCGGTTCTTTGTGGGCCTGGTGTGGTGTGTGCTGCTGGTGCTGGAGCTGATTGTGTGGGCCGCCAGCGCCGAGACCCAGAACCTGAATGCCGGCTGGACCGACACCGCCCACGGCAGCGGCATCATCCCCATGAAAACCGACCTGGAGCTGGACTTCAGCCTGCCTAGCAGCGCCTCCTACACCTACAGGCGGCAGCTGCAGAATCCTGCCAACGAGCAGGAGAAGATCCCCTTCCACCTGCAGCTGTCCAAGCAGGTGATCCACGCCGAGATTCAGCACCTGGGCCACTGGATGGACGCCACCTTCAACCTGAAAACCGCCTTCCACTGCTACGGCAGCTGTGAGAAGTACGCCTACCCTTGGCAGACCGCCGGCTGCTTCATCGAGAAGGACTACGAGTACGAGACCGGCTGGGGCTGTAATCCTCCTGATTGCCCCGGAGTGGGCACCGGCTGTACTGCATGTGGCGTGTACCTGGACAAGCTGAAGTCTGTGGGCAAGGTGTTCAAGATCGTGTCCCTGAGGTACACCCGGAAAGTGTGTATCCAGCTGGGCACCGAGCAGACCTGTAAGACCGTGGACAGCAACGATTGCCTGATCACAACCAGCGTGAAAGTGTGTCTGATCGGCACCATCAGCAAGTTCCAGCCCAGCGATACCCTGCTGTTTCTGGGCCCCCTGCAGCAGGGCGGCCTGATCTTCAAGCAGTGGTGTACCACCACCTGCCAGTTCGGCGATCCCGGCGATATCATGAGCACCCCCACCGGCATGAAGTGCCCTGAGCTGAACGGCAGCTTCCGGAAGAAGTGTGCCTTCGCCACCACCCCTGTGTGTCAGTTCGACGGCAACACCATCAGCGGCTACAAGCGGATGATCGCCACCAAGGACAGCTTCCAGTCCTTCAACGTGACCGAGCCCCACATCAGCACCAGCGCCCTGGAGTGGATCGATCCCGACAGCAGCCTGAGGGACCACATCAACGTGATCGTGTCCAGGGACCTGAGCTTCCAGGACCTGAGCGAGACCCCCTGCCAGATCGACCTGGCCACCGCCAGCATCGATGGCGCCTGGGGCAGCGGAGTGGGCTTCAACCTGGTGTGTACAGTGAGCCTGACCGAGTGTAGCGCCTTCCTGACCAGCATCAAAGCCTGTGACGCCGCCATGTGTTACGGCAGCACCACCGCCAACCTGGTGAGAGGCCAGAACACCATCCACATTGTGGGCAAAGGCGGCCACAGCGGCAGCAAGTTTATGTGCTGCCACGACACCAAGTGTAGCAGCACCGGCCTGGTGGCCGCTGCCCCCCACCTGGACAGAGTGACCGGCTACAACCAGGCCGACAGCGACAAGATTTTCGACGACGGAGCCCCTGAGTGTGGCATGAGTTGCTGGTTCAAGAAGAGCGGCGAGTGGATTCTGGGCGTGCTGAACGGGAATTGGATGGTGGTGGCCGTGCTGGTCGTGCTGCTGATCCTGAGCATCCTGCTGTTCACCCTGTGCTGCCCTAGGAGACCCAGCTACCGGAAGGAGCACAAGCCCTGA Plasmid pWRG/HTN-M(x)SEQ ID NO: 12 gggggggggg ggcgctgagg tctgcctcgt gaagaaggtg   40ttgctgactc ataccaggcc tgaatcgccc catcatccag   80ccagaaagtg agggagccac ggttgatgag agctttgttg  120taggtggacc agttggtgat tttgaacttt tgctttgcca  160cggaacggtc tgcgttgtcg ggaagatgcg tgatctgatc  200cttcaactca gcaaaagttc gatttattca acaaagccgc  240cgtcccgtca agtcagcgta atgctctgcc agtgttacaa  280ccaattaacc aattctgatt agaaaaactc atcgagcatc  320aaatgaaact gcaatttatt catatcagga ttatcaatac  360catatttttg aaaaagccgt ttctgtaatg aaggagaaaa  400ctcaccgagg cagttccata ggatggcaag atcctggtat  440cggtctgcga ttccgactcg tccaacatca atacaaccta  480ttaatttccc ctcgtcaaaa ataaggttat caagtgagaa  520atcaccatga gtgacgactg aatccggtga gaatggcaaa  560agcttatgca tttctttcca gacttgttca acaggccagc  600cattacgctc gtcatcaaaa tcactcgcat caaccaaacc  640gttattcatt cgtgattgcg cctgagcgag acgaaatacg  680cgatcgctgt taaaaggaca attacaaaca ggaatcgaat  720gcaaccggcg caggaacact gccagcgcat caacaatatt  760ttcacctgaa tcaggatatt cttctaatac ctggaatgct  800gttttcccgg ggatcgcagt ggtgagtaac catgcatcat  840caggagtacg gataaaatgc ttgatggtcg gaagaggcat  880aaattccgtc agccagttta gtctgaccat ctcatctgta  920acatcattgg caacgctacc tttgccatgt ttcagaaaca  960actctggcgc atcgggcttc ccatacaatc gatagattgt 1000cgcacctgat tgcccgacat tatcgcgagc ccatttatac 1040ccatataaat cagcatccat gttggaattt aatcgcggcc 1080tcgagcaaga cgtttcccgt tgaatatggc tcataacacc 1120ccttgtatta ctgtttatgt aagcagacag ttttattgtt 1160catgatgata tatttttatc ttgtgcaatg taacatcaga 1200gattttgaga cacaacgtgg ctttcccccc ccccccggca 1240tgcctgcagg tcgacaatat tggctattgg ccattgcata 1280cgttgtatct atatcataat atgtacattt atattggctc 1320atgtccaata tgaccgccat gttgacattg attattgact 1360agttattaat agtaatcaat tacggggtca ttagttcata 1400gcccatatat ggagttccgc gttacataac ttacggtaaa 1440tggcccgcct ggctgaccgc ccaacgaccc ccgcccattg 1480acgtcaataa tgacgtatgt tcccatagta acgccaatag 1520ggactttcca ttgacgtcaa tgggtggagt atttacggta 1560aactgcccac ttggcagtac atcaagtgta tcatatgcca 1600agtccgcccc ctattgacgt caatgacggt aaatggcccg 1640cctggcatta tgcccagtac atgaccttac gggactttcc 1680tacttggcag tacatctacg tattagtcat cgctattacc 1720atggtgatgc ggttttggca gtacaccaat gggcgtggat 1760agcggtttga ctcacgggga tttccaagtc tccaccccat 1800tgacgtcaat gggagtttgt tttggcacca aaatcaacgg 1840gactttccaa aatgtcgtaa taaccccgcc ccgttgacgc 1880aaatgggcgg taggcgtgta cggtgggagg tctatataag 1920cagagctcgt ttagtgaacc gtcagatcgc ctggagacgc 1960catccacgct gttttgacct gcatcgaaga caccgggacc 2000gatccagcct ccgcggccgg gaacggtgca ttggaacgcg 2040gattccccgt gccaagagtg acgtaagtac cgcctataga 2080ctctataggc acaccccttt ggctcttatg catgctatac 2120tgtttttggc ttggggccta tacacccccg cttccttatg 2160ctataggtga tggtatagct tagcctatag gtgtgggtta 2200ttgaccatta ttgaccactc ccctattggt gacgatactt 2240tccattacta atccataaca tggctctttg ccacaactat 2280ctctattggc tatatgccaa tactctgtcc ttcagagact 2320gacacggact ctgtattttt acaggatggg gtcccattta 2360ttatttacaa attcacatat acaacaacgc cgtcccccgt 2400gcccgcagtt tttattaaac atagcgtggg atctccacgc 2440gaatctcggg tacgtgttcc ggacatgggc tcttctccgg 2480tagcggcgga gcttccacat ccgagccctg gtcccatgcc 2520tccagcggct catggtcgct cggcagctcc ttgctcctaa 2560cagtggaggc cagacttagg cacagcacaa tgcccaccac 2600caccagtgtg ccgcacaagg ccgtggcggt agggtatgtg 2640tctgaaaatg agctcggaga ttgggctcgc accgctgacg 2680cagatggaag acttaaggca gcggcagaag aagatgcagg 2720cagctgagtt gttgtattct gataagagtc agaggtaact 2760cccgttgcgg tgctgttaac ggtggagggc agtgtagtct 2800gagcagtact cgttgctgcc gcgcgcgcca ccagacataa 2840tagctgacag actaacagac tgttcctttc catgggtctt 2880ttctgcagtc accgtccaag cttgcggccg cggatctgca 2920ggaattcggc acgagagtag tagactccgc aagaaacagc 2960agtcaatcag caacatgggg atatggaagt ggctagtgat 3000ggccagttta gtatggcctg ttttgacact gagaaatgtc 3040tatgacatga aaattgagtg cccccataca gtaagttttg 3080gggaaaacag tgtgataggt tatgtagaat taccccccgt 3120gccattggcc gacacagcac agatggtgcc tgagagttct 3160tgtagcatgg ataatcacca atcgttgaat acaataacaa 3200aatataccca agtaagttgg agaggaaagg ctgatcagtc 3240acagtctagt caaaattcat ttgagacagt gtccactgaa 3280gttgacttga aaggaacatg tgctctaaaa cacaaaatgg 3320tggaagaatc ataccgtagt aggaaatcag taacctgtta 3360cgacctgtct tgcaatagca cttactgcaa gccaacacta 3400tacatgattg taccaattca tgcatgcaat atgatgaaaa 3440gctgtttgat tgcattggga ccatacagag tacaggtggt 3480ttatgagaga tcttattgca tgacaggagt cctgattgaa 3520gggaaatgct ttgtcccaga tcaaagtgtg gtcagtatta 3560tcaagcatgg gatctttgat attgcaagtg ttcatattgt 3600atgtttcttt gttgcagtta aagggaatac ttataaaatt 3640tttgaacagg ttaagaaatc ctttgaatca acatgcaatg 3680atacagagaa taaagtgcaa ggatattata tttgtattgt 3720agggggaaac tctgcaccaa tatatgttcc aacacttgat 3760gatttcagat ccatggaagc atttacagga atcttcagat 3800caccacatgg ggaagatcat gatctggctg gagaagaaat 3840tgcatcttat tctatagtcg gacctgccaa tgcaaaagtt 3880cctcatagtg ctagctcaga tacattgagc ttgattgcct 3920attcaggtat accatcttat tcttccctta gcatcctaac 3960aagttcaaca gaagctaagc atgtattcag ccctgggttg 4000ttcccaaaac ttaatcacac aaattgtgat aaaagtgcca 4040taccactcat atggactggg atgattgatt tacctggata 4080ctacgaagct gtccaccctt gtacagtttt ttgcgtatta 4120tcaggtcctg gggcatcatg tgaagccttt tctgaaggcg 4160ggattttcaa cataacctct cccatgtgct tagtgtcaaa 4200acaaaatcga ttccggttaa cagaacagca agtgaatttt 4240gtgtgtcagc gagtggacat ggacattgtt gtgtactgca 4280acgggcagag gaaagtaata ttaacaaaaa ctctagttat 4320tggacagtgt atatatacta taacaagctt attctcatta 4360ctacctggag tagcacattc tattgctgtt gaattgtgtg 4400tacctgggtt ccatggttgg gccacagctg ctctgcttgt 4440tacattctgt ttcggatggg ttcttatacc agcaattaca 4480tttatcatac taacagtcct aaagttcatt gctaatattt 4520ttcacacaag taatcaagag aataggctaa aatcagtact 4560tagaaagata aaggaagagt ttgaaaaaac aaaaggctca 4600atggtatgtg atgtctgcaa gtatgagtgt gaaacctata 4640aagaattaaa ggcacacggg gtatcatgcc cccaatctca 4680atgtccttac tgttttactc attgtgaacc cacagaagca 4720gcattccaag ctcattacaa ggtatgccaa gttactcaca 4760gattcaggga tgatctaaag aaaactgtta ctcctcaaaa 4800ttttacacca ggatgttacc ggacactaaa tttatttaga 4840tacaaaagca ggtgctacat ctttacaatg tggatatttc 4880ttcttgtctt agaatccata ctgtgggctg caagtgcatc 4920agagacacca ttaactcctg tctggaatga caatgcccat 4960ggggtaggtt ctgttcctat gcatacagat ttagagcttg 5000atttctcttt aacatccagt tccaagtata cataccgtag 5040gaggttaaca aacccacttg aggaagcaca atccattgac 5080ctacatattg aaatagaaga acagacaatt ggtgttgatg 5120tgcatgctct aggacactgg tttgatggtc gtcttaacct 5160taaaacatcc tttcactgtt atggtgcttg tacaaagtat 5200gaataccctt ggcatactgc aaagtgccac tatgaaagag 5240attaccaata tgagacgagc tggggttgta atccatcaga 5280ttgtcctggg gtgggcacag gctgtacagc atgtggttta 5320tacctagatc aactgaaacc agttggtagt gcttataaaa 5360ttatcacaat aaggtacagc aggagagtct gtgttcagtt 5400tggggaggaa aacctttgta agataataga catgaatgat 5440tgttttgtat ctaggcatgt taaggtctgc ataattggta 5480cagtatctaa attctctcag ggtgatacct tattgttttt 5520tggaccgctt gaaggtggtg gtctaatatt taaacactgg 5560tgtacatcca catgtcaatt tggtgaccca ggagatatca 5600tgagtccaag agacaaaggt tttttatgcc ctgagtttcc 5640aggtagtttc aggaagaaat gcaactttgc tactacccct 5680atttgtgagt atgatggaaa tatggtctca ggttacaaga 5720aagtgatggc cacaattgat tccttccaat cttttaatac 5760aagcactatg cacttcactg atgaaaggat agagtggaaa 5800gaccctgatg gaatgctaag ggaccatata aacattttag 5840taacgaagga cattgacttt gataaccttg gtgaaaatcc 5880ttgcaaaatt ggcctacaaa catcttctat tgagggggcc 5920tggggttctg gtgtggggtt cacattaaca tgtctggtat 5960cactaacaga atgtcctacc tttttgacct caataaaggc 6000ttgtgataag gctatctgtt atggtgcaga gagtgtaaca 6040ttgacaagag gacaaaatac agtcaaggta tcagggaaag 6080gtggccatag tggttcaaca tttaggtgtt gccatgggga 6120ggactgttca caaattggac tccatgctgc tgcacctcac 6160cttgacaagg taaatgggat ttctgagata gaaaatagta 6200aagtatatga tgatggggca ccgcaatgtg ggataaaatg 6240ttggtttgtt aaatcagggg aatggatttc agggatattc 6280agtggtaatt ggattgtact cattgtcctc tgtgtatttc 6320tattgttctc cttggtttta ctaagcattc tctgtcccgt 6360aaggaagcat aaaaaatcat agctaaattc tgtgactatc 6400ctgttcttat gtatagcttt aacatatata ctaattttta 6440tattccagta tactctatct aacacactaa aaaaaatagt 6480agctttctaa ccacaaaacg gatctacgta tgatcagcct 6520cgactgtgcc ttctagttgc cagccatctg ttgtttgccc 6560ctcccccgtg ccttccttga ccctggaagg tgccactccc 6600actgtccttt cctaataaaa tgaggaaatt gcatcgcatt 6640gtctgagtag gtgtcattct attctggggg gtggggtggg 6680gcaggacagc aagggggagg attgggaaga caatagcagg 6720catgctgggg atgcggtggg ctctatggct tctgaggcgg 6760aaagaaccag ctggggctcg acagctcgac tctagaattg 6800cttcctcgct cactgactcg ctgcgctcgg tcgttcggct 6840gcggcgagcg gtatcagctc actcaaaggc ggtaatacgg 6880ttatccacag aatcagggga taacgcagga aagaacatgt 6920gagcaaaagg ccagcaaaag gccaggaacc gtaaaaaggc 6960cgcgttgctg gcgtttttcc ataggctccg cccccctgac 7000gagcatcaca aaaatcgacg ctcaagtcag aggtggcgaa 7040acccgacagg actataaaga taccaggcgt ttccccctgg 7080aagctccctc gtgcgctctc ctgttccgac cctgccgctt 7120accggatacc tgtccgcctt tctcccttcg ggaagcgtgg 7160cgctttctca tagctcacgc tgtaggtatc tcagttcggt 7200gtaggtcgtt cgctccaagc tgggctgtgt gcacgaaccc 7240cccgttcagc ccgaccgctg cgccttatcc ggtaactatc 7280gtcttgagtc caacccggta agacacgact tatcgccact 7320ggcagcagcc actggtaaca ggattagcag agcgaggtat 7360gtaggcggtg ctacagagtt cttgaagtgg tggcctaact 7400acggctacac tagaagaaca gtatttggta tctgcgctct 7440gctgaagcca gttaccttcg gaaaaagagt tggtagctct 7480tgatccggca aacaaaccac cgctggtagc ggtggttttt 7520ttgtttgcaa gcagcagatt acgcgcagaa aaaaaggatc 7560tcaagaagat cctttgatct tttctacggg gtctgacgct 7600cagtggaacg aaaactcacg ttaagggatt ttggtcatga 7640gattatcaaa aaggatcttc acctagatcc ttttaaatta 7680aaaatgaagt tttaaatcaa tctaaagtat atatgagtaa 7720acttggtctg acagttacca atgcttaatc agtgaggcac 7760ctatctcagc gatctgtcta tttcgttcat ccatagttgc 7800pWRG-SEO-M (Seoul hantavirus M segment, strainSR-11, subcloned into DNA vector pWRG7077)  SEQ ID NO: 13gggggggggg ggcgctgagg tctgcctcgt gaagaaggtg   40ttgctgactc ataccaggcc tgaatcgccc catcatccag   80ccagaaagtg agggagccac ggttgatgag agctttgttg  120taggtggacc agttggtgat tttgaacttt tgctttgcca  160cggaacggtc tgcgttgtcg ggaagatgcg tgatctgatc  200cttcaactca gcaaaagttc gatttattca acaaagccga  240cgtcccgtca agtcagcgta atgctctgcc agtgttacaa  280ccaattaacc aattctgatt agaaaaactc atcgagcatc  320aaatgaaact gcaatttatt catatcagga ttatcaatac  360catatttttg aaaaagccgt ttctgtaatg aaggagaaaa  400ctcaccgagg cagttccata ggatggcaag atcctggtat  440cggtctgcga ttccgactcg tccaacatca atacaaccta  480ttaatttccc ctcgtcaaaa ataaggttat caagtgagaa  520atcaccatga gtgacgactg aatccggtga gaatggcaaa  560agcttatgca tttctttcca gacttgttca acaggccagc  600cattacgctc gtcatcaaaa tcactcgcat caaccaaacc  640gttattcatt cgtgattgcg cctgagcgag acgaaatacg  680cgatcgctgt taaaaggaca attacaaaca ggaatcgaat  720gcaaccggcg caggaacact gccagcgcat caacaatatt  760ttcacctgaa tcaggatatt cttctaatac ctggaatgct  800gttttcccgg ggatcgcagt ggtgagtaac catgcatcat  840caggagtacg gataaaatgc ttgatggtcg gaagaggcat  880aaattccgtc agccagttta gtctgaccat ctcatctgta  920acatcattgg caacgctacc tttgccatgt ttcagaaaca  960actctggcgc atcgggcttc ccatacaatc gatagattgt 1000cgcacctgat tgccccacat tatcgcgagc ccatttatac 1040ccatataaat cagcatccat gttggaattt aatcgcggcc 1080tcgagcaaga cgtttcccgt tgaatatggc tcataacacc 1120ccttgtatta ctgtttatgt aagcagacag ttttattgtt 1160catgatgata tatttttatc ttgtgcaatg taacatcaga 1200gattttgaga cacaacgtgg ctttcccccc ccccccggca 1240tgcctgcagg tcgacataaa tcaatattgg ctattggcca 1280ttgcatacgt tgtatctata tcataatatg tacatttata 1320ttggctcatg tccaatatga ccgccatgtt gacattgatt 1360attgactagt tattaatagt aatcaattac ggggtcatta 1400gttcatagcc catatatgga gttccgcgtt acataactta 1440cggtaaatgg cccgcctcgt gaccgcccaa cgacccccgc 1480ccattgacgt caataatgac gtatgttccc atagtaacgc 1520caatagggac tttccattga cgtcaatggg tggagtattt 1560acggtaaact gcccacttgg cagtacatca agtgtatcat 1600atgccaagtc cggcccccta ttgacgtcaa tgacggtaaa 1640tggcccgcct ggcattatgc ccagtacatg accttacggg 1680actttcctac ttggcagtac atctacgtat tagtcatcgc 1720tattaccatg gtgatgcggt tttggcagta caccaatggg 1760cgtggatagc ggtttgactc acggggattt ccaagtctcc 1800accccattga cgtcaatggg agtttgtttt ggcaccaaaa 1840tcaacgggac tttccaaaat gtcgtaataa ccccgccccg 1880ttgacgcaaa tgggcggtag gcgtgtacgg tgggaggtct 1920atataagcag agctcgttta gtgaaccgtc agatcgcctg 1960gagacgccat ccacgctgtt ttgacctcca tagaagacac 2000cgggaccgat ccagcctccg cggccgggaa cggtgcattg 2040gaacgcggat tccccgtgcc aagagtgacg taagtaccgc 2080ctatagactc tataggcaca cccctttggc tcttatgcat 2120gctatactgt ttttggcttg gggcctatac acccccgctc 2160cttatgctat aggtgatggt atagcttagc ctataggtgt 2200gggttattga ccattattga ccactcccct attggtgacg 2240atactttcca ttactaatcc ataacatggc tctttgccac 2280aactatctct attggctata tgccaatact ctgtccttca 2320gagactgaca cggactctgt atttttacag gatggggtcc 2360catttattat ttacaaattc acatatacaa caacgccgtc 2400ccccgtgccc gcagttttta ttaaacatag cgtgggatct 2440ccacgcgaat ctcgggtacg tgttccggac atgggctctt 2480ctccggtagc ggcggagctt ccacatccga gccctggtcc 2520catgcctcca gcggctcatg gtcgctcggc agctccttgc 2560tcctaacagt ggaggccaga cttaggcaca gcacaatgcc 2600caccaccacc agtgtgccgc acaaggccgt ggcggtaggg 2640tatgtgtctg aaaatgagct cggagattgg gctcgcaccg 2680tgacgcagat ggaagactta aggcagcggc agaagaagat 2720gcaggcagct gagttgttgt attctgataa gagtcagagg 2760taactcccgt tgcggtgctg ttaacggtgg agggcagtgt 2800agtctgagca gtactcgttg ctgccgcgcg cgccaccaga 2840cataatagct gacagactaa cagactgttc ctttccatgg 2880gtcttttctg cagtcaccgt ccaagcttgc ggccgcggat 2920ctgcaggaat tcggcacgag agtagtagac tccgcaagaa 2960acagcagtta aagaacaata ggatcatgtg gagtttgcta 3000ttactggccg ctttagttgg ccaaggcttt gcattaaaaa 3040atgtatttga catgagaatt cagttgcccc actcagtcaa 3080ctttggggaa acaagtgtgt caggctatac agaatttccc 3120ccactctcat tacaggaggc agaacagcta gtgccagaga 3160gctcatgcaa catggacaac caccagtcac tctcaacaat 3200aaataaatta accaaggtca tatggcggaa aaaagcaaat 3240caggaatcag caaaccagaa ttcatttgaa gttgtggaaa 3280gtgaagtcag ctttaaaggg ttgtgtatgt taaagcatag 3320aatggttgaa gaatcatata gaaataggag atcagtaatc 3360tgttatgatc tagcctgtaa tagtacattc tgtaaaccaa 3400ctgtttatat gattgttcct atacatgctt gcaacatgat 3440gaaaagctgt ttgattggcc ttggccccta cagaatccag 3480gttgtctatg aaaggacata ctgcactacg ggtatattga 3520cagaaggaaa atgctttgtc cctgacaagg ctgttgtcag 3560tgcattgaaa agaggcatgt atgctatagc aagcatagag 3600acaatctgct tttttattca tcagaaaggg aatacatata 3640agatagtgac tgccattaca tcagcaatgg gctccaaatg 3680taataataca gatactaaag ttcaaggata ttatatctgt 3720attattggtg gaaactccgc ccctgtatat gcccctgctg 3760gtgaagactt cagagcaatg gaggtttttt ctgggattat 3800tacatcacca catggagaag accatgacct acccggcgaa 3840gaaatcgcaa cgtaccagat ttcagggcag atagaggcaa 3880aaatccctca tacagtgagc tccaaaaact taaaattgac 3920tgcttttgca ggtattccat catactcatc aactagtata 3960ttggctgctt cagaagatgg tcgtttcata tttagtcctg 4000gtttatttcc taacctaaat cagtcagtct gtgacaacaa 4040tgcactccct ttaatctgga ggggcctaat tgatttaacg 4080ggatactatg aggcagtcca cccttgcaat gtgttctgtg 4120tcttatcagg accaggtgct tcatgtgagg ccttttcaga 4160aggaggtatt ttcaatatta cttctccaat gtgtctggtg 4200tctaagcaaa atagatttag agcagctgag cagcagatta 4240gctttgtctg ccaaagagtt gatatggata ttatagtgta 4280ctgtaatggt cagaaaaaaa caatcctaac aaaaacatta 4320gttataggcc aatgtattta tactattaca agtctctttt 4360cactgttacc aggggttgcc cattctattg ctattgagtt 4400gtgtgttcca gggtttcatg gctgggccac agctgcactt 4440ttgattacat tctgcttcgg ctgggtattg attcctgcat 4480gtacattagc tattctttta gtccttaagt tctttgcaaa 4520tatccttcat acaagcaatc aagagaaccg attcaaagcc 4560attctacgga aaataaagga ggagtttgaa aaaacaaagg 4600gttccatggt ttgtgagatc tgtaagtatg agtgtgaaac 4640attaaaggaa ttgaaggcac ataacctatc atgtgttcaa 4680ggagagtgcc catattgctt tacccactgt gaaccgacag 4720aaactgcaat tcaggcacat tacaaagttt gtcaagccac 4760ccaccgattc agagaagatt taaaaaagac tgtaactcct 4800caaaatattg ggccaggctg ttaccgaaca ctaaatcttt 4840ttaggtataa aagtaggtgt tatattctga caatgtggac 4880tcttcttctc attattgaat ccatcctctg ggcagcaagt 4920gcagcagaaa tcccccttgt ccctctctgg acagataatg 4960ctcatggcgt tgggagtgtt cctatgcata cggatcttga 5000attagacttc tctttgccat ccagttctaa gtacacatac 5040aaaagacatc tcacaaaccc agttaatgac caacagagtg 5080tctcattgca tatagaaatt gaaagtcaag gcattggtgc 5120tgctgttcat catcttggac attggtatga tgcaagattg 5160aatctaaaaa cctcatttca ttgttatggt gcctgcacaa 5200aatatcaata cccatggcac actgcaaaat gccattttga 5240gaaagattat gagtatgaaa atagctgggc ttgcaacccc 5280ccagattgcc caggggttgg tacaggttgt actgcttgtg 5320gattatatct agatcaattg aagccggtag gaacagcctt 5360taaaattata agtgtaagat acagtagaaa agtgtgcgtg 5400cagtttggtg aagaacacct ttgtaaaaca attgatatga 5440atgattgctt tgtgactagg catgccaaaa tatgtataat 5480tgggactgta tctaagtttt ctcaaggtga cactctacta 5520tttctggggc ccatggaagg aggtggtata atctttaaac 5560actggtgtac atctacctgt cactttggag accctggtga 5600tgtcatgggt ccaaaagata aaccatttat ttgccctgaa 5640ttcccagggc aatttaggaa aaaatgtaac tttgccacaa 5680ctccagtttg tgaatatgat ggaaacatta tatcaggcta 5720taagaaagta cttgcaacaa ttgattcttt ccaatcattt 5760aacacaagca atatacactt cactgatgag agaattgaat 5800ggagagaccc tgatggcatg cttcgggatc atattaatat 5840tgttatttct aaagatattg attttgaaaa tttggctgag 5880aatccttgta aagtagggct ccaggcagca aacatagaag 5920gtgcctgggg ttcaggtgtc gggtttacac tcacatgcaa 5960ggtgtctctc acagaatgcc caacatttct tacatcaata 6000aaggcctgtg acatggcaat ttgttatggt gcagaaagtg 6040tgacactctc acgaggacaa aatactgtca aaattaccgg 6080gaaaggtggc catagtggtt cttcattcaa atgctgtcat 6120gggaaagaat gttcatcaac tggcctccaa gccagtgcac 6160cacatctgga taaggtaaat ggtatctctg agttagaaaa 6200cgagaaagtt tatgatgacg gtgcacctga atgtggcatt 6240acttgttggt ttaaaaaatc aggtgaatgg gttatgggta 6280taatcaatgg gaactgggtt gtcctaattg tcttgtgtgt 6320actgctgctc ttttctctta tcctgttgag catcttgtgt 6360cctgttagaa agcataaaaa atcataaatc ccacctaaca 6400atcttcacat catgtatcga ttttcaaaca ctttatcatt 6440tagaacttaa cttggcacta ctatctgata actgactttc 6480atttttattt ttatatggat taattactaa aaaaaatact 6520ctctcgtgcc gaattcgata tcaagcttat cgataccgtc 6560gacctcgagg gggggcccgg tacccgggat cctcgcaatc 6600cctaggagga ttaggcaagg gcttgagctc acgctcttgt 6640gagggacaga aatacaatca ggggcagtat atgaatactc 6680catggagaaa cccagatcta cgtatgatca gcctcgactg 6720tgccttctag ttgccagcca tctgttgttt gcccctcccc 6760cgtgccttcc ttgaccctgg aaggtgccac tcccactgtc 6800ctttcctaat aaaatgagga aattgcatcg cattgtctga 6840gtaggtgtca ttctattctg gggggtgggg tggggcagga 6880cagcaagggg gaggattggg aagacaatag caggcatgct 6920ggggatgcgg tgggctctat ggcttctgag gcggaaagaa 6960ccagctgggg ctcgacagct cgactctaga attgcttcct 7000cgctcactga ctcgctgcgc tcggtcgttc ggctgcggcg 7040agcggtatca gctcactcaa aggcggtaat acggttatcc 7080acagaatcag gggataacgc aggaaagaac atgtgagcaa 7120aaggccagca aaaggccagg aaccgtaaaa aggccgcgtt 7160gctggcgttt ttccataggc tccgcccccc tgacgagcat 7200cacaaaaatc gacgctcaag tcagaggtgg cgaaacccga 7240caggactata aagataccag gcgtttcccc ctggaagctc 7280cctcgtgcgc tctcctgttc cgaccctgcc gcttaccgga 7320tacctgtccg cctttctccc ttcgggaagc gtggcgcttt 7360ctcaatgctc acgctgtagg tatctcagtt cggtgtaggt 7400cgttcgctcc aagctgggct gtgtgcacga accccccgtt 7440cagcccgacc gctgcgcctt atccggtaac tatcgtcttg 7480agtccaaccc ggtaagacac gacttatcgc cactggcagc 7520agccactggt aacaggatta gcagagcgag gtatgtaggc 7560ggtgctacag agttcttgaa gtggtggcct aactacggct 7600acactagaag gacagtattt ggtatctgcg ctctgctgaa 7640gccagttacc ttcggaaaaa gagttggtag ctcttgatcc 7680ggcaaacaaa ccaccgctgg tagcggtggt ttttttgttt 7720gcaagcagca gattacgcgc agaaaaaaag gatctcaaga 7760agatcctttg atcttttcta cggggtctga cgctcagtgg 7800aacgaaaact cacgttaagg gattttggtc atcagattat 7840caaaaaggat cttcacctag atccttttaa attaaaaatg 7880aagttttaaa tcaatctaaa gtatatatga gtaaacttgg 7920tctgacagtt accaatgctt aatcagtgag gcacctatct 7960cagcgatctg tctatttcgt tcatccatag ttgcctgact 8000 c 8001More preferably, it further includes the Andes M-gene constructpWRG/AND-M(x) (SEQ ID NO:10), which strengthens the HPS component.

Where gene-gun delivery is contemplated, the DNA segments from differentviruses can be on different particles or on the same particle, whicheverresults in the desired immune response. The vaccine is designed toprotect against pathologies resulting from exposure to one or severalhantaviruses. The vaccine can also be combined with reagents whichincrease the antigenicity of the vaccine, or reduce its side effects. Asshown above, the delivery of a combination of vaccines byelectroporation involves mixtures of DNA. This demonstrates thatplasmids can be mixed and any interference from the respective DNA witheach other can be overcome—another advantage of this invention.

For DNA vaccinations described here, as appropriate, when inducingcellular, humoral, and protective immune responses after DNA vaccinationthe preferred target cells are epidermal cells, rather than cells ofdeeper skin layers such as the dermis. Epidermal cells are preferredrecipients of DNA vaccines because they are the most accessible cells ofthe body and may, therefore, be immunized non-invasively. Secondly, inaddition to eliciting a humoral immune response, DNA immunized epidermalcells also elicit a cytotoxic immune response that is stronger than thatgenerated in sub-epidermal cells. Delivery to epidermis also has theadvantages of being less invasive and delivering to cells which areultimately sloughed by the body.

Although it can be desirable to induce an immune response by deliveringgenetic material to a target animal, merely demonstrating an immuneresponse is not necessarily sufficient to confer protective advantage onthe animal. What is important is to achieve a protective immune responsethat manifests itself in a clinical difference. That is, a method iseffective only if it prevents infection or reduces the severity of thedisease symptoms. It is preferred that the immunization method be atleast 20% effective in preventing death in an immunized population afterchallenge with SNV or, if a multivalent vaccine is used, at least one ofthe other targeted hantaviruses. More preferably, the vaccination methodis 50% or more effective, and most preferably 70 100% effective, inpreventing death in an immunized population. The vaccination method isshown herein to be 100% effective in the hamster models for hantavirus.Hamsters have been used extensively as the laboratory models of choicefor assessment of protective immune responses to hantaviruses. Incontrast, unimmunized animals are uniformly infected by challenge withhantavirus. The inventor's results indicate that vaccination with ourSNV vaccines protects against infection with SNV. As is well known, hightiter antibody such as achieved by the inventor is predictive ofprotection.

Generally, the DNA vaccine administered may be in an amount of about 5ug-5 mg of DNA per dose and will depend on the delivery technology,subject to be treated, capacity of the subject's immune system todevelop the desired immune response, and the degree of protectiondesired. Precise amounts of the vaccine to be administered may depend onthe judgement of the practitioner and may be peculiar to each subjectand antigen. Delivery technology plays an important role in determiningdosage—e.g., an adjuvant may change the dosage or number of vaccinationsneeded.

The vaccine for eliciting an immune response against one or moreviruses, may be given in a single dose schedule, or if deemed necessaryor desirable, a multiple dose schedule in which a primary course ofvaccination may be with 1-8 separate doses, followed by other dosesgiven at subsequent time intervals required to maintain and or reinforcethe immune response, for example, at 14 months for a second dose, and ifneeded, a subsequent dose(s) after several months. Examples of suitableimmunization schedules include: (i) 0, 1 months and 6 months, (ii) 0, 7days and 1 month, (iii) 0 and 1 month, (iv) 0 and 6 months, or otherschedules sufficient to elicit the desired immune responses expected toconfer protective immunity, or reduce disease symptoms, or reduceseverity of disease.

In a related embodiment, this invention provides a method for raisinghigh titers of neutralizing antibodies against Sin Nombre virus in amammal or a bird. The method comprises the step of administering acomposition comprising a SNV plasmid DNA which comprises one or more ofthe recombinant DNA constructs described above (including SEQ ID NO:1,SEQ ID NO:2 or SEQ ID NOT:3); and a pharmacologically acceptablecarrier. The step of administering may need to be repeated as desired inorder to achieve the level of titer targeted. Preferably the titer ismeasured to be between 100 and 10,000.

Therapeutic Use of Polyclonal and Monoclonal Antibodies

In another embodiment, the present invention relates to polyclonalantibodies from vaccines receiving the DNA vaccines described above. Acomposition comprising the polyclonal antibodies can be used as aprophylactic or therapeutic effective in preventing onset of Sin Nombrevirus infection after exposure to it, and/or in treating Sin Nombrevirus disease. For example, the composition of the present invention iscomposed of polyclonal antiserum from a population of animals or humansvaccinated with a DNA vaccine comprised of a plasmid expressing theabove-described synthetic Sin Nombre virus M gene. The polyclonal serumwould contain neutralizing antibodies against Sin Nombre virus. Unlikeconventional polyclonal immune serum products, the process used to makethis invention (DNA vaccination to produce antibody in vaccines) doesnot involve live virus and does not require the identification ofpatients who have survived Sin Nombre virus disease.

Similarly, animals or humans vaccinated with one of the above-describedDNA vaccines can produce SNV-neutralizing monoclonal antibodies (Mab),which Mab can then be engineered into expression systems.

In one embodiment of this method, the invention contemplates a method totreat or prevent or ameliorate symptoms after onset of Sin Nombre virusinfection by administering a therapeutically or prophylacticallyeffective amount of serum of the present invention or a mixture ofantibodies of the present invention to a subject in need of suchtreatment. The antibodies are specific for peptides encoded by thenucleic acids described herein—e.g., where the Gn and Gc are encoded bythe nucleic acid of one of SEQ ID NO:1, SEQ ID NO:2 and/or SEQ ID NO:3.

The polyclonal antibodies described herein are characterized in that theantibody binds to the appropriate immunogen, i.e. Gn and Gc, as measuredby assays such as ELISA, immunoprecipitation, or immunofluorescence.Also, the antibodies must neutralize Sin Nombre virus as measured byplaque reduction neutralization test (PRNT). Any antibody retainingthese characteristics is related to the present invention. Thepolyclonal antibody may be concentrated, irradiated, and tested for acapacity to neutralize Sin Nombre virus. Serum lots with sufficientlyhigh neutralizing antibody titers, i.e., high enough to give adetectable response in the recipient after transfer, can be pooled. Theproduct can then be lyophilized for storage and reconstituted for use.

As described in greater detail in the examples, the present inventor hasfound that serum from a vaccine immunized with a DNA vaccine comprisingone of the above-described SNV sequences, contains antibodies able toneutralize hantavirus.

Given these results, polyclonal antibodies according to the presentinvention are suitable both as therapeutic and prophylactic agents fortreating or preventing SNV infection or disease in susceptibleSNV-exposed subjects. Subjects include rodents such as mice or guineapigs, avian, and mammals (including transgenic animals), includinghumans.

Any active form of the antibodies can be administered. Antibodies of thepresent invention can be produced in any system, including insect cells,baculovirus expression systems, chickens, rabbits, goats, cows, orplants such as tomato, potato, banana or strawberry. Methods for theproduction of antibodies in these systems are known to a person withordinary skill in the art. Preferably, the antibodies used arecompatible with the recipient species such that the immune response tothe antibodies does not result in clearance of the antibodies beforevirus can be controlled, and the induced immune response to theantibodies in the subject does not induce “serum sickness” in thesubject.

Treatment of individuals having SNV infection may comprise theadministration of a therapeutically effective amount of anti-SNVantibodies of the present invention. The antibodies can be provided in akit as described below. In providing a patient with antibodies, orfragments thereof, capable of binding to SNV, or an antibody capable ofprotecting against SNV in a recipient patient, the dosage ofadministered agent will vary depending upon such factors as thepatient's age, weight, height, sex, general medical condition, previousmedical history, etc.

In general, it is desirable to provide the recipient with a dosage ofantibody which is in the range of from about 1 pg/kg 100 pg/kg, 100pg/kg 500 pg/kg, 500 pg/kg 1 ng/kg, 1 ng/kg 100 ng/kg, 100 ng/kg 500ng/kg, 500 ng/kg 1 ug/kg, 1 ug/kg 100 ug/kg, 100 ug/kg 500 ug/kg, 500ug/kg 1 mg/kg, 1 mg/kg 50 mg/kg, 50 mg/kg 100 mg/kg, 100 mg/kg 500mg/kg, 500 mg/kg 1 g/kg, 1 g/kg 5 g/kg, 5 g/kg 10 g/kg (body weight ofrecipient), although a lower or higher dosage may be administered.

The antibodies capable of protecting against hantavirus are intended tobe provided to recipient subjects in an amount sufficient to effect areduction in the SNV infection symptoms. An amount is said to besufficient to “effect” the reduction of infection symptoms if thedosage, route of administration, etc. of the agent are sufficient toinfluence such a response. Responses to antibody administration can bemeasured by analysis of subject's vital signs.

A composition is said to be “pharmacologically acceptable” if itsadministration can be tolerated by a recipient patient. Such an agent issaid to be administered in a “therapeutically effective amount” if theamount administered is physiologically significant. An agent isphysiologically significant if its presence results in a detectablechange in the physiology of a recipient patient.

The compounds of the present invention can be formulated according toknown methods to prepare pharmaceutically useful compositions, wherebythese materials, or their functional derivatives, are combined inadmixture with a pharmaceutically acceptable carrier vehicle. Suitablevehicles and their formulation, inclusive of other human proteins, e.g.,human serum albumin, are described, for example, in Remington'sPharmaceutical Sciences (16th ed., Osol, A. ed., Mack Easton Pa.(1980)). In order to form a pharmaceutically acceptable compositionsuitable for effective administration, such compositions will contain aneffective amount of the above-described compounds together with asuitable amount of carrier vehicle.

Additional pharmaceutical methods may be employed to control theduration of action. Control release preparations may be achieved throughthe use of polymers to complex or absorb the compounds. The controlleddelivery may be exercised by selecting appropriate macromolecules (forexample polyesters, polyamino acids, polyvinyl, pyrrolidone,ethylenevinylacetate, methylcellulose, carboxymethylcellulose, orprotamine sulfate) and the concentration of macromolecules as well asthe method of incorporation in order to control release. Anotherpossible method to control the duration of action by controlled releasepreparations is to incorporate the compounds of the present inventioninto particles of a polymeric material such as polyesters, polyaminoacids, hydrogels, poly(lactic acid) or ethylene vinylacetate copolymers.Alternatively, instead of incorporating these agents into polymericparticles, it is possible to entrap these materials in microcapsulesprepared, for example, interfacial polymerization, for example,hydroxymethylcellulose or gelatin-microcapsules andpoly(methylmethacylate)-microcapsules, respectively, or in colloidaldrug delivery systems, for example, liposomes, albumin microspheres,microemulsions, nanoparticles, and nanocapsules or in macroemulsions.Such techniques are disclosed in Remington's Pharmaceutical Sciences(1980).

Administration of the antibodies disclosed herein may be carried out byany suitable means, including parenteral injection (such asintraperitoneal, subcutaneous, or intramuscular injection), in ovoinjection of birds, orally, or by topical application of the antibodies(typically carried in a pharmaceutical formulation) to an airwaysurface. Topical application of the antibodies to an airway surface canbe carried out by intranasal administration (e.g., by use of dropper,swab, or inhaler which deposits a pharmaceutical formulationintranasally). Topical application of the antibodies to an airwaysurface can also be carried out by inhalation administration, such as bycreating respirable particles of a pharmaceutical formulation (includingboth solid particles and liquid particles) containing the antibodies asan aerosol suspension, and then causing the subject to inhale therespirable particles. Methods and apparatus for administering respirableparticles of pharmaceutical formulations are well known, and anyconventional technique can be employed. Oral administration may be inthe form of an ingestable liquid or solid formulation.

The treatment may be given in a single dose schedule, or preferably amultiple dose schedule in which a primary course of treatment may bewith 1-10 separate doses, followed by other doses given at subsequenttime intervals required to maintain and or reinforce the response, forexample, at 1-4 months for a second dose, and if needed, a subsequentdose(s) after several months. Examples of suitable treatment schedulesinclude: (i) 0, 1 month and 6 months, (ii) 0, 7 days and 1 month, (iii)0 and 1 month, (iv) 0 and 6 months, or other schedules sufficient toelicit the desired responses expected to reduce disease symptoms, orreduce severity of disease.

Diagnostic Methods

The present invention still further pertains to a method for detectingSNV in a sample suspected of containing SNV. The method includescontacting the sample with polyclonal antibodies of the presentinvention which bind SNV antigens, allowing the antibody to bind to theSNV antigen(s) to form an immunological complex, detecting the formationof the immunological complex and correlating the presence or absence ofthe immunological complex with the presence or absence of SNV antigen inthe sample. The sample can be biological, environmental or a foodsample.

The language “detecting the formation of the immunological complex” isintended to include discovery of the presence or absence of SNV antigenin a sample. The presence or absence of SNV antigen can be detectedusing an immunoassay. A number of immunoassays used to detect and/orquantitate antigens are well known to those of ordinary skill in theart. See Harlow and Lane, Antibodies: A Laboratory Manual (Cold SpringHarbor Laboratory, New York 1988 555 612). Such immunoassays includeantibody capture assays, antigen capture assays, and two-antibodysandwich assays. These assays are commonly used by those of ordinaryskill in the art.

In an antibody capture assay, the antigen is attached to solid support,and labeled antibody is allowed to bind. After washing, the assay isquantitated by measuring the amount of antibody retained on the solidsupport. A variation of this assay is a competitive ELISA wherein theantigen is bound to the solid support and two solutions containingantibodies which bind the antigen, for example, serum from a SNV virusvaccine and the polyclonal antibodies of the present invention, areallowed to compete for binding of the antigen. The amount of polyclonalantibody bound is then measured, and a determination is made as towhether the serum contains anti SNV antigen antibodies. This competitiveELISA can be used to indicate immunity to known protective epitopes in avaccine following vaccination.

In an antigen capture assay, the antibody is attached to a solidsupport, and labeled antigen is allowed to bind. The unbound proteinsare removed by washing, and the assay is quantitated by measuring theamount of antigen that is bound. In a two-antibody sandwich assay, oneantibody is bound to a solid support, and the antigen is allowed to bindto this first antibody. The assay is quantitated by measuring the amountof a labeled second antibody that can bind to the antigen.

These immunoassays typically rely on labeled antigens, antibodies, orsecondary reagents for detection. These proteins can be labeled withradioactive compounds, enzymes, biotin, or fluorochromes of these,radioactive labeling can be used for almost all types of assays and withmost variations. Enzyme-conjugated labels are particularly useful whenradioactivity must be avoided or when quick results are needed.Biotin-coupled reagents usually are detected with labeled streptavidin.Streptavidin binds tightly and quickly to biotin and can be labeled withradioisotopes or enzymes. Fluorochromes, although requiring expensiveequipment for their use, provide a very sensitive method of detection.Antibodies useful in these assays include monoclonal antibodies,polyclonal antibodies, and affinity purified polyclonal antibodies.Those of ordinary skill in the art will know of other suitable labelswhich may be employed in accordance with the present invention. Thebinding of these labels to antibodies or fragments thereof can beaccomplished using standard techniques commonly known to those ofordinary skill in the art. Typical techniques are described by Kennedy,J. H., et al., 1976 (Clin. Chim Acta 70:1 31), and Schurs, A. H. W. M.,et al. 1977 (Clin Chim Acta 81:1 40). Coupling techniques mentioned inthe latter are the glutaraldehyde method, the periodate method, thedimaleimide method, and others, all of which are incorporated byreference herein.

The language “biological sample” is intended to include biologicalmaterial, e.g. cells, tissues, or biological fluid. By “environmentalsample” is meant a sample such as soil and water. Food samples includecanned goods, meats, and others.

Yet another aspect of the present invention is a kit for detectinghantavirus in a biological sample. The kit includes a container holdingone or more polyclonal antibodies of the present invention which binds aSNV antigen and instructions for using the antibody for the purpose ofbinding to SNV antigen to form an immunological complex and detectingthe formation of the immunological complex such that the presence orabsence of the immunological complex correlates with presence or absenceof SNV in the sample. Examples of containers include multiwell plateswhich allow simultaneous detection of SNV in multiple samples.

Production of Pseudotyped Virions

Another use of the invention is a method for producing pseudotypedvirions. One of the above-described DNA constructs is used to transfectcells, under conditions that pseudotyped virions or SNV glycoprotein isproduced. The pseudotyped viruses are useful in serologic assays ordelivery of gene therapies to endothelial cells targeted by hantavirusglycoproteins.

REFERENCES

-   1. Hooper J W, Custer D M, Thompson E, Schmaljohn C S. DNA    vaccination with the hantaan virus m gene protects hamsters against    three of four HFRS hantaviruses and elicits a high-titer    neutralizing antibody response in rhesus monkeys. J Virol 2001;    75(18): 8469-8477.-   2. Fuller D H, Loudon P, Schmaljohn C. Preclinical and clinical    progress of particle-mediated DNA vaccines for infectious diseases.    Methods 2006:40:86-97.-   3. Custer D M, Thompson E, Schmaljohn C S, et al. Active and passive    vaccination against hantavirus pulmonary syndrome with Andes virus M    genome segment-based DNA vaccine. J Virol 2003; 77(18):9894-9905.-   4. Hooper J W, Ferro A M, and Wahl-Jensen V Immune Serum Produced by    DNA Vaccination Protects Hamsters Against Lethal Respiratory    Challenge with Andes Virus. Journal of Virology 2008 82:1332-1338.-   5. Hooper J W, Kamrud K I, Elgh F, et al. DNA vaccination with    hantavirus M segment elicits neutralizing antibodies and protects    against Seoul virus infection. Virology 1999; 255:269-278.-   6. Hooper J W, Custer D M, Smith J., and Wahl-Jensen W.    Hantaan/Andes virus DNA vaccine elicits a broadly cross-reactive    neutralizing antibody response in nonhuman primates. Virology 2006;    347:208-216.-   7. Condon C, Watkins S C, Celluzzi C M, et al. DNA-based    immunization by in vivo transfection of dendritic cells. Nat Med    1996; 10:1122-1128.-   8. Barry M A, Johnston S A. Biological features of genetic    immunization. Vaccine 1997; 15:788-791.-   9. Yoshida A, Nagata T, Uchijima M, et al. Advantage of gene    gun-mediated over intramuscular inoculation of plasmid DNA vaccine    in reproducible induction of specific immune responses. Vaccine    2000; 18:1725-1729.-   10. Steele K E, Stabler K, VanderZanden L. Cutaneous DNA vaccination    against Ebola virus by particle bombardment: histopathology and    alteration of CD3-positive dendritic epidermal cells. Vet Path 2001;    38:203-215.-   11. Monteiro-Riviere N A, Riviere J. The pig as a model for    cutaneous pharmacology and toxicology research. In: Tumbleson M E,    Schook L B (eds). Advances in Swine in Biomedical Research, Vol. 2,    New York, Plenum Press, 1996, pp. 425-458.-   12. Draize J H, Woodward G, Calvery H O. Methods for the study of    irritation and toxicity of substances applied topically to the skin    and mucous membranes. J Pharmacol Exp Ther 1944; 82,377-390.-   13. Klinman D M, Sechler J M G, Conover J, et al. Contribution of    cells at the site of DNA vaccination to the generation of    antigen-specific immunity and memory. J Immunol 1998; 160:    2388-2392.-   14. Gurunathan S, Klinman D, Seder R. DNA vaccines. 2000 Ann Rev    Immunol 2000; 7-74.-   15. McElroy A K, Smith J M, Hooper J W, Schmaljohn C S. Andes virus    M genome segment is not sufficient to confer the virulence    associated with Andes virus in Syrian hamsters. Virology 2004;    326(1):130-139.-   16. Charles River Laboratories—Arkansas Division. Assessment of the    Local Skin Reactivity and Systemic Toxicity of Hantaan Virus DNA    Vaccine pWRG/HTN-M(x) following PowderJect® Delivery to Syrian    Hamster Skin. Final Study Report for Protocol Number JTA00001. 2005.-   17 Hammerbeck, C. D., Wahl-Jensen, V., Hooper, J. W. Hantavirus. In:    Vaccines for Biodefense and Emerging and Neglected Diseases    (A. D. T. Barrett and L. R. Stanberry, Eds.), pp. 379-411. London:    Academic Press, 2009.-   18. Jonsson C. B, J. Hooper, and G. Mertz (2008). Treatment of    hantavirus pulmonary syndrome. Antiviral Res. Antiviral Res.    78:162-169.-   23. Schmaljohn, C. S., and J. W. Hooper (Jan. 27, 2000). United    States Patent Application 09/491,974; publication number    2002/0114818, published Aug. 22, 2002, entitled “DNA vaccines    against hantavirus infections”-   24. Hooper, J. W., C. S. Schmaljohn and M. Custer. “Extraneous DNA    sequence that facilitates hantavirus gene expression. U.S. Pat. No.    7,217,812. Issued May 15, 2007.-   25. Hooper, J. W., C. S. Schmaljohn. DNA Vaccines Against    Hantavirus. Korean Patent 660040. Issued December 2006, and European    Patent EPO 00908388.2, issued January 2007-   26. Hooper, J. W. Puumala virus full-length M segment-based DNA    vaccines. U.S. application Ser. No. 12/449,504, filed Aug. 11, 2009;    PCT/US2008/001847, published Jan. 15, 2009

The contents of all cited references (including literature references,issued patents, published patent applications, and co-pending patentapplications) cited throughout this application are hereby expresslyincorporated by reference.

1-3. (canceled)
 4. The peptide encoded by the nucleic acid sequence ofclaim 1, which is set forth in SEQ ID NO:4. 5-9. (canceled)
 10. Avaccine composition comprising an effective immunizing amount of SNVplasmid DNA, which plasmid DNA comprises the recombinant DNA constructof claim 5, and a pharmacologically acceptable carrier, and optionallyan adjuvant.
 11. The vaccine composition of claim 10, wherein thepharmacologically acceptable carrier is selected from the groupconsisting of PBS, water, saline, TRIS-EDTA, and mixtures of these. 12.The vaccine composition of claim 10, wherein the immunizing amount ofSNV plasmid DNA is between about 5 micrograms and about 5 milligrams.13. The vaccine composition of claim 10, which further comprises theadditional vaccine component of an Andes M gene sequence.
 14. Thevaccine composition of claim 13, wherein the Andes M gene sequence isSEQ ID NO:10.
 15. The vaccine composition of claim 10, which furthercomprises the additional vaccine component of a Puumala M gene sequence,or a Hantaan M gene sequence, or a Seoul M gene sequence, or acombination of these.
 16. The vaccine composition of claim 15, whereinthe Puumala M gene sequence is SEQ ID NO:11, the Hantaan M gene sequenceis SEQ ID NO:12, and/or the Seoul M gene sequence is SEQ ID NO:13. 17.The vaccine composition of claim 13, which further comprises theadditional vaccine component of a Puumala M gene sequence, or a HantaanM gene sequence, or a Seoul M gene sequence, or a combination of these.18. The vaccine composition of claim 17, wherein the Andes M genesequence is SEQ ID NO:10, the Puumala M gene sequence is SEQ ID NO:11,the Hantaan M gene sequence is SEQ ID NO:12, and/or the Seoul M genesequence is SEQ ID NO:13.
 19. A Sin Nombre Virus vaccine comprising acomposition comprising inert particles and a nucleic acid coated ontothe inert particles producing nucleic acid coated particles, saidnucleic acid comprising a promoter operative in the cells of a mammaland a recombinant Sin Nombre Virus nucleic acid sequence selected fromthe group consisting of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3.
 20. Amethod for inducing a protective immune response against Sin Nombrevirus infection in a mammal, comprising the step of administering acomposition comprising an effective immunizing amount of SNV plasmidDNA, which plasmid DNA comprises the recombinant DNA construct of claim5; and a pharmacologically acceptable carrier.
 21. The method of claim20, wherein the composition is administered by needle inoculation orneedle-free jet injection, optionally with electroporation.
 22. Themethod of claim 20, which raises titers of neutralizing antibodiesagainst Sin Nombre virus in a mammal or a bird, wherein the titers areat least
 100. 23. The method of claim 22, wherein the titers are atleast 10,000.
 24. A therapeutic composition for ameliorating symptomsafter onset of Sin Nombre virus infection comprising antibodies specificfor peptides encoded by the nucleic acid of claim
 3. 25. A post-exposureprophylactic against Sin Nombre virus infection in someone who has beenexposed to Sin Nombre virus comprising a composition comprisingpolyclonal antibodies obtained from a population of human or animalvaccines vaccinated with a Sin Nombre virus DNA vaccine comprised of aplasmid expressing SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3.
 26. Thepost-exposure prophylactic of claim 25, wherein the plasmid ispWRG/SN-M(opt).
 27. A method for producing pseudotyped virions or SNVglycoprotein-containing cells, comprising the step of culturing therecombinant DNA construct of claim 5, under conditions that pseudotypedvirions or SNV glycoprotein is produced.